KOL | Harry Roger BüllerDepartment of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ... |
KOL Resume for Harry Roger Büller
| Year | |
|---|---|
| 2022 | Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands |
| 2021 | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.). Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.). |
| 2020 | From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.) Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands |
| 2019 | Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands |
| 2018 | Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| 2017 | Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands. From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy. |
| 2016 | Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands |
| 2015 | Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands |
| 2014 | From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.). Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and |
| 2013 | Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands Academic Medical Center, Amsterdam (H.R.B.) |
| 2012 | Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.) Vascular Medicine, AMC, Amsterdam, the Netherlands |
| 2011 | Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, From the Academic Medical Center and Slotervaart Hospital, Amsterdam |
Harry Roger Büller: Influence Statistics
Open the FULL List in Excel
| Concept | World rank |
|---|---|
| easier monitoring | #1 |
| dimer clinical | #1 |
| prospective management study | #1 |
| laalleles | #1 |
| uedvt clinical | #1 |
| travellers thrombosis | #1 |
| prothrombin individuals | #1 |
| leg ultrasonography patients | #1 |
| pulmonary embolism tests | #1 |
| diagnostic strategies strategies | #1 |
| non‐invasive diagnostic work‐up | #1 |
| 25mg apixaban | #1 |
| presenting vte location | #1 |
| elderly outpatients combination | #1 |
| evaluable patients apixaban | #1 |
| nadroparin aspirin | #1 |
| inr range ttr | #1 |
| cancer edoxaban | #1 |
| vte trial | #1 |
| asymptomatic extension | #1 |
| safety outcome | #1 |
| efficacy vte | #1 |
| vte arterial | #1 |
| tests venography | #1 |
| anticoagulant treatment patients | #1 |
| activecontrol placebo | #1 |
| rhir lmwh | #1 |
| adjusted dose ufh | #1 |
| 2 diagnostic management | #1 |
| smoking graft patency | #1 |
| rfviia idraparinux | #1 |
| intravenous injections lmwh | #1 |
| postthrombotic symptoms patients | #1 |
| bleeding risk treatment | #1 |
| heparinoid | #1 |
| vitamin anticoagulants | #1 |
| excluding pulmonary | #1 |
| avws prevalence | #1 |
| carriers thrombophilic defects | #1 |
| vka netherlands | #1 |
| edoxabantreated | #1 |
| presentation category | #1 |
| d‐dimer level | #1 |
| pulmonary embolism basis | #1 |
| popliteal veins sensitivity | #1 |
| uesvt patients | #1 |
| wells rules | #1 |
| cstatistic major bleeding | #1 |
| elevated cardiac troponins | #1 |
| 15 lmwh | #1 |
| united states rnapc2 | #1 |
| acute recurrent patients | #1 |
| intensity vkas doacs | #1 |
| oral anticoagulants phase | #1 |
| predefined outcomes | #1 |
| early time recurrence | #1 |
| heparins data | #1 |
| realtime bmode ultrasonography | #1 |
| members symptomatic carriers | #1 |
| category fxainhibitors | #1 |
| followup overt cancer | #1 |
| tinaquant assay comparison | #1 |
| diagnostic strategy primary | #1 |
| dose rnapc2 | #1 |
| lmwh acute treatment | #1 |
| probability cdr | #1 |
| vte day | #1 |
| mutation relatives | #1 |
| botticelli dvt dose‐ranging | #1 |
| exclusion pulmonary | #1 |
| cancer 145 patients | #1 |
| xageneration | #1 |
| relatives normal fviii | #1 |
| ventilation lung scanning | #1 |
| submassive incidence | #1 |
| elevated fviii age | #1 |
| cdr normal | #1 |
| lmwhmediated | #1 |
| einsteindvt | #1 |
| fviii hyperhomocysteinemia | #1 |
| compression ultrasonography detection | #1 |
| qscan 3 weeks | #1 |
| avidin placebo | #1 |
| relevant major | #1 |
| lmwh edoxaban | #1 |
| reocclusion antithrombotic drug | #1 |
| venous thrombosis vwf | #1 |
| patients unexplained dvt | #1 |
| fetal loss carriers | #1 |
| strategies diagnostic management | #1 |
| efficiency subgroups | #1 |
| study centre duration | #1 |
| age recurrent vte | #1 |
| monoclonal antibodies apc | #1 |
| fondaparinux rfviia injection | #1 |
| gentamicin patients netilmicin | #1 |
| clinically relevant disease | #1 |
| vte airline pilots | #1 |
| relatives normal levels | #1 |
| tests pulmonary embolism | #1 |
| selective beta‐blocker treatment | #1 |
| edoxaban dalteparin | #1 |
| subsequent diagnosis malignancy | #1 |
| venous thrombosis recurrence | #1 |
| amplify trial | #1 |
| matisse clinical trials | #1 |
| unexplained dvt patients | #1 |
| extensive screening cancer | #1 |
| pulmonary angiography ultrasonography | #1 |
| bmi fondaparinux | #1 |
| absolute thrombotic risk | #1 |
| acenocoumarol heparin | #1 |
| recurrent dvt dvt | #1 |
| thromboembolism relatives | #1 |
| diagnostic strategies patients | #1 |
| smoking patency | #1 |
| hokusaivte trial | #1 |
| 0·620·74 | #1 |
| clinical uedvt | #1 |
| lmwh immobilization | #1 |
| doubleheterozygotes | #1 |
| ctscanreading | #1 |
| systematic search cteph | #1 |
| molecular weight fondaparinux | #1 |
| heparin vitamin | #1 |
| loss subsequent pregnancy | #1 |
| single dose tb402 | #1 |
| simple diagnostic strategy | #1 |
| initial treatment dvt | #1 |
| patients treatment duration | #1 |
| gastrointestinal cancer edoxaban | #1 |
| anticoagulant treatment vte | #1 |
| warfarin cstatistic | #1 |
| factual hemorrhage heparin | #1 |
| simplified rule proportion | #1 |
| ipe expert radiologists | #1 |
| bleeding clinically | #1 |
| management study | #1 |
| einsteinextension | #1 |
| combination cdrscore | #1 |
| obese controls difference | #1 |
| standalone ddimer testing | #1 |
| silent dvt | #1 |
| malignancy achieved inr | #1 |
| standardintensity vkas doacs | #1 |
| abdominal pelvic strategies | #1 |
| category perelated death | #1 |
| compression ultrasonography presentation | #1 |
| fetal loss miscarriage | #1 |
| patients khorana | #1 |
| crptest | #1 |
| combined training gps | #1 |
| feasibility venography | #1 |
| proportion pulmonary embolism | #1 |
| cart lower levels | #1 |
| nadroparin patients | #1 |
| aptt org | #1 |
| incidence ctni | #1 |
| noncarriers annual incidence | #1 |
| patients artificial graft | #1 |
| wells cdr | #1 |
| idraparinux | #1 |
| 3633 patients edoxaban | #1 |
| enoxaparin heparin treatment | #1 |
| 0·2 3633 patients | #1 |
| org heparin | #1 |
| cdrscore combination | #1 |
| incidence venous | #1 |
| 5‐snp scores | #1 |
| controlled trials thrombophilia | #1 |
| treatment idraparinux | #1 |
| enoxaparin primary efficacy | #1 |
| vka recipients | #1 |
| baseline pvo | #1 |
| elevated levels fviii | #1 |
| elevated ctni patients | #1 |
| amplify trial apixaban | #1 |
| oral edoxaban dose | #1 |
| rivaroxaban replacement | #1 |
| test venography | #1 |
| elderly patients dvt | #1 |
| treated vka | #1 |
| replacement vka | #1 |
| aged nadroparin | #1 |
| evaluable patients 95 | #1 |
| perelated death category | #1 |
| outcome recurrent | #1 |
| age multiple comorbidities | #1 |
| thrombosis vitamin | #1 |
| dimer result | #1 |
| departments pharmacological prophylaxis | #1 |
| year prophylaxis | #1 |
| milliliter enoxaparin | #1 |
| neoplasms heparin | #1 |
| sgs pretest probability | #1 |
| crt cvc | #1 |
| graft patency patency | #1 |
| doacs initial heparin | #1 |
| long haul flights | #1 |
| uedvt recurrent vte | #1 |
| pulmonary angiography study | #1 |
| warfarin cancer patients | #1 |
| heparins vitamin antagonists | #1 |
| wellscdr | #1 |
| enoxaparin initial treatment | #1 |
| simplified geneva score | #1 |
| efficacy outcome | #1 |
| ivte clinical practice | #1 |
| ultrasonography dvt | #1 |
| lmwh plasma levels | #1 |
| acute treatment lmwh | #1 |
| double heterozygous carriers | #1 |
| treatment experimental thrombosis | #1 |
| fxainhibitors vka recipients | #1 |
| vte risk day | #1 |
| patients advanced malignancy | #1 |
| venography tests | #1 |
| hyperhomocysteinemia relatives | #1 |
| pharmacological methods prophylaxis | #1 |
| death vte studies | #1 |
| heparins inhibition | #1 |
| fviii concentration | #1 |
| rate recurrent | #1 |
| major bleeds vka | #1 |
| hellp syndrome mutations | #1 |
| 69 conclusions | #1 |
| acenocoumarol efficacy | #1 |
| normal lung scan | #1 |
| rnapc2 groups | #1 |
| beta thromboglobulin org | #1 |
| aged venous | #1 |
| uesvt | #1 |
| time recombinant | #1 |
| patients advanced prostate | #1 |
| initial heparin patients | #1 |
| ddimer levels cdr | #1 |
| acquired atiii deficiency | #1 |
| rivaroxaban lmwh vka | #1 |
| relatives elevated levels | #1 |
| 393 patients warfarin | #1 |
| pulmonary embolism cdr | #1 |
| sensitivity 100 percent | #1 |
| subcutaneous idraparinux | #1 |
| nondiagnostic lung scan | #1 |
| cip diagnostic management | #1 |
| 5395 patients | #1 |
| noacs prevention | #1 |
| qscan | #1 |
| endotoxemia tests | #1 |
| extra hospital visits | #1 |
| venous thrombosis hyperglycemia | #1 |
| apixaban extended treatment | #1 |
| risk percentage points | #1 |
| administration lmwh | #1 |
| vkas efficacy | #1 |
| idraparinux 25 | #1 |
| 95 3633 patients | #1 |
| prevention topic guidelines | #1 |
| normal dimer | #1 |
| suspected perfusion scan | #1 |
| —brachial | #1 |
| recurrent vte statin | #1 |
| major bleeding cancer | #1 |
| lowmolecularweight heparin 95 | #1 |
| intracranial clinical presentation | #1 |
| ldf cus | #1 |
| lmprovement | #1 |
| extended anticoagulation apixaban | #1 |
| apixaban conventional therapy | #1 |
| 023 relatives | #1 |
| lowmolecularweight heparin category | #1 |
| enoxaparin vkas treatment | #1 |
| 8h flight | #1 |
| presenting location women | #1 |
| idrabiotaparinux idraparinux | #1 |
| ventilation scan chest | #1 |
| hokusaivte trial patients | #1 |
| relatives tafi levels | #1 |
| cvc crt | #1 |
| thrombophilia late loss | #1 |
| patients tb402 | #1 |
| fondaparinux unfractionated | #1 |
| frequency venous thromboembolism | #1 |
| level loss patency | #1 |
| reduceddose noacs warfarin | #1 |
| death venous thromboembolism | #1 |
| wound haematoma | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| patients acute recurrent | #1 |
| phase doacs | #1 |
| rnapc2 patients | #1 |
| 95 intracranial | #1 |
| severity clinical presentation | #1 |
| selective ddimer thresholds | #1 |
| 9 incidence | #1 |
| 12 kg1 enoxaparin | #1 |
| annual incidence patients | #1 |
| travel‐related venous thrombosis | #1 |
| upper extremity uedvt | #1 |
| probability categories | #1 |
| crp test patients | #1 |
| proximal location ipe | #1 |
| sspe proximal | #1 |
| 95ci tb402 | #1 |
| progression vte | #1 |
| venous thromboembolism idraparinux | #1 |
| cancer patients ufh | #1 |
| practiceassistants | #1 |
| apc resistance factor | #1 |
| quantitative ddimer tests | #1 |
| therapeutic doses lmwh | #1 |
| included patients study | #1 |
| clinically suspected uedvt | #1 |
| types major bleeding | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| idraparinux versus | #1 |
| dvt costs | #1 |
| wellsrule | #1 |
| treat thrombosis | #1 |
| ddimer test | #1 |
| orthopedic surgery netherlands | #1 |
| heparins cancer patients | #1 |
| embolism radionuclide | #1 |
| patients uedvt uesvt | #1 |
| presenting location vte | #1 |
| chest perfusion scintigraphy | #1 |
| probabilityscan | #1 |
| bleeding risk lmwh | #1 |
| heparin acenocoumarol | #1 |
| plateletactivating antibodies risk | #1 |
| 2479 relatives | #1 |
| embolism wells | #1 |
| cancer patients uedvt | #1 |
| nadroparin therapeutic dose | #1 |
| carriers pulmonary embolism | #1 |
| pulmonary angiography strategies | #1 |
| thiazoles venous | #1 |
| vte fatal | #1 |
| 547253 | #1 |
| months standard therapy | #1 |
| specificity pulmonary embolism | #1 |
| strategies abdominal pelvic | #1 |
| acenocoumarol initial treatment | #1 |
| deficiency proteins | #1 |
| simplified wells rule | #1 |
| doses 75 microg | #1 |
| limited screening 95 | #1 |
| preference doacs | #1 |
| idraparinux patients | #1 |
| treatment venous | #1 |
| 20210a mutation | #1 |
| 6 months avidin | #1 |
| protecht shr | #1 |
| gogh dvt trial | #1 |
| symptomatic venous | #1 |
| vte risk coc | #1 |
| netherlands lmwh | #1 |
| threemonth incidence | #1 |
| pulmonary embolism carriers | #1 |
| screening carriers | #1 |
| submassive elevated ctni | #1 |
| anticoagulants chemotherapy | #1 |
| withheld | #1 |
| study ecq | #1 |
| anticoagulants probability | #1 |
| inr studies | #1 |
| apixaban randomized patients | #1 |
| patients wells rule | #1 |
| patients protein deficiencies | #1 |
| excluded pulmonary | #1 |
| venous thrombosis pregnancy | #1 |
| p0001 saline | #1 |
| age∗10μg | #1 |
| cancer patients cancer | #1 |
| quantitative dimer | #1 |
| departments orthopedic surgery | #1 |
| ml1 ctpa | #1 |
| low levels ft4 | #1 |
| pulmonary embolism fondaparinux | #1 |
| patency smokers | #1 |
| ankle brachial prevalence | #1 |
| avidin idrabiotaparinux | #1 |
| extended treatment edoxaban | #1 |
| venous thrombus growth | #1 |
| bleeding einstein | #1 |
| topic thrombophlebitis | #1 |
| vte difference | #1 |
| symptomatic legs dvt | #1 |
| quantitative ddimer test | #1 |
| rnapc2 inhibition | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| cdrscore | #1 |
| flebography | #1 |
| 5mg apixaban | #1 |
| pulmonary embolism idraparinux | #1 |
| standard therapy months | #1 |
| riskstroponin | #1 |
| carriers recurrence | #1 |
| studies 3 months | #1 |
| combination nonhigh cdr | #1 |
| intrinsic coagulation vivo | #1 |
| intestinal microbiota coagulation | #1 |
| patients idraparinux | #1 |
| achieved inr patients | #1 |
| clinically suspected cancer | #1 |
| nonhigh cdr | #1 |
| ldf diagnosis | #1 |
| animal female heparin | #1 |
| extended anticoagulation doacs | #1 |
| levels procoagulant factors | #1 |
| hokusaivte study | #1 |
| fviii homocysteine | #1 |
| reduceddose noacs | #1 |
| rabinov | #1 |
| safety clinical utility | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| diagnosis deepvein thrombosis | #1 |
| deep vein thrombosis | #1 |
| clinically suspected dvt | #1 |
| recurrent thrombosis pts | #1 |
| risk homozygous women | #1 |
| tsh antitpo | #1 |
| oral rivaroxaban treatment | #1 |
| individualized duration | #1 |
| idraparinux 6 months | #1 |
| dose daily edoxaban | #1 |
| respondents lmwh | #1 |
| fviii normal levels | #1 |
| dimer test | #1 |
| risk pulmonary embolism | #1 |
| cdrs patients | #1 |
| rnapc2 united states | #1 |
| patients mismatched scan | #1 |
| doacs factor | #1 |
| conventional therapy enoxaparin | #1 |
| studies ttr | #1 |
| international thrombosis experts | #1 |
| cancer clinical presentation | #1 |
| wells rule exclusion | #1 |
| venous thromboembolism edoxaban | #1 |
| dvt 3 | #1 |
| edoxaban warfarin groups | #1 |
| absolute annual incidences | #1 |
| anticoagulation period | #1 |
| cdr ddimer levels | #1 |
| patients clinical probability | #1 |
| association travel | #1 |
| vte study | #1 |
| anticoagulant fondaparinux | #1 |
| recurrent vte immobilization | #1 |
| normotensive patients studies | #1 |
| intravenous unfractionated | #1 |
| scenarioanalysis | #1 |
| s1p1activation | #1 |
| lmwh replacement | #1 |
| 7268 patients suspected | #1 |
| poc test patients | #1 |
| mortality postthrombotic symptoms | #1 |
| ctscan qscan | #1 |
| iii plg | #1 |
| thrombo‐embolic events | #1 |
| fibrinolysis levels | #1 |
| dalteparin 6 months | #1 |
| 12 months edoxaban | #1 |
| elevated fviii | #1 |
| cancer patients cvcs | #1 |
| ddimer test patients | #1 |
| pulmonary embolism life | #1 |
| p0424 | #1 |
| subcutaneous length life | #1 |
| relatives mutation | #1 |
| thrombophilia patients doacs | #1 |
| undvt | #1 |
| false normal | #1 |
| failure cip | #1 |
| weight heparinoid | #1 |
| individuals air travel | #1 |
| ifngamma pselectin | #1 |
| rivaroxaban dvt treatment | #1 |
| subsequent symptomatic cancer | #1 |
| association protein levels | #1 |
| suspected symptomatic | #1 |
| elevated fviii patients | #1 |
| isolated deficiencies proteins | #1 |
| guidelines abi | #1 |
| apc resistance tests | #1 |
| elevated biomarkers hospital | #1 |
| fviii vte | #1 |
| uedvt terms | #1 |
| ufh grade | #1 |
| protein resistance control | #1 |
| rnapc2 groups placebo | #1 |
| clinical presentation category | #1 |
| carriers relative risks | #1 |
| studies doac treatment | #1 |
| strategies ultrasonography | #1 |
| avidin vte | #1 |
| scores occult cancer | #1 |
| embolism randomized | #1 |
| heparin vitamin antagonist | #1 |
| 208791 | #1 |
| wells clinical | #1 |
| calf dvt ultrasound | #1 |
| women elevated levels | #1 |
| relevant bleeding | #1 |
| 53 amputations | #1 |
| pvo qscan | #1 |
| vitamin antagonists time | #1 |
| clinical decision rule | #1 |
| recurrence major bleeding | #1 |
| thromboembolism 3 | #1 |
| hokusai‐vte cancer study | #1 |
| clinical probability exclusion | #1 |
| abnormal ipg | #1 |
| respondents 60 | #1 |
| embolism sensitivity | #1 |
| patients retropubic prostatectomy | #1 |
| dalteparin major bleeding | #1 |
| rule cdr | #1 |
| superficial thrombophlebitis incidence | #1 |
| lmwh venous thrombosis | #1 |
| xainhibitors | #1 |
| initial heparin edoxaban | #1 |
| netherlands 5 years | #1 |
| segmental subsegmental | #1 |
| compression ultrasonography patients | #1 |
| patients compression ultrasonography | #1 |
| 95 elevated ctni | #1 |
| rfviia 3 | #1 |
| anticoagulants double | #1 |
| symptomatic recurrent vte | #1 |
| prescriptionbased | #1 |
| wells rule primary | #1 |
| mdct expert radiologist | #1 |
| ldfr symptomatic legs | #1 |
| deepvein thrombosis incidence | #1 |
| ultrasound strategies patients | #1 |
| oral apixaban treatment | #1 |
| laalleles platelets | #1 |
| ultrasound compression ultrasound | #1 |
| severe presentation patients | #1 |
| lowmolecularweight heparin treatment | #1 |
| recommendations dvt | #1 |
| doacs anatomical extent | #1 |
| heparins cancer spread | #1 |
| cdr physicians | #1 |
| normal ddimer concentration | #1 |
| 560 pharmacies | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| 00515 | #1 |
| plasma concentration fviii | #1 |
| outpatients symptomatic dvt | #1 |
| residual thrombotic mass | #1 |
| quantitative ddimer testing | #1 |
| platelets iqr | #1 |
| org aptt | #1 |
| cdr ddimer test | #1 |
| venography feasibility | #1 |
| 50 rivaroxaban | #1 |
| uesvt mortality | #1 |
| oral administration bsf | #1 |
| older patients cdr | #1 |
| death category | #1 |
| inherited thrombophilia patients | #1 |
| lmwh users incidence | #1 |
| standardintensity vkas | #1 |
| idraparinux recurrent thromboembolism | #1 |
| coagulation clinical | #1 |
| controlledstudy | #1 |
| dvt impedance plethysmography | #1 |
| compression ultrasonography | #1 |
| orthopedic thromboprophylaxis | #1 |
| hokusai vte cancer | #1 |
| vte addition | #1 |
| lmwh rtap | #1 |
| survival fondaparinux | #1 |
| combination cdrs | #1 |
| pregnancyrelated complications relatives | #1 |
| failure diagnostic management | #1 |
| models development studies | #1 |
| matisse trials | #1 |
| matisse dvt | #1 |
| somittrial | #1 |
| idraparinux vitamin antagonist | #1 |
| local radiologist experts | #1 |
| normal levels fviii | #1 |
| atherosclerosis hemophilia patients | #1 |
| scan pulmonary embolism | #1 |
| pvo ctscan | #1 |
| tb402 50 | #1 |
| presence venous thrombosis | #1 |
| enoxaparin vkas | #1 |
| ecq ankle brachial | #1 |
| proportion 75 years | #1 |
| category death | #1 |
| rtap lmwh | #1 |
| mutation arg506 | #1 |
| antithrombotic prescriptions adherence | #1 |
| 7268 patients | #1 |
| tests prevalence abi | #1 |
| dalteparin vte treatment | #1 |
| patients deep | #1 |
| dvt 56 | #1 |
| ultrasonography leg veins | #1 |
| baseline characteristics duration | #1 |
| protein levels mortality | #1 |
| tb402 enoxaparin | #1 |
| polyethylenglycolhirudin | #1 |
| suspected cdr | #1 |
| synthetic selective factor | #1 |
| diagnostic management patients | #1 |
| reported incidence vte | #1 |
| thromboembolism treated | #1 |
| cancer patients cdr | #1 |
| total vte patients | #1 |
| combination cdr | #1 |
| coagulation factors markers | #1 |
| prolactin venous thrombosis | #1 |
| chest perfusion scan | #1 |
| svt lmwh | #1 |
| perfusion scan | #1 |
| prothrombin 20210a mutation | #1 |
| increasing levels ft4 | #1 |
| vka treatment treatment | #1 |
| lmwhs 95 | #1 |
| control anticardiolipin antibodies | #1 |
| 97 compression ultrasonography | #1 |
| hokusai‐vte trial | #1 |
| incidental symptomatic vte | #1 |
| falsenormal | #1 |
| suspected deep | #1 |
| equinox study | #1 |
| antidote vitamin | #1 |
| coagulationinhibiting | #1 |
| factor viii homocysteine | #1 |
| factor viii relatives | #1 |
| vitamin antagonist patients | #1 |
| successful attenuation | #1 |
| analysis hokusai | #1 |
| venous thromboembolism episode | #1 |
| placebo 25mg apixaban | #1 |
| 5 avidin infusion | #1 |
| 378 patients edoxaban | #1 |
| ft4 level patients | #1 |
| randomized studies efficacy | #1 |
| single‐detector row | #1 |
| ivte | #1 |
| ddimer test combination | #1 |
| wells simplified | #1 |
| puerperium diagnostic suspicion | #1 |
| decisions duration | #1 |
| patients enoxaparin vkas | #1 |
| dvt anticoagulants | #1 |
| procoagulant factors levels | #1 |
| vte procoagulant activity | #1 |
| ambulatory computers | #1 |
| early discharge strategies | #1 |
| efficacy heparin therapy | #1 |
| symptomatic pts | #1 |
| 2630 pilots | #1 |
| rule dimer | #1 |
| normal venogram | #1 |
| venous thrombosis mutations | #1 |
| treatment cumulative incidence | #1 |
| obstetric complications relatives | #1 |
| uesvt median | #1 |
| daily dalteparin treatment | #1 |
| current practise | #1 |
| 50 years combination | #1 |
| ultrasonography diagnostic | #1 |
| tb402 prevention | #1 |
| ddimer result | #1 |
| prevalence coagulation | #1 |
| patients initial heparin | #1 |
| questionnaires thrombosis | #1 |
| 65±9years | #1 |
| pyridines recurrence | #1 |
| patients laalleles | #1 |
| recurrence bleeding risk | #1 |
| dose response apixaban | #1 |
| einstein dvt patients | #1 |
| patients ivte | #1 |
| rfviia fondaparinux | #1 |
| tb402 12 kg1 | #1 |
| prophylaxis crt | #1 |
| standard treatment idraparinux | #1 |
| safety idraparinux | #1 |
| comparison vidas assay | #1 |
| beneficial lmwh | #1 |
| wellscdrscore | #1 |
| role exclusion | #1 |
| referral basis | #1 |
| proximal extent ipe | #1 |
| vka share | #1 |
| timeperiod | #1 |
| 0·2 edoxabantreated | #1 |
| presentation major | #1 |
| prediction models recurrence | #1 |
| heparin initial | #1 |
| sustained antithrombotic effects | #1 |
| fviii venous thromboembolism | #1 |
| women factor leiden | #1 |
| echocardiography normotensive patients | #1 |
| ddimer test result | #1 |
| local radiologist | #1 |
| patients tests prevalence | #1 |
| fxiaso enoxaparin | #1 |
| predefined outcomes vte | #1 |
| thrombophlebitis tomography | #1 |
| impedance thrombophlebitis | #1 |
| thrice daily gentamicin | #1 |
| scores riete score | #1 |
| combination ddimer testing | #1 |
| idraparinux vte | #1 |
| vte occurred | #1 |
| pulmonary embolism | #1 |
| failure rate efficiency | #1 |
| prophylaxis idraparinux | #1 |
| patients inherited thrombophilia | #1 |
| heparin survival | #1 |
| symptomatic recurrent | #1 |
| rivaroxaban acute dvt | #1 |
| presentation 1 week | #1 |
| fxainhibitors | #1 |
| clinical probability patients | #1 |
| preferred oral anticoagulant | #1 |
| longhaul flight | #1 |
| outcome clinically | #1 |
| influenza case patients | #1 |
| idraparinux months | #1 |
| method factor | #1 |
| probability lung scan | #1 |
| tomography angiography vte | #1 |
| standard therapy rivaroxaban | #1 |
| casedescription | #1 |
| ccus 4 | #1 |
| ili score | #1 |
| heparin org 10172 | #1 |
| d‐dimer test | #1 |
| cancer cdr | #1 |
| cus strategies | #1 |
| edoxaban risk factors | #1 |
| fetal loss stillbirth | #1 |
| netherlands vka | #1 |
| pulmonary embolism metaanalysis | #1 |
| embolism suspected | #1 |
| messages justification | #1 |
| duration heparin treatment | #1 |
| pioped study study | #1 |
| patients reduceddose noacs | #1 |
| placebo rnapc2 | #1 |
| edoxaban east asian | #1 |
| double reports | #1 |
| compression ultrasound dvt | #1 |
| women edoxaban | #1 |
| clinical probability risk | #1 |
| doac recipients | #1 |
| infections gentamicin | #1 |
| hemorrhage heparin | #1 |
| alternative diagnoses patients | #1 |
| 250 patients cancer | #1 |
| leg veins patients | #1 |
| desogestrelcontaining coagulation factors | #1 |
| normal ddimer result | #1 |
| heparin initial treatment | #1 |
| dvt 69 | #1 |
| 3 idraparinux | #1 |
| doacs cirrhosis patients | #1 |
| patients antithrombotic prescriptions | #1 |
| timerequirement | #1 |
| revascularisation procedures patients | #1 |
| idraparinux placebo | #1 |
| lmwh departments | #1 |
| guideline adherence justification | #1 |
| dvt symptomatic | #1 |
| adjunct thrombolysis | #1 |
| relatives antithrombin | #1 |
| cstatistic model discrimination | #1 |
| uesvt uedvt | #1 |
| abelacimab | #1 |
| variable d‐dimer thresholds | #1 |
| idraparinux standard therapy | #1 |
| vitamin antagonists treatment | #1 |
| patients normal tests | #1 |
| reduceddose noacs stroke | #1 |
| axa activity 5 | #1 |
| 5 years lmwh | #1 |
| consensus strategy strategy | #1 |
| positive vte | #1 |
| coagulation fibrinolytic proteins | #1 |
| cancer patients patients | #1 |
| survival lmwh | #1 |
| patients malignancy | #1 |
| uesvt recurrent vte | #1 |
| probability normal | #1 |
| pvoq | #1 |
| abnormal vaginal bleeding | #1 |
| fviii women | #1 |
| strategy abdominal pelvic | #1 |
| thrombosis vte | #1 |
| perelated death classification | #1 |
| rabinovpaulin | #1 |
| rule exclusion | #1 |
| relative risks carriers | #1 |
| calfvein thrombi | #1 |
| bleeding rates quality | #1 |
| 3 rfviia | #1 |
| obese hemophilic patients | #1 |
| vte location | #1 |
| initial treatment patients | #1 |
| pulmonary embolism role | #1 |
| 500 org | #1 |
| vkas lmwh | #1 |
| vivo coagulation factor | #1 |
| distal clots | #1 |
| principal safety | #1 |
| unexplained dvt | #1 |
| 750 μg l1 | #1 |
| original wells | #1 |
| subcutaneous nadroparin placebo | #1 |
| 36 papers | #1 |
| 3633 patients edoxabantreated | #1 |
| ufh grade 1a | #1 |
| rivaroxaban standard therapy | #1 |
| ventricular dysfunction edoxaban | #1 |
| chromogenic endotoxin | #1 |
| lmwh delivery | #1 |
| patients examiner | #1 |
| cdr dimer | #1 |
| enoxaparin tb402 | #1 |
| recurrent vte doacs | #1 |
| safety 60 dose | #1 |
| efficacy conventional treatment | #1 |
| khorana | #1 |
| aptt org 10172 | #1 |
| protein mortality | #1 |
| previous surveys netherlands | #1 |
| current comprehensions | #1 |
| pulmonary embolism studies | #1 |
| progression svt | #1 |
| 123362 | #1 |
| constans score | #1 |
| travel venous thromboembolism | #1 |
| probability ventilation | #1 |
| edoxaban cancer patients | #1 |
| advanced malignancy | #1 |
| thrombophilic defects risk | #2 |
| quality warfarin treatment | #2 |
| vein compressibility | #2 |
| suspected pulmonary embolism | #2 |
| ufh 6 months | #2 |
| warfarintreated | #2 |
| major bleeding edoxaban | #2 |
| inflammation neutrophils thrombosis | #2 |
| efficiency strategy | #2 |
| nct00633893 | #2 |
| normal ddimer test | #2 |
| clinical pretest probability | #2 |
| primary efficacy outcome | #2 |
| raskob | #2 |
| events severe | #2 |
| score dimer | #2 |
| enoxaparin difference | #2 |
| efficiency diagnostic strategies | #2 |
| major clinically | #2 |
| embolism deep | #2 |
| regression pravastatin | #2 |
| composite scores area | #2 |
| sspe patients patients | #2 |
| rule proportion | #2 |
| hokusai vte | #2 |
| patients abi measurement | #2 |
| clinically suspected | #2 |
| decision rule | #2 |
| absolute incidence | #2 |
| hokusai vtecancer study | #2 |
| euro138 | #2 |
| gauge plethysmography | #2 |
| exclusion pulmonary embolism | #2 |
| impedance plethysmography diagnosis | #2 |
| limits cancer | #2 |
| f5 r506q | #2 |
| mutations propeptide | #2 |
| ddimer assay | #2 |
| years 36 | #2 |
| heparin nadroparin | #2 |
| mutations cleavage sites | #2 |
| protein rnapc2 | #2 |
| primary hospitalbased strategies | #2 |
| healthcare settings findings | #2 |
| nematode anticoagulant | #2 |
| thrombosis normal | #2 |
| pentasaccharide fondaparinux | #2 |
| major bleeding recurrent | #2 |
| incidence recurrent | #2 |
| pravastatin therapy children | #2 |
| vte svt | #2 |
| thyroid hormone coagulation | #2 |
| recurrent deep | #2 |
| gcpg | #2 |
| fvl carriers carriers | #2 |
| performance constans rule | #2 |
| influenza coagulation | #2 |
| hospitalbased strategies | #2 |
| tinaquant vidas | #2 |
| plasma d‐dimer concentration | #2 |
| secondary efficiency | #2 |
| safety pravastatin therapy | #2 |
| 95 cancer patients | #2 |
| standardised time intervals | #2 |
| influenza prothrombotic state | #2 |
| fibrinolytic proteins | #2 |
| treatment deep | #2 |
| hasbled score hemorr2hages | #2 |
| lower clinical utility | #2 |
| crd42017056309 | #2 |
| 8 wk risk | #2 |
| factor iia | #2 |
| n832 | #2 |
| treated anticoagulants | #2 |
| levothyroxine exposure | #2 |
| adapted ddimer thresholds | #2 |
| subcutaneous length | #2 |
| plasmin activity inhibition | #2 |
| alife study | #2 |
| model cancer patients | #2 |
| patients peripheral graft | #2 |
| thromboembolism thrombophilia | #2 |
| pulmonary embolism purpose | #2 |
| vte elevated fviii | #2 |
| cancer addition | #2 |
| incidental venous | #2 |
| oral direct inhibitors | #2 |
| cdr variables cdr | #2 |
| diagnostic lung | #2 |
| rule combined | #2 |
| age‐adjusted d‐dimer testing | #2 |
| received edoxaban | #2 |
| incidental vte | #2 |
| endotoxininduced activation coagulation | #2 |
| venous thromboembolism enoxaparin | #2 |
| treated edoxaban | #2 |
| ddimer determination | #2 |
| major bleeding cindexes | #2 |
| uedvt efficiency | #2 |
| resource utilisation treatment | #2 |
| prothrombin pulmonary embolism | #2 |
| rivaroxaban 30 bid | #2 |
| thrombophilic disorders | #2 |
| comparator individuals 95 | #2 |
| duration anticoagulant | #2 |
| crnm bleeds | #2 |
| 17 apixaban | #2 |
| vte 12 | #2 |
| 95 comparator individuals | #2 |
| subsegmental emboli | #2 |
| extended constans score | #2 |
| coagulation fibrinolytic | #2 |
| arterial thrombotic disease | #2 |
| compression doppler | #2 |
| vitamin antagonist rivaroxaban | #2 |
| suspected pulmonary | #2 |
| ageadjusted ddimer testing | #2 |
| pregnancy coc | #2 |
| surgical casts | #2 |
| heparin treatment influenza | #2 |
| pharmacological strategies | #2 |
| prolactin relation | #2 |
| annual incidences | #2 |
| treatment ttr | #2 |
| months 25 | #2 |
| medscape | #2 |
| low‐molecular‐weight heparin | #2 |
| cdr wells cdr | #2 |
| ufh survival | #2 |
| 95 dvt | #2 |
| idraparinux vitamin | #2 |
| heparin effective | #2 |
| undiagnosed malignancy | #2 |
| travel venous | #2 |
| major bleeding intermediate | #2 |
| bleeding occurred | #2 |
| duration anticoagulant treatment | #2 |
| vitamin antagonists quality | #2 |
| lmwh efficacy | #2 |
| interleukin‐10 response | #2 |
| hemorr2hages atria scores | #2 |
| risk anticoagulation therapy | #2 |
| recombinant hirudin cgp | #2 |
| antagonists vka | #2 |
| patients hemorr2hages | #2 |
| coumarin sensitivity | #2 |
| impedance plethysmography patients | #2 |
| enoxaparin warfarin | #2 |
| fibrinolysis influenza | #2 |
| uedvt performance | #2 |
| sustained antithrombotic | #2 |
| serum tnf activity | #2 |
| mdct reference standard | #2 |
| efficiency original score | #2 |
| computerized impedance | #2 |
| amadeus study | #2 |
| hmb primary outcome | #2 |
| exposure flights | #2 |
| brain metastases doacs | #2 |
| dimer thresholds | #2 |
| venous | #2 |
| heparin administered | #2 |
| angioplasty clopidogrel | #2 |
| acquired antithrombin | #2 |
| blood coagulation inhibition | #2 |
| apixaban lmwh vka | #2 |
| secondary strategies | #2 |
| patients prior vte | #2 |
| clinical probability estimate | #2 |
| rivaroxaban thiazoles | #2 |
| 6 months scores | #2 |
| c1173t dimorphism | #2 |
| statins recurrent vte | #2 |
| women therapeutic doses | #2 |
| ultrasonography patients | #2 |
| patients oral factor | #2 |
| deficiencies proteins | #2 |
| concomitant thrombophilic | #2 |
| sr34006 | #2 |
| measurement ankle brachial | #2 |
| 8292 patients | #2 |
| negative ageadjusted ddimer | #2 |
| blood coagulation rnapc2 | #2 |
| hyperglycemia diagnosis | #2 |
| patients low probability | #2 |
| global public awareness | #2 |
| relation coagulation factors | #2 |
| vte orthopedic surgery | #2 |
| embolism primary | #2 |
| pregnancy venous thrombosis | #2 |
| beta‐receptor blockade | #2 |
| graft occlusion patients | #2 |
| venous thrombophlebitis | #2 |
| common alternative diagnoses | #2 |
| embolism safely | #2 |
| normohomocysteinemic relatives | #2 |
| nonpermanent heart failure | #2 |
| central localization | #2 |
| anticoagulated patients permanent | #2 |
| simplified wells | #2 |
| primary healthcare secondary | #2 |
| lmwh users | #2 |
| n1423 | #2 |
| uptake noacs | #2 |
| current clinical challenges | #2 |
| apixaban enoxaparin warfarin | #2 |
| test cancer | #2 |
| computed venous | #2 |
| khorana protecht | #2 |
| employees longhaul flight | #2 |
| wells cdr cdr | #2 |
| bleeding edoxaban | #2 |
| ate cancer patients | #2 |
| biomarkers casecontrol studies | #2 |
| single administration tb402 | #2 |
| wells cdr patients | #2 |
| rfviia injection rfviia | #2 |
| risk deep | #2 |
| 3306 patients | #2 |
| rnapc2 doses | #2 |
| lowmolecularweight heparin women | #2 |
| outcome symptomatic | #2 |
| venographically | #2 |
| relevant patient subgroups | #2 |
| patients khorana score | #2 |
| uedvt cancer patients | #2 |
| 95 0·2 | #2 |
| presentation dvt | #2 |
| rnapc2 | #2 |
| symptomatic outpatients | #2 |
| coagulation factors prolactin | #2 |
| clinical prediction model | #2 |
| risk khorana | #2 |
| pulmonary embolism efficacy | #2 |
| analysis venous | #2 |
| vidas assay | #2 |
| principal safety outcome | #2 |
| pulmonary embolism asthma | #2 |
| administration rviia | #2 |
| referred patients secondary | #2 |
| heparin compounds | #2 |
| mutation 35 | #2 |
| exclude pulmonary | #2 |
| recurrent vte risk | #2 |
| vte 1000 personyears | #2 |
| 20210a mutations | #2 |
| mild risk factor | #2 |
| screening fvl | #2 |
| recombinant nematode | #2 |
| fibrinolysis pentoxifylline | #2 |
| failure rate strategy | #2 |
| scan normal | #2 |
| hellp syndrome prevalence | #2 |
| endogenous activated protein | #2 |
| intrinsic cascade | #2 |
| cancer recurrent vte | #2 |
| amuse strategy | #2 |
| ventilation scanning | #2 |
| fviii increased risk | #2 |
| simplired test | #2 |
| bleeding complications treatment | #2 |
| thromboinflammation cardiovascular disease | #2 |
| bleeding rate patients | #2 |
| levels coagulation factors | #2 |
| life treatment duration | #2 |
| recurrence thromboembolism | #2 |
| cha2ds2vasc nri | #2 |
| death vte | #2 |
| suspected upper | #2 |
| plasma concentrations endotoxin | #2 |
| intermediate phenotype vte | #2 |
| ddimer threshold | #3 |
| activecontrol | #3 |
| venous thromboembolism apixaban | #3 |
| einstein patients | #3 |
| primary rule | #3 |
| cancer patients ate | #3 |
| older children vte | #3 |
| dimer blood | #3 |
| prevalence avws | #3 |
| 6575 years | #3 |
| thromboembolism low | #3 |
| rnapc2 fviia | #3 |
| normal ctnt presentation | #3 |
| studies cus strategies | #3 |
| placebo n4 | #3 |
| normal result | #3 |
| predictable pharmacokinetics | #3 |
| composite stroke | #3 |
| safely excluded | #3 |
| enoxaparin follow | #3 |
| patients 6 months | #3 |
| compensated dic | #3 |
| capillary blood sample | #3 |
| recurrence thrombophlebitis | #3 |
| 02011 | #3 |
| 100 years year | #3 |
| dvt systematic differences | #3 |
| thromboembolism background | #3 |
| presenting location | #3 |
| heparins cancer | #3 |
| outpatients dvt | #3 |
| dalteparin difference | #3 |
| outpatient treatment dvt | #3 |
| nadroparin placebo | #3 |
| efficacy heparin | #3 |
| vte venous thrombosis | #3 |
| pph lmwh | #3 |
| treatment lowmolecularweight heparin | #3 |
| patients venography | #3 |
| einstein studies | #3 |
| einstein dvt | #3 |
| standard therapy treatment | #3 |
| subcutaneous fondaparinux | #3 |
| apc protective | #3 |
| vte low | #3 |
| diagnosis pulmonary | #3 |
| 3month incidence | #3 |
| multiple comorbidities polypharmacy | #3 |
| administration rnapc2 | #3 |
| pulmonary embolism‐related death | #3 |
| warfarin subgroup | #3 |
| subcutaneous lmwh | #3 |
| dvt primary | #3 |
| lowmolecularweight heparin placebo | #3 |
| embolism‐related | #3 |
| intravenous loading dose | #3 |
| patients venous | #3 |
| healthy donor fmt | #3 |
| diagnosis deep | #3 |
| mechanisms heparin | #3 |
| safely exclude | #3 |
| plethysmography impedance | #3 |
| deep vein | #3 |
| selectine | #3 |
| discontinuation ufh | #3 |
| low probability models | #3 |
| pad smokers | #3 |
| patients 6575 years | #3 |
| venous thrombosis positive | #3 |
| impedance predictive | #3 |
| patients proximalvein thrombosis | #3 |
| heparin edoxaban | #3 |
| safety acenocoumarol | #3 |
| factors prothrombin | #3 |
| introduction mdct | #3 |
| idiopathic venous | #3 |
| ctnt risk stratification | #3 |
| atria hemorr2hages | #3 |
| oral hormonal cross | #3 |
| dip placebo | #3 |
| ddimer assays | #3 |
| hasbled | #3 |
| protein thrombophilia | #3 |
| treatment vte recurrence | #3 |
| pulmonary embolism gestalt | #3 |
| ventilation scan | #3 |
| approaches primary | #3 |
| lmwh pph | #3 |
| knee factor | #3 |
| cardiac troponine | #3 |
| clinical models patients | #3 |
| 3month vte incidence | #3 |
| influence heparins | #3 |
| users incidence | #3 |
| pulmonary embolism primary | #3 |
| therapy venous | #3 |
| “gestalt | #3 |
| alternative diagnoses | #3 |
| dose reduction edoxaban | #3 |
| vte 3 | #3 |
| vte major burden | #3 |
| sensitivity compression | #3 |
| platelet agents | #3 |
| gestalt probability | #3 |
| incidental pulmonary embolism | #3 |
| dvt einstein | #3 |
| desogestrelcontaining | #3 |
| recombinant hirudin rhir | #3 |
| treatment vka | #3 |
| favour lmwh | #3 |
| monoclonal replacement | #3 |
| proximalvein thrombosis | #3 |
| venous thromboembolism | #3 |
| products follow | #3 |
| definition perelated death | #3 |
| factor viiic | #3 |
| cdr combination | #3 |
| tb‐402 | #3 |
| recurrent thromboembolic | #3 |
| thombosis | #3 |
| prevalence hemostatic abnormalities | #3 |
| ultrasonography strategies | #3 |
| vte performance | #3 |
| crt cancer patients | #3 |
| cohort study employees | #3 |
| iii deficiency | #3 |
| patients ft4 level | #3 |
| vte denmark | #3 |
| antithrombin iii concentrate | #3 |
| coagulation air travel | #3 |
| idrabiotaparinux warfarin | #3 |
| ipe cancer patients | #3 |
| bleeding 3 | #3 |
| inhibition blood coagulation | #3 |
| cancer randomised trials | #3 |
| female hemorrhage humans | #3 |
| probability dimer | #3 |
| wells rule gestalt | #3 |
| stable acute | #3 |
| coagulation influence | #3 |
| tfindependent | #3 |
| safely | #3 |
| gestalt 95 | #3 |
| lowmolecularweight humans length | #3 |
| time venous thrombosis | #3 |
| diagnosis pulmonary embolism | #3 |
| revised geneva efficiency | #3 |
| idrabiotaparinux | #3 |
| mutation venous | #3 |
| patients incidental vte | #3 |
| studies hemorrhage | #3 |
| incidence total vte | #3 |
| venous thrombosis cancer | #3 |
| axa activity | #3 |
| thiophenes venous | #3 |
| thrombophilic defect | #3 |
| negative predictive proportion | #3 |
| topic heparin heparin | #3 |
| fxiaso | #3 |
| age annual incidence | #3 |
| lmwh | #3 |
| simplified wells specificity | #3 |
| chemotherapy prophylaxis | #3 |
| primary wells rule | #3 |
| prolactin controls | #3 |
| strategies efficiency | #3 |
| dvt hip | #3 |
| outcome venous | #3 |
| travel venous thrombosis | #3 |
| patients ultrasonography | #3 |
| cancer active cancer | #3 |
| adult patients vte | #3 |
| 95 wells rule | #3 |
| thrombophlebitis treatment | #3 |
| 12month study period | #3 |
| wells rule dvt | #3 |
| patients gastrointestinal cancer | #3 |
| ft4 risk | #3 |
| patients wells | #3 |
| single diagnostic | #3 |
| nct00643201 | #3 |
| endogenous apc | #3 |
| svt vte | #3 |
| death clinical studies | #3 |
| failurerate | #3 |
| female humans inhibitors | #3 |
| extensive screening | #3 |
| tinaquant assay | #3 |
| heparin heparin | #3 |
| baseline values placebo | #3 |
| dvt major | #3 |
| hf severity risk | #3 |
| vein thrombosis | #3 |
| pulmonary embolism models | #3 |
| bleeding major | #3 |
| cancer patients ipe | #3 |
| detection dvt | #3 |
| incidence enoxaparin | #3 |
| treatment low | #3 |
| hokusai‐vte | #3 |
| 20210ga | #3 |
| combination wells score | #3 |
| 3633 patients | #3 |
| venous arterial | #3 |
| venous thrombosis travel | #3 |
| treatment vitamin antagonists | #3 |
| venous thromboembolism thrombophilia | #3 |
| thrombosis symptomatic | #4 |
| thrombosis ischemic stroke | #4 |
| apixaban efficacy | #4 |
| coagulation endotoxin | #4 |
| venography patients | #4 |
| vka treatment | #4 |
| noacs cancer patients | #4 |
| vitamin antagonists patients | #4 |
| patients submassive | #4 |
| embolism roc | #4 |
| cancer vwf | #4 |
| tinaquant | #4 |
| contraindications treatment | #4 |
| idiopathic venous thrombosis | #4 |
| edoxaban patients | #4 |
| dutch orthopedic | #4 |
| enoxaparin day | #4 |
| levels ft4 | #4 |
| sankyo | #4 |
| rviia thrombin generation | #4 |
| netherlands pulmonary | #4 |
| thrombophilia 95 | #4 |
| doac studies | #4 |
| diagnosis uedvt | #4 |
| daily netilmicin | #4 |
| vte netherlands | #4 |
| patients clinically | #4 |
| chinese korean ethnicity | #4 |
| 150 microg desogestrel | #4 |
| ageadjusted cutoff patients | #4 |
| clot resolution | #4 |
| chromogenic compounds | #4 |
| treatment unfractionated heparin | #4 |
| thrombosis uedvt | #4 |
| serial impedance | #4 |
| 35±4 | #4 |
| patients venous thromboembolism | #4 |
| lowmolecularweight heparin | #4 |
| vte global | #4 |
| chemotherapy shr | #4 |
| thrombosis air | #4 |
| lmwh cancer patients | #4 |
| women normal levels | #4 |
| point dimer | #4 |
| rivaroxaban 20 | #4 |
| embolism tomography | #4 |
| ultrasonography venous | #4 |
| embolism dimer | #4 |
| questionnaires venous | #4 |
| prophylaxis lmwh | #4 |
| estrogen therapy patients | #4 |
| disease vte | #4 |
| risk vkas | #4 |
| global burden vte | #4 |
| amadeus trial | #4 |
| safety pravastatin | #4 |
| coagulation factors risk | #4 |
| vte global burden | #4 |
| symptomatic deep | #4 |
| episode venous | #4 |
| proximal patients | #4 |
| vte highincome countries | #4 |
| preexisting heparin | #4 |
| primary failure rate | #4 |
| dose noacs | #4 |
| patient education treatment | #4 |
| “reversal | #4 |
| patients alternative diagnosis | #4 |
| diagnostic management | #4 |
| gramnegative bacteria humans | #4 |
| patients nonpermanent | #4 |
| thromboembolism treatment | #4 |
| chads2 p0001 | #4 |
| 10172 | #4 |
| criteria dose reduction | #4 |
| probability prospective | #4 |
| dimer assays | #4 |
| vitamin antagonists | #4 |
| rfviia injection | #4 |
| hemorr2hages | #4 |
| recurrent vte months | #4 |
| mbe patients | #4 |
| 150 microg levonorgestrel | #4 |
| 0651 | #4 |
| hemostatic profile | #4 |
| fibrin generation test | #4 |
| diagnostic management strategies | #4 |
| nct00571649 | #4 |
| 3587 | #4 |
| clot lysis patients | #4 |
| received warfarin | #4 |
| arterial thrombotic | #4 |
| abdomen relationship | #4 |
| serial impedance plethysmography | #4 |
| measurement abi | #4 |
| chemotherapy vte prophylaxis | #4 |
| risk occult cancer | #4 |
| enoxaparin female humans | #4 |
| total vte | #4 |
| warfarin 3 months | #4 |
| hyperhomocysteinemic relatives | #4 |
| population rivaroxaban | #4 |
| bleeding anticoagulants | #4 |
| thromboembolism factor | #4 |
| rule pulmonary | #4 |
| vte treatment patients | #4 |
| predilution postdilution | #4 |
| thrombosis deep | #4 |
| primary pulmonary embolism | #4 |
| thromboembolism vitamin | #4 |
| procoagulant factors | #4 |
| life duration | #4 |
| 6 months prophylaxis | #4 |
| extended treatment | #4 |
| venous thrombosis levels | #4 |
| control anticoagulation | #4 |
| patient category | #4 |
| thromboembolism arterial | #4 |
| women apc resistance | #4 |
| noacs netherlands | #4 |
| disease burden vte | #4 |
| thromboembolism systematic | #4 |
| patients primary healthcare | #4 |
| embolism background | #4 |
| protecht | #4 |
| cleavage sites apc | #4 |
| refuted | #4 |
| 335 patients | #4 |
| impedance plethysmography | #4 |
| postthrombotic symptoms | #4 |
| pregnancies carriers | #4 |
| travel thrombosis | #4 |
| patients fondaparinux | #4 |
| vitamin antagonist treatment | #4 |
| death survey | #4 |
| series venograms | #4 |
| lmwhs standard heparin | #4 |
| oral rivaroxaban | #4 |
| lmwh female heparin | #4 |
| vte total | #4 |
| patients dimer | #4 |
| lowmolecular weight heparins | #4 |
| leiden carriers | #4 |
| thrombophilic families | #4 |
| global disease burden | #4 |
| thromboembolism occurred | #4 |
| patients edoxaban | #4 |
| advanced cancer 95 | #4 |
| ddimer assay patients | #4 |
| negative point | #4 |
| venous thromboembolism patients | #4 |
| clinically relevant bleeding | #4 |
| patients crcl 60 | #4 |
| activation fibrinolytic | #4 |
| thromboembolism study | #4 |
| diagnostic prediction models | #4 |
| 2 rules | #5 |
| thromboembolism | #5 |
| antithrombotic drug treatment | #5 |
| lmwh incidence | #5 |
| consensus strategy | #5 |
| factor leiden 95 | #5 |
| thromboembolism thrombosis | #5 |
| risk prediction scores | #5 |
| low molecularweight humans | #5 |
| patients recurrent dvt | #5 |
| outcome major | #5 |
| 8292 | #5 |
| ventricular dysfunction echocardiography | #5 |
| treatment acute dvt | #5 |
| thrombosis leg | #5 |
| clinical probability | #5 |
| thrombosis upper | #5 |
| fviia rnapc2 | #5 |
| bleeding cancer | #5 |
| venous thromboembolism studies | #5 |
| women warfarin | #5 |
| burden vte | #5 |
| patients pulmonary embolism | #5 |
| pulmonary embolism patients | #5 |
| compression ultrasound | #5 |
| 8491 | #5 |
| isolated calfvein thrombosis | #5 |
| treatment fondaparinux | #5 |
| thrombophlebitis ultrasonography | #5 |
| ft4 level | #5 |
| molecularweight heparin | #5 |
| patients parenteral anticoagulants | #5 |
| thromboembolism studies | #5 |
| cgp 39393 | #5 |
| vte patients cancer | #5 |
| diagnosis questionnaire | #5 |
| coronary angioplasty angioplasty | #5 |
| thromboembolism idraparinux | #5 |
| suspected uedvt | #5 |
| pregnancy pph | #5 |
| secondary venous thrombosis | #5 |
| preschool contraceptives | #5 |
| netilmicin patients | #5 |
| repeated ultrasonography | #5 |
| inhibition plasminogen activation | #5 |
| adjusted dimer | #5 |
| severe pph women | #5 |
| endogenous activated | #5 |
| coc pregnancy | #5 |
| efficiency patients | #5 |
| deepvein thrombosis | #5 |
| fviii families | #5 |
| patients subtherapeutic | #5 |
| previous venous thromboembolism | #5 |
| patients wells score | #5 |
| thrombosis primary | #5 |
| diagnostic strategies | #5 |
| patients superficial thrombophlebitis | #5 |
| cdr patients | #5 |
| fh patients cvd | #5 |
| clinical presentation clinical | #5 |
| vte factor | #5 |
| pad smoking | #5 |
| medea study | #5 |
| hirudin treatment | #5 |
| specificity thrombophlebitis | #5 |
| low‐molecular‐weight | #5 |
| elevated plasma level | #5 |
| endotoxin chimpanzees | #5 |
| dvt prevalence | #5 |
| rivaroxaban enoxaparin vka | #5 |
| dimer combination | #5 |
| panwards | #5 |
| clinical probability assessment | #5 |
| predilution | #5 |
| phlebography plethysmography | #5 |
| daiichi sankyo | #5 |
| embolism reproducibility | #5 |
| vka patients | #5 |
| endotoxin testing | #5 |
| secondary dvt | #5 |
| recurrent dvt patients | #5 |
| day rivaroxaban | #5 |
| sensitivity negative predictive | #5 |
| heparin compared | #5 |
| outpatients hospital | #5 |
| lmwh recommended | #5 |
| asymptomatic carriers mutation | #5 |
| iii plasminogen | #5 |
| incidence prognostic significance | #5 |
| exclusion venous thromboembolism | #5 |
| upper extremity thrombosis | #5 |
| vte 6 | #5 |
| normal ctpa | #5 |
| cancer strategy | #5 |
| transfusion blood loss | #5 |
| hokusai | #5 |
| gestalt | #5 |
| southern latin america | #5 |
| symptoms intermittent claudication | #6 |
| patients suspected | #6 |
| 39393 | #6 |
| subcutaneous low | #6 |
| risk khorana score | #6 |
| edoxaban efficacy | #6 |
| apixaban treatment dose | #6 |
| vte anticoagulant treatment | #6 |
| daily gentamicin | #6 |
| vka | #6 |
| conventional therapy treatment | #6 |
| treatment ufh | #6 |
| svt extension | #6 |
| subcutaneous nadroparin | #6 |
| lmwh users users | #6 |
| venograms | #6 |
| patients tests | #6 |
| clinically relevant subgroups | #6 |
| anticoagulants female | #6 |
| treatment pulmonary embolism | #6 |
| patients proximal | #6 |
| 049 95 | #6 |
| proportion cancer patients | #6 |
| vte controls | #6 |
| isolated deficiencies | #6 |
| 12month cumulative incidence | #6 |
| repeatedly normal | #6 |
| outcome occurred | #6 |
| factor leiden carriers | #6 |
| compression stockings patients | #6 |
| ft4 patients | #6 |
| women hyperhomocysteinemia | #6 |
| probability pulmonary | #6 |
| 10±4 | #6 |
| recurrent pulmonary | #6 |
| combined utility | #6 |
| d‐dimer testing | #6 |
| patients iohexol | #6 |
| standardized morbidity ratio | #6 |
| blood coagulation mechanism | #6 |
| treatment intermittent claudication | #6 |
| endotoxininduced activation | #6 |
| pembqol questionnaire | #6 |
| dimer cut | #6 |
| grade 1a ufh | #6 |
| arterial cardiovascular | #6 |
| severe dic | #6 |
| effects levonorgestrel | #6 |
| 393 patients | #6 |
| risk increasing levels | #6 |
| fviia inhibition | #6 |
| cancer primary patients | #6 |
| c1173 | #6 |
| neoplasms pulmonary embolism | #6 |
| funding bayer | #6 |
| patients pulmonary angiography | #6 |
| levonorgestrel desogestrel | #6 |
| initial heparin treatment | #6 |
| thrombophilic defects | #6 |
| rate major bleeding | #6 |
| wells rule | #6 |
| oral edoxaban | #6 |
| anticoagulant treatment | #6 |
| effects ufh | #6 |
| pulmonary embolism presence | #6 |
| efficiency proportion | #6 |
| patients diagnostic | #6 |
| synthetic pentasaccharides | #6 |
| symptomatic legs | #6 |
| stressinduced hyperglycaemia | #6 |
| oral anticoagulants dabigatran | #6 |
| antagonists treatment | #6 |
| dvt trial | #6 |
| patients factor mutation | #6 |
| selective beta | #6 |
| myocardial infarction ctni | #6 |
| thromboembolism bleeding | #6 |
| low absolute risk | #6 |
| severe antithrombin | #6 |
| dabigatran etexilate dabigatran | #6 |
| warfarin venous thromboembolism | #6 |
| patients lowmolecularweight heparin | #6 |
| prevalence vte | #6 |
| enoxaparin incidence | #6 |
| patients uedvt | #6 |
| dalteparin dose | #6 |
| treatment svt | #6 |
| patients anticoagulation clinic | #6 |
| anticoagulants hemorrhage | #6 |
| duration rivaroxaban | #6 |
| ultrasonography normal | #6 |
| leiden | #6 |
| elisapositive | #6 |
| lmwh cancer | #6 |
| perioperative blood loss | #6 |
| fixeddose regimen | #6 |
| vte cancer | #6 |
| embolism ventricular | #6 |
| amplify | #6 |
| thrombosis guidelines | #6 |
| endotoxin assays | #6 |
| simplired dimer | #6 |
| subjects vte | #6 |
| embolism pulmonary | #6 |
| assay fibrin | #6 |
| incidence recurrence | #6 |
| diagnostic workup | #6 |
| anticoagulant parameters | #7 |
| mpc1609 | #7 |
| diagnosis venous thrombosis | #7 |
| venous thrombosis treatment | #7 |
| treatment doac | #7 |
| unselected women | #7 |
| antithrombin protein | #7 |
| phenprocoumon polymorphism | #7 |
| patients standard heparin | #7 |
| ottawa score | #7 |
| vitamin antagonists vka | #7 |
| levels factor viii | #7 |
| relation prolactin levels | #7 |
| 597939 | #7 |
| tb402 | #7 |
| proportion older patients | #7 |
| factor female humans | #7 |
| presence cteph | #7 |
| primary efficacy | #7 |
| combination ipg | #7 |
| deepvein thrombosis patients | #7 |
| major bleeding | #7 |
| stockings control | #7 |
| thromboembolism total | #7 |
| embolism prospective | #7 |
| primary dvt | #7 |
| prothrombin risk | #7 |
| silent pulmonary embolism | #7 |
| leg ultrasonography | #7 |
| pulmonary embolism sensitivity | #7 |
| negative ddimer test | #7 |
| vka therapy | #7 |
| administration bsf | #7 |
| major bleeding vkas | #7 |
| negative predictive npv | #7 |
| nondiagnostic lung scans | #7 |
| coagulation humans | #7 |
| inhibitor apixaban | #7 |
| noncompressibility | #7 |
| day initial treatment | #7 |
| mutations factor viii | #7 |
| carriers venous thromboembolism | #7 |
| major bleeding rate | #7 |
| heparin org | #7 |
| 680 | #7 |
| thromboembolism vte | #7 |
| rates edoxaban | #7 |
| thrombophlebitis adolescent | #7 |
| thromboembolism adult | #7 |
| specific antidotes | #7 |
| recurrent dvt | #7 |
| relation levels | #7 |
| thrombophilia pregnancy loss | #7 |
| ufh treatment | #7 |
| doppler skin | #7 |
| arterial cardiovascular disease | #7 |
| lung scan | #7 |
| etexilate oral | #7 |
| dvt ipg | #7 |
| plasma levels ifngamma | #7 |
| neoplasms pulmonary | #7 |
| tnf injection | #7 |
| 220 dabigatran | #7 |
| diagnostic suspicion | #7 |
| vte cancer diagnosis | #7 |
| blood coagulation humans | #7 |
| statin treatment risk | #7 |
| incidence recurrent vte | #7 |
| general practitioners guideline | #7 |
| placebo rivaroxaban | #7 |
| aspirin combined | #7 |
| spiral sensitivity | #7 |
| perelated death | #7 |
| rivaroxaban 10 | #7 |
| protein protein deficiencies | #7 |
| carriers defects | #7 |
| v617f jak2 | #8 |
| optimal intensity | #8 |
| dimer concentration | #8 |
| proximal deepvein thrombosis | #8 |
| products humans | #8 |
| inr determination | #8 |
| euro55 | #8 |
| increased fibrinolytic | #8 |
| compression surveys | #8 |
| bnp ctnt | #8 |
| consecutive outpatients | #8 |
| vitamin antagonists vkas | #8 |
| ufh initial treatment | #8 |
| nondiagnostic scan | #8 |
| enoxaparin vka | #8 |
| probability lung | #8 |
| normal computed | #8 |
| homocysteine markers | #8 |
| wells scores | #8 |
| anticoagulation unprovoked vte | #8 |
| severe preeclampsia patients | #8 |
| 0·2 | #8 |
| current approach | #8 |
| aged phlebography | #8 |
| levonorgestrelcontaining | #8 |
| vte score | #8 |
| inr values patients | #8 |
| leiden prothrombin | #8 |
| dimer tests | #8 |
| thrombosis adolescent | #8 |
| nafronyl | #8 |
| p0001 hasbled score | #8 |
| low clinical probability | #8 |
| symptomatic deepvein thrombosis | #8 |
| contrast venography | #8 |
| proximal deep | #8 |
| lmwh grade 1a | #8 |
| oac adherence | #8 |
| tests pulmonary | #8 |
| thrombosis prophylaxis | #8 |
| treatment venous thrombosis | #8 |
| analysis apixaban | #8 |
| deficiency antithrombin | #8 |
| recurrent vte mb | #8 |
| recurrent vte bleeding | #8 |
| arg506 factor | #8 |
| administration low | #8 |
| vka lmwh | #8 |
| risks dvt | #8 |
| discontinuation anticoagulant treatment | #8 |
| anticoagulants antineoplastic | #8 |
| patients extended anticoagulation | #8 |
| 97 95 | #8 |
| prospective management | #8 |
| agnelli | #8 |
| carriers fvl | #8 |
| apixaban enoxaparin | #8 |
| point ultrasonography | #8 |
| testing rule | #8 |
| heparin vitamin antagonists | #8 |
| 1599 patients | #8 |
| cancer pulmonary embolism | #8 |
| acute symptomatic vte | #8 |
| unprovoked vte patients | #8 |
| occult cancer patients | #8 |
| years cumulative incidence | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| funding daiichi | #8 |
| risk employees | #8 |
| persistent risk factors | #8 |
| structured algorithm | #8 |
| overt cancer | #8 |
| prevention vte | #8 |
| patients excluded | #8 |
| comorbidity polypharmacy | #8 |
| pvoct | #8 |
| oral glucocorticoids risk | #8 |
| inherited thrombophilic | #8 |
| patients symptomatic vte | #8 |
| initial heparin | #8 |
| physicians stockings | #8 |
| ageadjusted ddimer cutoff | #8 |
| duration treatment | #8 |
| warfarin hazard ratio | #8 |
| chemotherapy low risk | #8 |
| 150 enoxaparin | #8 |
| objectively confirmed | #8 |
| xii deficient | #8 |
| fxi aso | #8 |
| vascular endothelial barrier | #8 |
| international organisations | #8 |
| oral apixaban | #8 |
| patients fxa inhibitors | #9 |
| cancer episode | #9 |
| thromboembolism cancer | #9 |
| vte rcts | #9 |
| ultrasonogram | #9 |
| compression stockings prevention | #9 |
| treatment prophylaxis | #9 |
| abnormal vaginal | #9 |
| thrombosis venous thromboembolism | #9 |
| therapeutic dose patients | #9 |
| atiii concentrates | #9 |
| heparin therapy patients | #9 |
| incidental pulmonary | #9 |
| lipoproteina women | #9 |
| apixaban oral factor | #9 |
| oral antithrombins | #9 |
| normal ddimer | #9 |
| comorbidities polypharmacy | #9 |
| independent committee | #9 |
| longterm treatment vte | #9 |
| major bleeding treatment | #9 |
| diagnosis mdct | #9 |
| bled bleeding | #9 |
| treatment edoxaban | #9 |
| büller | #9 |
| tafi levels | #9 |
| enoxaparin factor | #9 |
| lmwh mortality | #9 |
| oral contraceptive pregnancy | #9 |
| carriers factor leiden | #9 |
| iii concentrate | #9 |
| concomitant cancer | #9 |
| thrombosis thromboinflammation | #9 |
| cancer factor | #9 |
| anticoagulant pathways | #9 |
| hemorr2hages atria | #9 |
| factors thrombophlebitis | #9 |
| cancer cell extravasation | #9 |
| embolism venous | #9 |
| daiichisankyo | #9 |
| strategies dimer | #9 |
| male oligosaccharides | #9 |
| weight heparin | #9 |
| placebo plasma levels | #9 |
| cofact | #9 |
| postdilution | #9 |
| nonpermanent | #9 |
| diagnostic prediction model | #9 |
| edoxaban major bleeding | #9 |
| characteristics severity | #9 |
| acute medical illnesses | #9 |
| crcl 60 | #9 |
| generation pill | #9 |
| vte relatives | #9 |
| fxa inhibitor | #9 |
| fondaparinux cancer patients | #9 |
| method enoxaparin | #9 |
| patients active cancer | #9 |
| homocysteine women | #9 |
| prothrombin 20210a | #9 |
| incidence postthrombotic syndrome | #9 |
| discontinuing anticoagulation | #9 |
| months efficacy | #9 |
| thrombosis compared | #9 |
| serotonin platelet | #9 |
| combination stroke | #9 |
| crp test | #10 |
| cvd fh patients | #10 |
| 4470 | #10 |
| embolism clinical | #10 |
| anticoagulants | #10 |
| oral administration dabigatran | #10 |
| snp scores | #10 |
| thrombophlebitis adult | #10 |
| vnv | #10 |
| animal heparin | #10 |
| treatment vitamin | #10 |
| patients endotoxemia | #10 |
| probability pulmonary embolism | #10 |
| nadroparine | #10 |
| rfviia blood loss | #10 |
| rates recurrent vte | #10 |
| magellan study | #10 |
| retrospective study efficacy | #10 |
| injection avidin | #10 |
| heparin nomogram | #10 |
| fii mutation | #10 |
| pregnancy carriers | #10 |
| cus diagnosis | #10 |
| year years | #10 |
| ageadjusted cutoff | #10 |
| factor levels patients | #10 |
| ddimer concentration | #10 |
| inherited thrombophilic factors | #10 |
| deficiencies antithrombin | #10 |
| gramnegative septicemia | #10 |
| embolism patients | #10 |
| extremity deep | #10 |
| vte efficacy | #10 |
| incidence major bleeding | #10 |
| normohomocysteinemic | #10 |
| fondaparinux risk | #10 |
| bled scores | #10 |
| aged antithrombin | #10 |
| leg veins | #10 |
| simplified geneva | #10 |
| intimamedia thickness imt | #10 |
| thrombosis background | #10 |
| incidence 1000 personyears | #10 |
| major bleeding crnmb | #10 |
| subcutaneous metaanalysis | #10 |
| 100 years discontinuation | #10 |
| venous thromboembolic event | #10 |
| lmwh studies | #10 |
| dvt lower extremity | #10 |
| wells | #10 |
| thr incidence | #10 |
| factor prevention | #10 |
| venous thrombosis | #10 |
| cancer patients lmwh | #10 |
| oral thrombin inhibitor | #10 |
| severity clinical | #10 |
| inr cases | #10 |
| 598 patients | #10 |
| rabbits administration | #10 |
| protein dic | #10 |
| treatment aprotinin | #10 |
| patients venous thrombosis | #10 |
| schedule heparin | #10 |
| single loss | #10 |
| cancer patients vte | #10 |
| induced coagulation | #10 |
| treatment uedvt | #10 |
| 1215 patients | #10 |
| hypocoagulable state | #10 |
| asymptomatic pulmonary embolism | #10 |
| magellan trial | #10 |
| sulfates dermatan | #11 |
| dvt | #11 |
| crnmb 95 | #11 |
| dabigatran enoxaparin | #11 |
| mutations prevalence | #11 |
| knee clinical trials | #11 |
| pyridines thiazoles | #11 |
| vte vwf | #11 |
| pulmonary angiography venography | #11 |
| intensity anticoagulation | #11 |
| adult anticoagulants | #11 |
| haemophilia vwd | #11 |
| edoxaban | #11 |
| ldfr | #11 |
| endotoxin pentoxifylline | #11 |
| screening cancer | #11 |
| oral dabigatran | #11 |
| combination dimer | #11 |
| incidence major | #11 |
| patients cancer vte | #11 |
| 880 patients | #11 |
| air travel | #11 |
| lmwh pregnancies | #11 |
| endotoxin assay | #11 |
| hospital lmwh | #11 |
| carriers factor | #11 |
| 750 μg | #11 |
| weight humans | #11 |
| fondaparinux hemorrhage | #11 |
| d‐dimer levels | #11 |
| clinical pretest | #11 |
| lmwh pregnancy | #11 |
| embolism recurrence | #11 |
| inhibitors hemorrhage | #11 |
| recombinant human tnf | #11 |
| heparinoid org | #11 |
| medical conferences | #11 |
| thromboembolism major | #11 |
| cancer patients evidence | #11 |
| pcc dabigatran | #11 |
| levels prolactin | #11 |
| patients anticoagulant treatment | #11 |
| embolism prevalence | #11 |
| pregnancyrelated complications | #11 |
| reference testing | #11 |
| patients probability | #11 |
| variation inr | #11 |
| pulmonary embolism incidence | #11 |
| gps training | #11 |
| ufh studies | #11 |
| patients cvcs | #11 |
| factor venous | #11 |
| gentamicin treatment patients | #11 |
| 30 microg ethinylestradiol | #11 |
| org 10172 | #11 |
| cancer patients dvt | #11 |
| previous venous | #11 |
| topic venous | #12 |
| thrombin generation fibrinolysis | #12 |
| outpatient management patients | #12 |
| factor leiden prothrombin | #12 |
| risk venous | #12 |
| safety efficiency | #12 |
| observation risk | #12 |
| thrombophilic | #12 |
| bayer schering pharma | #12 |
| geneva score | #12 |
| dvt treatment | #12 |
| doseadjustment | #12 |
| livebirth rate | #12 |
| nephro | #12 |
| 72 children | #12 |
| warfarin treated | #12 |
| pioped study | #12 |
| crd42013003526 | #12 |
| venous thromboembolism incidence | #12 |
| perelated | #12 |
| hirulog1 | #12 |
| anticoagulant factor | #12 |
| fondaparinux unfractionated heparin | #12 |
| event recurrence | #12 |
| bnp cardiac troponin | #12 |
| patients incidental | #12 |
| concomitant disorders | #12 |
| anticoagulation unprovoked | #12 |
| prevention venous thrombosis | #12 |
| annual incidence vte | #12 |
| patients lupus anticoagulant | #12 |
| proximal vein | #12 |
| female heparin humans | #12 |
| warfarin recurrent vte | #12 |
| noacs vka | #12 |
| recurrent vte anticoagulation | #12 |
| vka noacs | #12 |
| months primary | #12 |
| recurrent vte | #12 |
| women factor | #12 |
| outcomes venous thromboembolism | #12 |
| humanized arthroplasty | #12 |
| paulin | #12 |
| treatment crt | #12 |
| subsegmental pulmonary emboli | #12 |
| patients lmwhs | #12 |
| hemodynamically stable | #12 |
| control metaanalysis | #12 |
| vte recurrence risk | #12 |
| deficient women | #12 |
| warfarin therapy inr | #12 |
| peghirudin | #12 |
| ageadjusted ddimer | #12 |
| proximal veins | #12 |
| thrombosis dvt | #12 |
| 9295 | #12 |
| stopping anticoagulation | #12 |
| 9702 | #12 |
| 95 carriers | #13 |
| thrombosis young | #13 |
| bleeding events edoxaban | #13 |
| plethysmograms | #13 |
| obesity haemophilia patients | #13 |
| heparin low | #13 |
| antithrombin iii activity | #13 |
| dimer testing | #13 |
| vte recurrence 95 | #13 |
| groups inr | #13 |
| vte 64 | #13 |
| dabigatran 220 | #13 |
| patients thrombophilia | #13 |
| inhibition tnf | #13 |
| association venous thrombosis | #13 |
| safety oral | #13 |
| conventional anticoagulants | #13 |
| clinical decision rules | #13 |
| vte female humans | #13 |
| bayer healthcare | #13 |
| arterial thromboembolism ate | #13 |
| continuous intravenous heparin | #13 |
| strain gauge plethysmography | #13 |
| pselectin patients | #13 |
| deepvein thrombosis dvt | #13 |
| dabigatran vte | #13 |
| treatment venous thromboembolism | #13 |
| recombinant hirudin rhirudin | #13 |
| patients anticoagulant | #13 |
| daily subcutaneous | #13 |
| randomized cross | #13 |
| inferiority efficacy | #13 |
| factor leiden mutation | #13 |
| vte | #13 |
| occult cancer | #13 |
| safety doacs | #13 |
| category studies | #13 |
| uedvt | #13 |
| factor viii apc | #13 |
| prevention venous thromboembolism | #13 |
| selective testing | #13 |
| thrombosis acute | #13 |
| nct00986154 | #13 |
| marder score | #13 |
| time prothrombin | #13 |
| spiral computed tomography | #13 |
| ufh dalteparin | #13 |
| vte major | #13 |
| arixtra | #13 |
| dimer threshold | #13 |
| levels factor | #13 |
| hematologic pregnancy trimester | #13 |
| vte groups | #13 |
| rivaroxaban thiophenes | #13 |
| 86 percent | #13 |
| superficial thrombophlebitis | #13 |
| indication anticoagulation | #13 |
| major hip | #13 |
| dvt lower | #13 |
| plethysmography | #13 |
| concomitant antiplatelet therapy | #13 |
| gastrointestinal bleeding patients | #14 |
| cadherins endothelium | #14 |
| unprovoked vte vte | #14 |
| thrombophilia patients | #14 |
| anticoagulant rivaroxaban | #14 |
| aged plethysmography | #14 |
| vte statin | #14 |
| 12 kg1 | #14 |
| plasminogen apoa | #14 |
| recurrent venous thromboembolism | #14 |
| female fibrin | #14 |
| standard heparin | #14 |
| riete score | #14 |
| recurrent venous | #14 |
| fvl carriers | #14 |
| vte months | #14 |
| incidence severe pph | #14 |
| aged anticoagulants | #14 |
| thrombosis | #14 |
| ultrasound strategies | #14 |
| placebo rfviia | #14 |
| cancer patients anticoagulation | #14 |
| 17 placebo | #14 |
| obstetric complications women | #14 |
| bolus intravenous injection | #14 |
| patients vka therapy | #14 |
| patients dvt | #14 |
| treated lmwh | #14 |
| higher ddimer levels | #14 |
| revised geneva | #14 |
| experimental endotoxaemia | #14 |
| safety edoxaban | #14 |
| edoxaban oral factor | #14 |
| low molecular | #14 |
| lmwh vka | #14 |
| factor viii levels | #14 |
| dvt lower extremities | #14 |
| loss women | #14 |
| costs dvt | #14 |
| conventionaltherapy | #14 |
| awareness pad | #14 |
| acute deep | #14 |
| doseranging study | #14 |
| pregnancy venous | #14 |
| patients acute vte | #14 |
| limited screening | #14 |
| effects hyperthyroidism | #14 |
| patients outpatients | #14 |
| edoxaban warfarin | #14 |
| atiii deficiency | #14 |
| aspirin women | #14 |
| crnm | #14 |
| symptomatic pulmonary | #14 |
| thromboembolism age | #14 |
| treatment duration patients | #14 |
| anticoagulants patients | #15 |
| symptomatic events | #15 |
| arg562 | #15 |
| recombinant factor viia | #15 |
| coc vte | #15 |
| lmwh ufh | #15 |
| treatment 12 months | #15 |
| lomoparan | #15 |
| vitaminkantagonists | #15 |
| patients vitamin antagonists | #15 |
| coagulation | #15 |
| primary safety outcome | #15 |
| thrombinography | #15 |
| established vte | #15 |
| prior venous thromboembolism | #15 |
| antagonist vka | #15 |
| factor leiden | #15 |
| control subjects prevalence | #15 |
| clinically relevant endpoints | #15 |
| generation oral | #15 |
| experimental thrombosis | #15 |
| oral direct factor | #15 |
| khorana score | #15 |
| studies pulmonary | #15 |
| subcutaneous enoxaparin | #15 |
| edoxaban treatment | #15 |
| inr range | #15 |
| 500 pg | #15 |
| cardiovascular diseases thrombosis | #15 |
| enoxaparin vte | #15 |
| inr patient | #15 |
| arg506 | #15 |
| prophylaxis venous thromboembolism | #15 |
| thrombosis diagnosis | #15 |
| thyroid hormone excess | #15 |
| activation contact | #15 |
| probability assessment | #15 |
| thrombus growth | #15 |
| abdominal pelvic | #15 |
| diagnosis venous | #15 |
| doacs aspirin | #15 |
| subcutaneous regimen | #15 |
| pregnancy outcome pregnancy | #15 |
| patients ctpa | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| cteph incidence | #15 |
| fondaparinux efficacy | #15 |
| thromboembolism time | #16 |
| warfarin acenocoumarol | #16 |
| positivity threshold | #16 |
| major bleeding events | #16 |
| netilmicin gentamicin | #16 |
| dvt lmwh | #16 |
| avws patients | #16 |
| subsequent pregnancy loss | #16 |
| deep venous thrombosis | #16 |
| thrombosis association | #16 |
| major bleeding anticoagulation | #16 |
| venous thrombosis warfarin | #16 |
| test clinical | #16 |
| thrombosis adult | #16 |
| combination clinical | #16 |
| impaired fibrinolysis | #16 |
| vterelated death | #16 |
| arterial vascular events | #16 |
| risk clinically | #16 |
| postthrombotic syndrome children | #16 |
| ddimer levels patients | #16 |
| vte khorana score | #16 |
| factor inhibitor | #16 |
| analysis rivaroxaban | #16 |
| 100 95 | #16 |
| occult cancer detection | #16 |
| thrombosis haemostasis | #16 |
| cancer cancer patients | #16 |
| viia activity | #16 |
| bleeding aged | #16 |
| women unexplained | #16 |
| abdomino | #16 |
| thrombosis low | #16 |
| cancer screening patients | #16 |
| patients acenocoumarol | #16 |
| factors major | #16 |
| 6 months placebo | #16 |
| recurrent symptomatic | #16 |
| prohemostatic | #17 |
| anticoagulant therapy patients | #17 |
| diagnosis svt | #17 |
| rivaroxaban oral factor | #17 |
| mutation women | #17 |
| recurrent vte events | #17 |
| ctscans | #17 |
| topic hemorrhage humans | #17 |
| vkorc1 gene | #17 |
| lower specificity | #17 |
| thromboembolism patients | #17 |
| fibrinolysis treatment | #17 |
| fragment f1 | #17 |
| anticoagulants drug | #17 |
| factor monoclonal | #17 |
| permanent patients | #17 |
| anticoagulants clinical | #17 |
| patients overt hypothyroidism | #17 |
| excessive blood loss | #17 |
| gentamicin netilmicin | #17 |
| dimer assay | #17 |
| 12 months patients | #17 |
| factors venous | #17 |
| female humans vte | #17 |
| 2688 | #17 |
| dvt prevention | #17 |
| vte edoxaban | #17 |
| lmwhs patients | #17 |
| hematoma heparin | #17 |
| patients impedance | #17 |
| endotoxemia bacteremia | #17 |
| pharmo record linkage | #17 |
| women mutation | #17 |
| 516 patients | #17 |
| thrombosis clinical | #17 |
| incidence pts | #17 |
| scan classification | #17 |
| management crt | #17 |
| compared enoxaparin | #17 |
| relevant nonmajor | #18 |
| treatment vkas | #18 |
| aptt heparin | #18 |
| 4 clinical | #18 |
| vka vte | #18 |
| warfarin hazard | #18 |
| 023 | #18 |
| hivinfected patients cart | #18 |
| weight adjusted | #18 |
| cancer vte | #18 |
| lmwh doacs | #18 |
| proximal vein thrombosis | #18 |
| edoxaban vte | #18 |
| favor lmwh | #18 |
| patients strategy | #18 |
| diagnostic strategy | #18 |
| thrombosis total | #18 |
| intravenous heparin therapy | #18 |
| combined form | #18 |
| commercial airline pilots | #18 |
| prothrombin g20210a | #18 |
| antithrombotic treatment patients | #18 |
| women pregnancy loss | #18 |
| annual incidence | #18 |
| flight hours | #18 |
| sanofi aventis | #18 |
| stable anticoagulation | #18 |
| poc test | #18 |
| simplired | #18 |
| apc thrombin generation | #18 |
| thromboembolism venous | #18 |
| thrombosis pulmonary | #18 |
| vka edoxaban | #18 |
| venous thromboembolism rivaroxaban | #18 |
| outcome events | #18 |
| patients elevated biomarkers | #19 |
| extended oral | #19 |
| ipdma | #19 |
| patients derivation | #19 |
| recurrent venous thrombosis | #19 |
| retropubic prostatectomy | #19 |
| adjusted dose | #19 |
| low platelets | #19 |
| endogenous fibrinolysis | #19 |
| studies factor | #19 |
| vitamin antagonist | #19 |
| 56 95 | #19 |
| acute recurrent | #19 |
| active search | #19 |
| doubleblinding | #19 |
| lmwh patients | #19 |
| 35 women | #19 |
| versions version | #19 |
| venography sensitivity | #19 |
| ddimer tests | #19 |
| increased risk relatives | #19 |
| ufh lmwh | #19 |
| venous thromboembolism relatives | #19 |
| abnormal ultrasound | #19 |
| thromboembolism administration | #19 |
| subcutaneous dalteparin | #19 |
| patients prevalence | #19 |
| fibrinolytic response | #19 |
| antibodynegative | #19 |
| local angiogenesis | #19 |
| symptomatic dvt | #19 |
| patients major bleeding | #19 |
| coagulation studies | #19 |
| treatment heparin | #19 |
| fondaparinux enoxaparin | #19 |
| vwf vte | #19 |
| recurrence vte | #19 |
| oral dabigatran enoxaparin | #19 |
| increased fibrinolytic activity | #19 |
| prognostic echocardiography | #19 |
| edoxaban dose | #19 |
| dvt rivaroxaban | #19 |
| objective testing | #19 |
| systemic activation coagulation | #19 |
| patients sspe | #19 |
| standardtherapy hazard ratio | #20 |
| blindly | #20 |
| abi risk factors | #20 |
| risk thrombophilia | #20 |
| intravenous injections | #20 |
| carriers prothrombin | #20 |
| thrombophilia vte | #20 |
| malignancy time | #20 |
| warfarin edoxaban | #20 |
| antagonists vkas | #20 |
| calf veins | #20 |
| excluded patients | #20 |
| established atherosclerosis | #20 |
| prothrombin mutation | #20 |
| incidences death | #20 |
| pregnancyrelated vte | #20 |
| guidance ssc | #20 |
| ctnt bnp | #20 |
| recurrence bleeding | #20 |
| treatment vte | #20 |
| dabigatran 150 | #20 |
| absolute risk | #20 |
| statin vte | #20 |
| versions questionnaire | #20 |
| life venous thrombosis | #20 |
| injections subcutaneous | #20 |
| abi measurement | #20 |
| synthetic cross | #20 |
| thrombosis ultrasonography | #20 |
| diagnostic workup patients | #20 |
| proteins thrombin | #20 |
| new agent | #20 |
| patients ddimer testing | #20 |
| antitpo | #20 |
| cancer severity | #20 |
| portola | #20 |
| anticoagulation clinic | #20 |
| subsegmental | #20 |
| symptomatic venous thrombosis | #20 |
| impedance plethysmography ipg | #20 |
| nadroparin | #20 |
| compared ufh | #20 |
| single criterion | #20 |
| therapy rivaroxaban | #20 |
| control situation | #20 |
| shr 95 | #20 |
| distance treatment | #20 |
| residual venous | #20 |
| thromb | #21 |
| prothrombin 20210 | #21 |
| hemostatic abnormalities | #21 |
| treatment acenocoumarol | #21 |
| concomitant anti | #21 |
| disease ischemic | #21 |
| occult malignancy | #21 |
| ddimer concentrations | #21 |
| deep venous | #21 |
| vte patients | #21 |
| patients 3 months | #21 |
| doacs lmwhs | #21 |
| distance quality | #21 |
| thrombosis anticoagulants | #21 |
| major bleeding patients | #21 |
| discriminatory performance | #21 |
| internists cardiologists | #21 |
| venogram | #21 |
| treatment apixaban | #21 |
| fibrinolysis inflammation | #21 |
| current standard treatment | #21 |
| hemodynamically stable patients | #21 |
| risk cohort study | #21 |
| outcome incidence | #21 |
| carriers noncarriers | #21 |
| d‐dimer | #21 |
| hormonal cross | #22 |
| bleeding treatment | #22 |
| patientyears | #22 |
| acute vte | #22 |
| host defense response | #22 |
| ttr inr | #22 |
| patients recurrent symptoms | #22 |
| doppler venous thrombosis | #22 |
| venous thromboembolic | #22 |
| cttr | #22 |
| public awareness | #22 |
| time inr | #22 |
| thrombophilia screening | #22 |
| dichotomously | #22 |
| dose subcutaneous | #22 |
| daily enoxaparin | #22 |
| safety treatment | #22 |
| patients severe hf | #22 |
| dimer age | #22 |
| recurrent thromboembolism | #22 |
| riskbenefit ratio | #22 |
| vascular endotoxins | #22 |
| anticoagulants humans | #22 |
| alternative anticoagulation | #22 |
| patients immobilization | #22 |
| lpa plasminogen | #22 |
| anticoagulants heparin | #22 |
| treatment dvt | #22 |
| cmax ctrough | #22 |
| normal angiogram | #23 |
| patients coagulation disorders | #23 |
| vte studies | #23 |
| clotbound thrombin | #23 |
| percentage increase | #23 |
| kakkar | #23 |
| enoxaparin 40 | #23 |
| thromboembolism anticoagulants | #23 |
| venous arterial thrombosis | #23 |
| 011 | #23 |
| cancer patients risk | #23 |
| n1157 | #23 |
| time platelet | #23 |
| ambulatory cancer patients | #23 |
| bidirectional relation | #23 |
| direct factor inhibitors | #23 |
| rivaroxaban dosing | #23 |
| 5392 | #23 |
| 2 investigators | #23 |
| lower extremity amputation | #23 |
| hasbled score | #23 |
| elevated ctni | #23 |
| development dic | #23 |
| odis | #23 |
| fondaparinux | #23 |
| standardduration | #23 |
| gentamicin patients | #23 |
| recurrence venous | #23 |
| prevalence venous thromboembolism | #23 |
| life pulmonary embolism | #23 |
| presence dvt | #24 |
| fondaparinux placebo | #24 |
| overt hyperthyroidism | #24 |
| ddimer testing | #24 |
| specific antidote | #24 |
| recurrent pulmonary embolism | #24 |
| bleeding complication | #24 |
| a21gly | #24 |
| therapy heparin | #24 |
| patients severe bleeding | #24 |
| patients acute treatment | #24 |
| subtherapeutic | #24 |
| followup incidence | #24 |
| parameters fibrinolysis | #24 |
| independent external validation | #24 |
| patients abnormal perfusion | #24 |
| desogestrel levonorgestrel | #24 |
| recurrent thromboembolism patients | #24 |
| rates venous thromboembolism | #24 |
| ufh patients | #24 |
| thrombosis carriers | #24 |
| 049 | #24 |
| safety fondaparinux | #24 |
| levels fviii | #24 |
| prevalence deficiencies | #24 |
| lowmolecularweight humans | #24 |
| years episode | #24 |
| predefined criteria | #24 |
| viiic | #24 |
| month incidence | #24 |
| food drugs | #24 |
| treatment symptomatic | #25 |
| studies lmwh | #25 |
| middeldorp | #25 |
| expert radiologists | #25 |
| thromboembolism acute | #25 |
| fibrinogen degradation | #25 |
| specificity efficiency | #25 |
| perfusion lung scan | #25 |
| factors anticoagulants | #25 |
| patients gastrointestinal bleeding | #25 |
| sepsis intravascular coagulation | #25 |
| anatomical extent | #25 |
| influence smoking | #25 |
| vte clinical | #25 |
| lmwh treatment | #25 |
| fatima | #25 |
| xii activity | #25 |
| f1 2 levels | #25 |
| amadeus | #25 |
| willebrand factor adamts13 | #25 |
| suggestions improvement | #25 |
| cha2ds2vasc chads2 | #25 |
| specificity negative predictive | #26 |
| hormonal manipulation | #26 |
| major bleeding bleeding | #26 |
| rate recurrent vte | #26 |
| rethoracotomy | #26 |
| 9715 | #26 |
| venous thromboemboli | #26 |
| edoxaban vka | #26 |
| treatment lmwh | #26 |
| homozygous carriers | #26 |
| unprovoked vte | #26 |
| dalteparin ufh | #26 |
| doacs vitamin antagonists | #26 |
| edoxaban versus | #26 |
| parameters risk | #26 |
| events year | #26 |
| failure rate | #26 |
| patients essential thrombocythaemia | #26 |
| miscarriage stillbirth | #26 |
| viia complex | #26 |
| patients symptomatic dvt | #26 |
| asymptomatic carriers | #26 |
| ecq | #26 |
| patients cdr | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| training gps | #27 |
| unprovoked venous | #27 |
| anticoagulants blood | #27 |
| enoxaparin female | #27 |
| thrombosis venous | #27 |
| extremity venous | #27 |
| patients elevated levels | #27 |
| vte thr | #27 |
| patients 50 | #27 |
| thrombocytopenia antibodies | #27 |
| patients major hemorrhage | #27 |
| airline pilots | #27 |
| months studies | #27 |
| lmwh prophylaxis | #27 |
| venous thromboembolism carriers | #27 |
| 0·63 | #27 |
| npv patients | #27 |
| low molecularweight heparin | #27 |
| thrombophlebitis | #27 |
| combined training | #27 |
| female heterozygote | #27 |
| cancer spread | #27 |
| vte doacs | #27 |
| perfusion lung | #27 |
| treating physician | #27 |
| day 35 | #27 |
| nonmajor | #27 |
| noncarriers 95 | #27 |
| current guidance | #27 |
| lowmolecularweight heparin patients | #27 |
| anticoagulants factor | #27 |
| embolism retrospective | #28 |
| hirudin therapy | #28 |
| monitoring therapy | #28 |
| rfviia placebo | #28 |
| anticoagulation women | #28 |
| vitamin aged | #28 |
| patients unprovoked | #28 |
| presentation followup | #28 |
| pph severe pph | #28 |
| tests diagnostic | #28 |
| unexplained | #28 |
| factors recurrent | #28 |
| 4650 | #28 |
| 2½ | #28 |
| specific reversal agent | #28 |
| apc plasma | #28 |
| pembqol | #28 |
| acutely medical patients | #28 |
| coagulation tissue factor | #28 |
| vte 6 months | #28 |
| anticoagulants compared | #28 |
| objective tests | #28 |
| receiving rivaroxaban | #28 |
| cancer venous thromboembolism | #28 |
| therapeutic doses | #28 |
| diagnosis dvt | #29 |
| years year | #29 |
| patients standard therapy | #29 |
| prediction scores | #29 |
| pbac score | #29 |
| patients avws | #29 |
| dvt pulmonary embolism | #29 |
| thrombosis 95 | #29 |
| pulmonary angiography | #29 |
| pulmonary embolism death | #29 |
| septicemia | #29 |
| major bleeding rivaroxaban | #29 |
| dutch famine | #29 |
| acenocoumarol patients | #29 |
| aspirin placebo | #29 |
| sex‐specific differences | #29 |
| oral glucocorticoids | #29 |
| heparin versus | #29 |
| g20210a mutation | #29 |
| aged morpholines | #29 |
| spread cancer | #29 |
| bleeding increased | #29 |
| 8240 | #29 |
| pulmonary embolism recurrence | #29 |
| recurrence svt | #29 |
| cindexes | #29 |
| current management strategies | #29 |
| direct oral anticoagulants | #29 |
| blind trials | #29 |
| authors incidence | #29 |
| aminoglycoside therapy | #29 |
| plateletactivating antibodies | #29 |
| dabigatran pcc | #29 |
| thrombosis treatment | #29 |
| thrombo | #29 |
| resistance activated protein | #29 |
| 1000 individuals | #29 |
| rule patients | #30 |
| subcutaneous heparin | #30 |
| residual thrombosis | #30 |
| thromboembolism warfarin | #30 |
| support techniques | #30 |
| administration pentoxifylline | #30 |
| vte coc | #30 |
| 95 risk | #30 |
| f1 2 | #30 |
| new anticoagulants | #30 |
| costs diagnosis | #30 |
| direct oral factor | #30 |
| markers coagulation activation | #30 |
| cancer venous | #30 |
| doac vka | #30 |
| ufh vte | #30 |
| prevention venous | #30 |
| patients vte | #30 |
| xii factor | #30 |
| 1000 personyears incidence | #30 |
| embolism risk | #30 |
| prevalence probability | #31 |
| rfviia novoseven | #31 |
| ventilation scintigraphy | #31 |
| incidence pph | #31 |
| bled | #31 |
| antithrombotic therapies | #31 |
| rhir | #31 |
| 8755 | #31 |
| thromboprophylaxis risk | #31 |
| pharmacological prophylaxis | #31 |
| 0206 | #31 |
| dvt pulmonary | #31 |
| activation blood coagulation | #31 |
| recurrent patients | #31 |
| analysis reviewers | #31 |
| ufh fondaparinux | #31 |
| experimental endotoxemia | #31 |
| recurrent vte patients | #31 |
| 2 antiplasmin | #31 |
| incidence cteph | #31 |
| extended prophylaxis | #31 |
| iii activity | #31 |
| placebo observation | #31 |
| term risk | #31 |
| patients deepvein thrombosis | #31 |
| vte ufh | #31 |
| inhibitor edoxaban | #31 |
| apixaban placebo | #31 |
| imaging sensitivity specificity | #31 |
| women recurrent miscarriage | #31 |
| events 95 | #31 |
| recurrent episode | #31 |
| thromboembolism adolescent | #31 |
| dimer cutoff | #31 |
| standardtherapy | #31 |
| year 95 | #32 |
| varicosis | #32 |
| ufh | #32 |
| negative septicemia | #32 |
| warfarin vte | #32 |
| normal genotype | #32 |
| low clinical | #32 |
| age adjusted | #32 |
| suspected patients | #32 |
| generation patients | #32 |
| khorana score patients | #32 |
| negative dimer | #32 |
| factors thrombolytic | #32 |
| factor female | #32 |
| parenteral anticoagulants | #32 |
| netherlands predictive | #32 |
| treatment anticoagulants | #32 |
| international society thrombosis | #32 |
| parenteral anticoagulation | #32 |
| leiden mutation | #32 |
| resistance activated | #32 |
| heparin lmwh | #33 |
| warfarin risks | #33 |
| mega study | #33 |
| anticoagulant protein | #33 |
| thromboembolism young | #33 |
| rhirudin | #33 |
| pulmonary angiogram | #33 |
| additional tests | #33 |
| apixaban treatment | #33 |
| active implementation | #33 |
| unitage | #33 |
| data meta | #33 |
| low probability | #33 |
| cancer patients diagnosis | #33 |
| activation factors | #33 |
| factor viii patients | #33 |
| subcutaneous male | #33 |
| chapter patients | #33 |
| prophylaxis vte | #33 |
| nephrotoxicity gentamicin | #33 |
| grade 1a | #34 |
| subsegmental pulmonary embolism | #34 |
| lmwh unfractionated heparin | #34 |
| warfarin adult | #34 |
| compare efficacy | #34 |
| anticoagulant | #34 |
| deficiency protein | #34 |
| bilateral venography | #34 |
| vte thrombophilia | #34 |
| pregnancy loss women | #34 |
| thrombosis lower | #34 |
| 9241 | #34 |
| 10 95 | #34 |
| 3 months treatment | #34 |
| reocclusion patients | #34 |
| phytonadione | #34 |
| 590 | #34 |
| control trials | #34 |
| plasmin alpha | #34 |
| hemorrhage heparin humans | #34 |
| apcsr | #34 |
| vte compared | #34 |
| enoxaparin prevention | #35 |
| risk members | #35 |
| patients efficiency | #35 |
| pph blood loss | #35 |
| surgery hip | #35 |
| radiologists diagnosis | #35 |
| rviia | #35 |
| activation coagulation | #35 |
| lung scanning | #35 |
| neoplasms venous | #35 |
| weekly subcutaneous | #35 |
| statin association | #35 |
| prevention model | #35 |
| anticoagulants benzimidazoles | #35 |
| embolism | #35 |
| 36 95 | #35 |
| acute symptomatic | #36 |
| fibrinogen depletion | #36 |
| factors travel | #36 |
| hellp patients | #36 |
| dose reduction patients | #36 |
| 287 patients | #36 |
| venous thromboembolic disease | #36 |
| levels coagulation | #36 |
| novoseven | #36 |
| studies echocardiography | #36 |
| 4139 | #36 |
| fibrinolytic activation | #36 |
| catheterrelated infection | #36 |
| viii levels | #36 |
| 1698 | #36 |
| peripheral endovascular | #36 |
| regular monitoring | #36 |
| treatment acute vte | #36 |
| inherited risk factors | #36 |
| thrombophilia venous | #36 |
| venous thromboembolism dabigatran | #36 |
| riskbenefit | #36 |
| iii antithrombin | #36 |
| perelated mortality | #37 |
| risk factors pts | #37 |
| bagsvaerd | #37 |
| venography | #37 |
| suspected venous | #37 |
| thrombosis humans | #37 |
| anticoagulants prevention | #37 |
| outcome composite | #37 |
| factors thrombophilia | #37 |
| screening occult | #37 |
| anticoagulant action | #37 |
| ototoxicity nephrotoxicity | #37 |
| genotype 95 | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| prophylactic heparin | #37 |
| tat complexes | #37 |
| pad studies | #37 |
| recombinant hirudin | #37 |
| risk venous thrombosis | #37 |
| ctpa patients | #37 |
| vte increased | #37 |
| excluding | #37 |
| lwmh | #37 |
| magellan | #37 |
| cumulative incidence vte | #37 |
| warfarin 95 | #37 |
| 3306 | #38 |
| catheterrelated thrombosis | #38 |
| submassive pulmonary | #38 |
| 2835 | #38 |
| rivaroxaban placebo | #38 |
| congenital deficiencies | #38 |
| coagulation protein | #38 |
| nonmajor bleeding | #38 |
| restenosis reocclusion | #38 |
| vte cancer patients | #38 |
| 10 total | #38 |
| fetal loss women | #38 |
| doac lmwh | #38 |
| patients ddimer levels | #38 |
| sensitivity biomarkers | #38 |
| recurrence day | #38 |
| age recurrence | #38 |
| anticoagulants female humans | #38 |
| vte bleeding | #38 |
| incidence cancer | #39 |
| continued treatment | #39 |
| enoxaparin placebo | #39 |
| embolus | #39 |
| low molecular weight | #39 |
| heparins lmwhs | #39 |
| time compression | #39 |
| submassive | #39 |
| superficial vein thrombosis | #39 |
| fibrin fibrinogen | #39 |
| 277 patients | #39 |
| diagnostic prediction | #39 |
| compression stocking | #39 |
| systemic inflammatory responses | #39 |
| children familial hypercholesterolemia | #39 |
| septic syndrome | #39 |
| specificity patients | #39 |
| subcutaneous intention | #39 |
| incidence patients | #39 |
| doacs | #39 |
| ambulatory cancer | #40 |
| standardized definition | #40 |
| endotoxininduced | #40 |
| arterial vascular | #40 |
| anticoagulation therapy patients | #40 |
| grade 1a patients | #40 |
| fviiic | #40 |
| pemb | #40 |
| anticoagulant therapy | #40 |
| clotting activation | #40 |
| dalteparin treatment | #40 |
| international clinical | #40 |
| therapeutic dosages | #40 |
| tfmp | #40 |
| thrombinantithrombin complexes | #40 |
| activatable fibrinolysis | #40 |
| patients normal | #40 |
| episode venous thromboembolism | #40 |
| common femoral vein | #40 |
| bleeding | #40 |
| day 6 months | #40 |
| pentasaccharides | #41 |
| dabigatran etexilate | #41 |
| lung scintigraphy | #41 |
| calf vein thrombosis | #41 |
| heparin therapy | #41 |
| endotoxin induced | #41 |
| submassive pulmonary embolism | #41 |
| cancer lmwh | #41 |
| 95 genotype | #41 |
| 7268 | #41 |
| triage tests | #41 |
| risk recurrent vte | #41 |
| lowmolecularweight heparins | #41 |
| placebo 6 months | #41 |
| anticoagulated patients | #41 |
| patients vasopressors | #42 |
| anticoagulation risk | #42 |
| cell extravasation | #42 |
| patients silent | #42 |
| standardization committee | #42 |
| type graft | #42 |
| neoplasms thrombosis | #42 |
| major contributor | #42 |
| patients prospective | #42 |
| prophylaxis venous | #42 |
| 8101 | #42 |
| stroke thrombosis | #42 |
| thrombosis administration | #42 |
| netilmicin | #42 |
| fetal loss | #43 |
| patients vte risk | #43 |
| warfarin anticoagulants | #43 |
| 543 patients | #43 |
| monthly incidence | #43 |
| initial treatment | #43 |
| post‐thrombotic syndrome | #43 |
| rtap | #43 |
| heparin risk | #43 |
| cancer adjusted | #43 |
| venous thromboembolism vte | #43 |
| venous thrombosis thrombophilia | #43 |
| probability patients | #43 |
| vkas patients | #43 |
| ischemic events | #43 |
| draft document | #43 |
| patients tinzaparin | #44 |
| restoration euthyroidism | #44 |
| mild hyperhomocysteinaemia | #44 |
| efficiency models | #44 |
| indications patients | #44 |
| 95 pulmonary embolism | #44 |
| recurrent vte 95 | #44 |
| rate venous | #44 |
| 10–14 | #44 |
| role coagulation | #44 |
| protein sepsis | #44 |
| factors thromboembolism | #44 |
| nonvka oral anticoagulants | #44 |
| edoxaban therapy | #44 |
| 20 30 | #44 |
| uedvt patients | #44 |
| expert physicians | #44 |
| enoxaparin risk | #44 |
| experimental venous thrombosis | #44 |
| treated warfarin | #45 |
| dose lmwh | #45 |
| 95 warfarin | #45 |
| coumarin therapy | #45 |
| oral direct | #45 |
| fondaparinux patients | #45 |
| revascularisation procedures | #45 |
| wells score | #45 |
| venous thrombotic | #45 |
| dvt patients | #45 |
| coagulation activation | #45 |
| patients bnp | #45 |
| years algorithm | #45 |
| dose adjusted | #45 |
| standard therapy | #46 |
| treatment model | #46 |
| stroke risk assessment | #46 |
| prothrombin fragment f1 | #46 |
| hospital outpatients | #46 |
| patients unprovoked vte | #46 |
| ruling | #46 |
| abtpo | #46 |
| ssc isth | #46 |
| day levels | #46 |
| management venous | #46 |
| bleeding rivaroxaban | #46 |
| healthcare settings | #46 |
| extended duration | #46 |
| pioped | #46 |
| daily rivaroxaban | #46 |
| major bleeding placebo | #46 |
| percent confidence | #46 |
| ambulatory anticoagulants | #47 |
| boehringer ingelheim | #47 |
| outcome vitamin | #47 |
| iiia receptors | #47 |
| central venous lines | #47 |
| episode vte | #47 |
| male methimazole | #47 |
| new oral anticoagulant | #47 |
| bristol myers squibb | #47 |
| roccurve | #47 |
| mutation pregnancy | #47 |
| plasma ddimer levels | #47 |
| mechanical prophylaxis | #47 |
| thromboprophylactic | #48 |
| subcommittee | #48 |
| elevated plasma levels | #48 |
| risk recurrent | #48 |
| rivaroxaban compared | #48 |
| intermediate risk risk | #48 |
| fondaparinux heparin | #48 |
| factors rivaroxaban | #48 |
| small studies | #48 |
| daiichi | #48 |
| thrombotic burden | #48 |
| recurrence venous thromboembolism | #48 |
| patients pulmonary | #48 |
| travel risk | #48 |
| diagnosis physicians | #48 |
| patients acute dvt | #48 |
| rivaroxaban prevention | #49 |
| vte diagnosis | #49 |
| calf vein | #49 |
| levels protein | #49 |
| women aspirin | #49 |
| lowmolecularweight heparin lmwh | #49 |
| enoxaparin | #49 |
| factor viii deficiency | #49 |
| acute respiratory insufficiency | #50 |
| prospective diagnostic | #50 |
| incidence venous thromboembolism | #50 |
| cardiac surgery mortality | #50 |
| transient risk factor | #50 |
| etexilate | #50 |
| intensity treatment | #50 |
| nonselective betablockers | #50 |
| thromboembolism aged | #50 |
| outpatient therapy | #50 |
| treatment threshold | #50 |
| atria patients | #50 |
| buller | #50 |
| vitamink antagonists | #50 |
| dvt diagnosis | #50 |
| protein deficiencies | #51 |
| discrimination model | #51 |
| 95 apixaban | #51 |
| acenocoumarol | #51 |
| tomography pulmonary | #51 |
| patients 11 | #51 |
| effects coagulation | #51 |
| normal perfusion | #51 |
| strategies treatment | #51 |
| global disease | #51 |
| previous survey | #51 |
| factor vte | #51 |
| hematologic malignancies patients | #52 |
| patients comorbid conditions | #52 |
| pdvt | #52 |
| svt patients | #52 |
| inhibitors heparin | #52 |
| unnecessarily | #52 |
| doacs vka | #52 |
| free thyroxine ft4 | #52 |
| lmwh fondaparinux | #52 |
| risk venous thromboembolism | #52 |
| 3 month | #52 |
| apixaban vte | #52 |
| vte major bleeding | #52 |
| lung scans | #52 |
| 1·12 | #52 |
| versus enoxaparin | #53 |
| thromboembolism prevention | #53 |
| absolute risks | #53 |
| patients initially | #53 |
| thrombophilic factors | #53 |
| warfarintreated patients | #53 |
| reported incidence | #53 |
| postthrombotic syndrome | #53 |
| suspected venous thromboembolism | #53 |
| 479 patients | #53 |
| 1522 | #53 |
| preference patients | #53 |
| cross study | #53 |
| 40 daily | #53 |
| hemostatic balance | #53 |
| patients obese | #54 |
| chads2 cha2ds2vasc | #54 |
| familial thrombophilia | #54 |
| 2537 | #54 |
| endocrine disorders | #54 |
| antithrombotic drug | #54 |
| 034 | #54 |
| acquired risk factors | #54 |
| prethrombotic | #54 |
| male pulmonary embolism | #54 |
| pai1 levels patients | #54 |
| 378 patients | #54 |
| bled score | #54 |
| major bleeds | #54 |
| patients incidence | #54 |
| vte mortality | #54 |
| thromboembolism death | #54 |
| unfractionated heparin | #55 |
| legs patients | #55 |
| treatment thresholds | #55 |
| compared lmwh | #55 |
| dosereduction | #55 |
| long term risk | #55 |
| methods randomized | #55 |
| rivaroxaban | #55 |
| anticoagulants arthroplasty replacement | #55 |
| unfractionated heparin ufh | #55 |
| insurances | #55 |
| proximal extent | #55 |
| nondeficient | #55 |
| biological pan | #55 |
| vitamin warfarin | #56 |
| time event | #56 |
| major bleeding apixaban | #56 |
| vte death | #56 |
| level mortality | #56 |
| preeclampsia hellp syndrome | #56 |
| vasopressors | #56 |
| deficiency prevalence | #56 |
| enoxaparin patients | #56 |
| seventh accp conference | #56 |
| 20210a | #56 |
| weight heparins | #56 |
| tromboembólica | #56 |
| physicians guidelines | #56 |
| risk major bleeding | #56 |
| inr values | #56 |
| venous outflow obstruction | #56 |
| reduced capacity | #56 |
| enoxaparin rivaroxaban | #56 |
| ctscan | #57 |
| clinical models | #57 |
| inhibitors female humans | #57 |
| calf dvt | #57 |
| risk factors vte | #57 |
| subsegmental pulmonary | #57 |
| antithrombin iii heparin | #57 |
| levels survival | #57 |
| inhibitors female | #58 |
| unfractionated heparin patients | #58 |
| fibrinolysis humans | #58 |
| ruled | #58 |
| spiral computed | #58 |
| lowmolecular weight heparin | #58 |
| thrombin activatable | #58 |
| malignancy mortality | #58 |
| pharmo | #58 |
| doacs patients | #58 |
| mutation prothrombin | #59 |
| factor generation | #59 |
| risk periods | #59 |
| clot lysis time | #59 |
| safety warfarin | #59 |
| bias trial | #59 |
| acute venous thromboembolism | #59 |
| warfarin treatment | #59 |
| thrombosis aged | #59 |
| risk vte | #59 |
| incidence symptomatic | #59 |
| aventis | #59 |
| heterozygous factor | #59 |
| direct oral | #59 |
| risk factors sensitivity | #59 |
| acute pulmonary embolism | #60 |
| awareness risk factors | #60 |
| women difference | #60 |
| fixeddose | #60 |
| pulmonary embolism 95 | #60 |
| hemorrhage humans | #60 |
| target inr | #60 |
| constans | #60 |
| anticoagulants treatment | #60 |
| atrial fibrillation metaanalysis | #60 |
| 079 95 | #60 |
| prevalence pulmonary | #60 |
| pediatric venous thromboembolism | #60 |
| long‐term treatment | #61 |
| 3633 | #61 |
| free thyroxine | #61 |
| rosendaal | #61 |
| month surgery | #61 |
| amuse | #61 |
| association protein | #61 |
| hypocoagulable | #61 |
| dvt 95 | #61 |
| cdr score | #61 |
| tests prevalence | #61 |
| benzimidazoles dabigatran | #61 |
| perfusion ventilation | #61 |
| 250 patients | #62 |
| procoagulant state | #62 |
| activated partial | #62 |
| combined contraceptives oral | #62 |
| general practitioners patients | #62 |
| ttr patients | #62 |
| human endotoxemia | #62 |
| post thrombotic | #62 |
| 273 patients | #62 |
| informatizado | #62 |
| protein fibrinogen | #62 |
| patients administration | #62 |
| rivaroxaban lmwh | #63 |
| smoking smoking cessation | #63 |
| treatment network | #63 |
| physicians predictive | #63 |
| revised geneva score | #63 |
| injection endotoxin | #63 |
| cvrs | #63 |
| vte thromboprophylaxis | #63 |
| common odds ratio | #63 |
| venous thromboembolisms | #63 |
| quantitative test | #63 |
| management anticoagulation | #63 |
| 33 women | #63 |
| factor leiden risk | #63 |
| symptoms dvt | #63 |
| women mutations | #63 |
| acute pulmonary | #64 |
| thrombophilic risk | #64 |
| prior vte | #64 |
| cancer noncancer patients | #64 |
| dvts | #64 |
| superficial vein | #64 |
| selfadjustment | #64 |
| oral thrombin | #64 |
| factor inhibitors | #64 |
| patients aortic valve | #64 |
| blinded trial | #64 |
| decision rules | #64 |
| bleeding events patients | #64 |
| vkas treatment | #64 |
| heparin fondaparinux | #64 |
| postthrombotic | #64 |
| stroke thromboembolism | #65 |
| prevalence abnormalities | #65 |
| accuracy diagnostic tests | #65 |
| treatment pad | #65 |
| fvl vte | #65 |
| ultrasonograms | #65 |
| prothrombin g20210a mutation | #65 |
| statin therapy risk | #66 |
| elfa | #66 |
| 95 bleeding | #66 |
| newer anticoagulants | #66 |
| 0 points | #66 |
| rapid triage | #66 |
| death classification | #66 |
| dvt sensitivity | #66 |
| female heparin | #66 |
| risk factor thrombosis | #66 |
| axa | #66 |
| patients tertiles | #67 |
| rate major | #67 |
| patients factor | #67 |
| atrial fibrillation stroke | #67 |
| standard therapy patients | #67 |
| apixaban | #67 |
| 1127 | #67 |
| academic medical centre | #68 |
| 1894 | #68 |
| 05 95 | #68 |
| perioperative blood | #68 |
| ranging study | #68 |
| 20210g | #68 |
| 3594 | #68 |
| patients bnp levels | #68 |
| patients benefits | #68 |
| fibrinolytic | #68 |
| coagulation fibrinolysis | #68 |
| thrombosis blood | #69 |
| plasma interleukin | #69 |
| postphlebitic | #69 |
| suspected | #69 |
| heparin ufh | #69 |
| certoparin | #69 |
| recurrent thrombosis patients | #69 |
| justify | #69 |
| enfermedad tromboembólica | #69 |
| ionis | #69 |
| elevated cardiac | #70 |
| gramnegative sepsis | #70 |
| ischemic events patients | #70 |
| withhold | #70 |
| rivaroxaban treatment | #70 |
| α2ap | #70 |
| thrombosis recurrence | #70 |
| fixed dose | #70 |
| major bleeding complications | #70 |
| aged predictive | #70 |
| 8190 | #70 |
| cutoff levels | #70 |
| patients protein | #70 |
| test patients | #70 |
| vwfrco | #70 |
| mantelhaenszel | #70 |
| vte vka | #71 |
| unfractionated | #71 |
| thromboprophylaxis | #71 |
| tests prospective | #71 |
| plasminogen plg | #71 |
| diagnostic sensitivity specificity | #71 |
| clopidogrel placebo | #71 |
| topic costs | #71 |
| asymptomatic atherosclerosis | #71 |
| levels vwf | #71 |
| viia factor | #72 |
| versus vitamin | #72 |
| hf studies | #72 |
| new anticoagulant | #72 |
| antithrombin iii iii | #72 |
| activation prothrombin | #72 |
| ddimer values | #72 |
| elevated factor | #72 |
| patients lmwh | #72 |
| overt hypothyroidism | #72 |
| pooled rate | #72 |
| trifurcation | #72 |
| complications hematologic | #72 |
| noacs | #73 |
| 12 months 95 | #73 |
| analysis diagnostic | #73 |
| reversal agent | #73 |
| prolongations | #73 |
| tomography spiral | #73 |
| ingelheim | #73 |
| ddimer measurement | #73 |
| soluble fibrin | #73 |
| 2550 | #74 |
| suspected dvt | #74 |
| female hemorrhage | #74 |
| 5395 | #74 |
| study selection | #74 |
| carriers | #74 |
| dvt study | #74 |
| prethrombotic state | #74 |
| 1732 | #74 |
| 2124 | #74 |
| experimental metastasis | #74 |
| longterm risk | #74 |
| proteins patients | #74 |
| soluble thrombomodulin | #74 |
| carotid femoral arteries | #75 |
| selective factor | #75 |
| thrombolytic therapy patients | #75 |
| 2904 | #75 |
| incidence bleeding events | #75 |
| retrospective follow | #75 |
| 1334 | #75 |
| 8492 | #75 |
| postoperative dvt | #75 |
| tests primary | #76 |
| early time | #76 |
| oral combined contraceptives | #76 |
| angiography ctpa | #76 |
| duration thromboprophylaxis | #76 |
| risk thrombosis | #76 |
| extended anticoagulation | #76 |
| combined contraceptives | #76 |
| factor xii deficiency | #76 |
| thrombosis pregnancy | #77 |
| social aspects | #77 |
| boehringer | #77 |
| individual patient | #77 |
| p023 | #77 |
| patients secondary | #77 |
| elevated dimer | #78 |
| arterial wall thickness | #78 |
| unprovoked | #78 |
| women thrombophilia | #78 |
| ipg | #78 |
| arterial thromboembolism | #78 |
| 20 daily | #78 |
| female fibrinolysis | #78 |
| suspected acute | #79 |
| time therapeutic | #79 |
| limulus test | #79 |
| factor adult | #79 |
| topic heparin | #79 |
| humans pulmonary | #79 |
| vte fvl | #79 |
| 2486 | #79 |
| efficacy agents | #79 |
| vkas | #79 |
| validation models | #80 |
| thromboembolism incidence | #80 |
| alife | #80 |
| heterozygous deficiency | #80 |
| daily bid | #80 |
| patient data | #80 |
| sspe patients | #80 |
| subhazard ratio | #80 |
| 95 05 | #80 |
| bleeding mortality | #80 |
| suspected cancer | #80 |
| vte rate | #80 |
| walking distance | #81 |
| test evaluation | #81 |
| vascular events | #81 |
| knee arthroplasty patients | #81 |
| weitz | #81 |
| lmwh vte | #81 |
| topic risk | #81 |
| systemic inflammatory | #81 |
| prothrombin complex concentrate | #81 |
| outpatient basis | #81 |
| thrombosis incidence | #82 |
| thrombosis thrombophilia | #82 |
| placebo women | #82 |
| crnmb | #82 |
| heparin prevention | #82 |
| mammography patients | #82 |
| symptomatic carriers | #82 |
| thrombolytic drugs | #82 |
| 50 micrograms | #82 |
| posthoc analysis | #82 |
| clinical sign | #82 |
| prospective validation | #82 |
| common practice | #82 |
| 3month followup | #82 |
| timeperiods | #82 |
| elective coronary | #83 |
| dimer patients | #83 |
| patients thrombi | #83 |
| 2213 | #83 |
| bistro | #83 |
| 287 | #83 |
| inhibitor dabigatran | #83 |
| bleeding women | #83 |
| screening humans | #84 |
| inhibitor rivaroxaban | #84 |
| normotensive patients | #84 |
| diagnostic outcome | #84 |
| duration therapy | #84 |
| healthcare setting | #84 |
| inherited thrombophilia | #84 |
| prophylactic dose | #84 |
| heparin treatment | #84 |
| anticoagulants antiphospholipid | #85 |
| endotoxins | #85 |
| thrombosis svt | #85 |
| asymptomatic dvt | #85 |
| normal levels | #85 |
| peripheral vascular diseases | #85 |
| antithrombin iii protein | #85 |
| venous thrombosis patients | #85 |
| major bleeding warfarin | #86 |
| dabigatran vka | #86 |
| elevated ddimer levels | #86 |
| 4576 | #86 |
| 10⁶ | #86 |
| venovenous hemofiltration | #86 |
| 75 microg | #86 |
| rhapc | #86 |
| post‐hoc analysis | #87 |
| clinical impact | #87 |
| acute venous | #87 |
| ≤50 | #87 |
| obstetric patients | #87 |
| 95 100 | #87 |
| patients 28 | #87 |
| avws | #87 |
| contact activation | #87 |
| vidas | #87 |
| 4 points | #88 |
| venographic | #88 |
| lmwhs | #88 |
| aged multicenter | #88 |
| treatment incidence | #88 |
| washout period | #88 |
| internist | #88 |
| 3319 | #88 |
| treatment statins | #88 |
| cdr | #88 |
| activation factor | #88 |
| cytokine release | #89 |
| beta blockers | #89 |
| adequate treatment | #89 |
| rates major bleeding | #89 |
| vte venous thromboembolism | #89 |
| matisse | #89 |
| costs patient | #89 |
| stroke bleeding | #89 |
| ventilation lung | #89 |
| smoking incidence | #89 |
| severe hf | #89 |
| safety noacs | #89 |
| anticoagulants dabigatran | #89 |
| ddimer | #89 |
| reversal strategies | #89 |
| tests test | #89 |
| unexplained recurrent | #89 |
| popliteal vein | #90 |
| outweighs | #90 |
| venous thrombosis risk | #90 |
| vka dabigatran | #90 |
| fibrinolytic factors | #90 |
| thrombophilic risk factors | #90 |
| pediatric venous | #90 |
| 2293 | #90 |
| new patients | #90 |
| primary thromboprophylaxis | #90 |
| cdrs | #91 |
| anticoagulants doacs | #91 |
| thrombosis women | #91 |
| 60 95 | #91 |
| 20210 | #91 |
| pyridines pyridones | #91 |
| agents hemorrhage | #91 |
| thromboembolism pregnancy | #91 |
| inconvenience | #91 |
| perfusion ratio | #91 |
| prophylaxis incidence | #92 |
| combined clinical | #92 |
| thrombotic disease | #92 |
| single intravenous | #92 |
| rivaroxaban edoxaban | #93 |
| incidence knee | #93 |
| compression patients | #93 |
| 95 years | #93 |
| scenario analyses | #93 |
| anticoagulation reversal | #93 |
| direct thrombin inhibitors | #93 |
| hf severity | #94 |
| test result | #94 |
| patients symptomatic | #94 |
| heparins | #94 |
| children vte | #94 |
| atherogenic lipid | #94 |
| 1027 | #94 |
| 125 patients | #94 |
| vte surgery | #94 |
| viia rfviia | #95 |
| 2 levels | #95 |
| european consensus statement | #95 |
| direct oral anticoagulant | #95 |
| efficacy rivaroxaban | #96 |
| 6 12 months | #96 |
| fondaparinux treatment | #96 |
| randomised crossover study | #96 |
| risk symptomatic | #96 |
| symptomatic vte | #96 |
| ddimer level | #96 |
| xii deficiency | #96 |
| invasive testing | #97 |
| pyrazoles pyridones | #97 |
| haemophilia patients | #97 |
| fibrin generation | #97 |
| doacs risk | #97 |
| symptomatic pulmonary embolism | #97 |
| tpa release | #97 |
| studies evaluated | #97 |
| abnormal perfusion | #97 |
| difference rates | #97 |
| hypercoagulable | #98 |
| activated protein apc | #98 |
| 2875 | #98 |
| simplify | #98 |
| 16slice | #98 |
| pregnancy postpartum period | #98 |
| major bleed | #98 |
| essential thrombocythaemia | #98 |
| supervised exercise therapy | #98 |
| probast | #99 |
| unselected | #99 |
| risk arterial | #99 |
| hirudin | #99 |
| acute dvt | #99 |
| perfusion scintigraphy | #99 |
| lmwh warfarin | #99 |
| 2·0 | #99 |
| previews | #100 |
| 3 trials | #100 |
| gbd 2010 | #100 |
| increasing levels | #100 |
| doubleblind trial | #100 |
| warfarin patients | #100 |
| prevention recurrent | #100 |
| fatty foods | #100 |
| 1116 | #100 |
| patient groups | #100 |
| morpholines | #101 |
| factor viia | #101 |
| factor vii factor | #101 |
| aptts | #101 |
| alternative diagnosis | #102 |
| low pretest probability | #102 |
| pts patients | #102 |
| enoxaparin fondaparinux | #102 |
| 40 microg | #102 |
| venous thromboembolism women | #102 |
| 265 patients | #102 |
| 338 | #103 |
| cteph patients | #103 |
| endogenous thrombin | #103 |
| therapeutic consequences | #103 |
| pregnancy puerperium | #103 |
| adjudicated | #103 |
| arthroscopic anterior | #103 |
| doppler method | #103 |
| assay variation | #104 |
| oral factor | #104 |
| term treatment | #104 |
| diagnostic imaging humans | #104 |
| heparin pregnancy | #104 |
| fibrin degradation products | #104 |
| recurrence women | #104 |
| antithrombin iii | #104 |
| apparent increase | #104 |
| absolute increase | #104 |
| separate analyses | #104 |
| partial restoration | #104 |
| embryo loss | #105 |
| 7 children | #105 |
| conventional therapy patients | #105 |
| 1089 | #105 |
| study total | #106 |
| 314 | #106 |
| essentials | #106 |
| thrombophilia | #106 |
| elevated levels | #106 |
| thrombosis age | #106 |
| thromboprophylaxis patients | #106 |
| blind double | #106 |
| chest ray | #106 |
| hospitalized patients hf | #106 |
| 2479 | #106 |
| fibrinolytic systems | #106 |
| definition classification | #107 |
| vte risk | #107 |
| thromboembolic | #107 |
| topic recurrence | #107 |
| ddimer levels | #107 |
| survival cancer patients | #107 |
| simplified version | #107 |
| human volunteers | #108 |
| noncancer patients | #108 |
| patients cancer | #108 |
| cardiovascular death stroke | #108 |
| specific subgroups | #108 |
| grade 1c | #108 |
| post thrombotic syndrome | #108 |
| anticoagulants cohort | #109 |
| routine coagulation | #109 |
| viia | #109 |
| embolism treatment | #109 |
| synthetic pentasaccharide | #109 |
| 1235 | #109 |
| 039 | #109 |
| thrombin antithrombin | #109 |
| 500μg | #109 |
| evaluation studies | #109 |
| factor mutation | #109 |
| inferiority trial | #110 |
| cancer activity | #110 |
| primary safety | #110 |
| thrombosis treated | #110 |
| subsequent pregnancy | #110 |
| antiplasmin | #110 |
| embolism quality | #110 |
| vka doac | #110 |
| obstetric complications | #111 |
| siset | #111 |
| negative predictive 100 | #111 |
| comparison control | #111 |
| anticoagulants biomarkers | #111 |
| treatment risk factors | #111 |
| predefined | #111 |
| humans intermittent | #111 |
| chromogenic | #112 |
| patients ventricular dysfunction | #112 |
| topic guidelines | #112 |
| epidemiology risk factors | #112 |
| patients 70 | #112 |
| thromboembolic diseases | #112 |
| publication anticoagulants | #112 |
| efficacy prevention | #112 |
| rivaroxaban enoxaparin | #112 |
| recurrence treatment | #112 |
| risk rivaroxaban | #112 |
| emergency situations | #112 |
| heterozygous carriers | #113 |
| nonionic contrast | #113 |
| inappropriate treatment | #113 |
| patients nephrotoxicity | #113 |
| lmwh risk | #113 |
| metabolic response | #113 |
| cancerassociated vte | #114 |
| 0·0 | #114 |
| dialysers | #114 |
| patients intermediate | #114 |
| study centre | #114 |
| total knee replacement | #114 |
| postphlebitic syndrome | #114 |
| 393 | #115 |
| patients recurrent | #115 |
| fibrinogen vwf | #115 |
| global public | #115 |
| positive predictive values | #115 |
| hyperhomocysteinaemia | #115 |
| anticoagulants arthroplasty | #116 |
| topic dabigatran | #116 |
| computed tomography patients | #116 |
| major bleeding 95 | #116 |
| heparin warfarin | #116 |
| life treatment | #116 |
| women severe preeclampsia | #116 |
| reference standard | #116 |
| effects tnf | #116 |
| agents heparin | #116 |
| vte data | #116 |
| 2460 | #117 |
| arthroscopies | #117 |
| vte complications | #117 |
| women caesarean | #117 |
| protein inhibitor pci | #117 |
| fibrinolytic parameters | #117 |
| vte children | #117 |
| protein resistance | #117 |
| proximal dvt | #118 |
| arterial thrombosis patients | #118 |
| 4118 | #118 |
| 2744 | #118 |
| patients extensive | #118 |
| autopsyconfirmed | #118 |
| compression stockings | #119 |
| compared warfarin | #119 |
| incidence pulmonary embolism | #119 |
| patients doac | #119 |
| humans leg | #119 |
| mortality diseases | #120 |
| lactoferrin leukocyte | #120 |
| months follow | #120 |
| healthy humans | #120 |
| thrombosis study | #120 |
| previous vte | #120 |
| rivaroxaban patients | #120 |
| risk thromboembolism | #120 |
| dabigatran factor | #120 |
| acquired deficiency | #120 |
| patients prostatic cancer | #121 |
| thrombocytopenia thrombosis | #121 |
| fatal pulmonary embolism | #122 |
| oral hormonal | #122 |
| studies venous | #122 |
| anti factor | #122 |
| patients 6 | #122 |
| 100 patients | #123 |
| heparin hirudin | #123 |
| heparin | #123 |
| acute infection | #123 |
| early dynamics | #123 |
| minor bleeding | #123 |
| placebo standard | #123 |
| venous thromboembolism pregnancy | #123 |
| factor xia | #123 |
| vte lmwh | #124 |
| association level | #124 |
| atherogenic lipid profile | #124 |
| statin risk | #124 |
| thrombophilia pregnancy | #124 |
| treatment data | #124 |
| ft4 levels | #124 |
| bayer | #125 |
| thromboembolism recurrence | #125 |
| peripheral arterial disease | #125 |
| fibrinolysis inhibitor | #125 |
| nonsignificantly | #125 |
| intravenous heparin | #125 |
| treatment indication | #125 |
| skin perfusion | #125 |
| puerperal disorders | #125 |
| diseases mortality | #125 |
| incidence thrombosis | #125 |
| elevated liver enzymes | #125 |
| doacs treatment | #126 |
| upper extremity | #126 |
| distal dvt | #126 |
| unacceptably | #127 |
| occurrence vte | #127 |
| thromboprophylaxis lmwh | #127 |
| performance scores | #127 |
| patients ventilation | #127 |
| marder | #127 |
| patients permanent | #127 |
| treatment months | #128 |
| prevention | #128 |
| patients conventional therapy | #128 |
| venous thromboembolism risk | #128 |
| 50 age | #128 |
| development vte | #128 |
| resistance apc | #128 |
| direct factor | #128 |
| 060 | #129 |
| mortality cancer patients | #129 |
| 1041 | #129 |
| riete registry | #129 |
| elevated biomarkers | #129 |
| ctrough | #129 |
| day 10 | #130 |
| internists | #130 |
| 220 | #130 |
| plaster cast | #130 |
| anticoagulants antithrombins | #130 |
| hospital discharge records | #130 |
| patients episode | #130 |
| 194 patients | #130 |
| tests specificity | #131 |
| pooled incidence | #131 |
| long‐term clinical outcomes | #131 |
| 05 patients | #131 |
| linear interpolation | #131 |
| obviating | #131 |
| hoc analysis | #132 |
| rivaroxaban versus | #132 |
| postpartum period women | #132 |
| hypocoagulability | #132 |
| enoxaparin treatment | #133 |
| fxa inhibitors | #133 |
| 80 anticoagulants | #133 |
| cha2ds2vasc | #133 |
| started | #133 |
| avidin | #133 |
| direct inhibitors | #133 |
| rco vwf | #134 |
| embolism acute | #134 |
| risk pad | #134 |
| selectin levels | #134 |
| pulmonary angiography patients | #134 |
| instituted | #134 |
| bnp concentration | #135 |
| prevalence dvt | #135 |
| activator plasminogen | #135 |
| anticoagulant prophylaxis | #135 |
| clinical prediction | #136 |
| 0056 | #136 |
| severe pph | #136 |
| months anticoagulation | #136 |
| apixaban edoxaban | #136 |
| thrombotic syndrome | #136 |
| east asian patients | #136 |
| followup patients | #136 |
| factor prothrombin | #137 |
| 99 patients | #137 |
| acquired thrombophilia | #137 |
| point‐of‐care | #137 |
| sequential application | #137 |
| phase 3 trials | #137 |
| diagnostic work | #137 |
| 2283 | #137 |
| intravascular coagulation dic | #138 |
| bleeding warfarin | #138 |
| national guidelines | #138 |
| studies mortality | #138 |
| complete inhibition | #138 |
| enhanced factor | #138 |
| antidote | #138 |
| patients comparison | #139 |
| 95 major bleeding | #139 |
| 2465 | #139 |
| factor viii factor | #139 |
| direct inhibitor | #139 |
| 3 weeks | #139 |
| reproducibility risk | #139 |
| risk fatal | #139 |
| oral anticoagulant treatment | #139 |
| human activated | #140 |
| 80 cohort | #140 |
| 20 iu | #140 |
| distal deep | #140 |
| dvt incidence | #140 |
| vwf rco | #140 |
| 12 95 | #140 |
| ottawa | #140 |
| 0114 | #140 |
| antidotes | #141 |
| thromboembolic disorders | #141 |
| pharmacy records | #141 |
| carriership | #142 |
| thrombin potential | #142 |
| points 95 | #143 |
| ischaemic events | #143 |
| jugular veins | #143 |
| geneva | #143 |
| active malignancy | #143 |
| treatment pulmonary | #143 |
| escherichia humans | #143 |
| warfarin administration | #143 |
| compared treatment | #144 |
| management vte | #144 |
| topic practice patterns | #144 |
| postoperative venous | #144 |
| fatal pulmonary | #144 |
| pregnancy female humans | #144 |
| doac treatment | #144 |
| patient populations | #145 |
| thrombosis model | #145 |
| dose rivaroxaban | #145 |
| hyperthyroxinemia | #145 |
| filters venous | #145 |
| serial testing | #145 |
| referred patients | #145 |
| death cancer patients | #146 |
| protein factor | #146 |
| derived microvesicles | #146 |
| months treatment | #146 |
| personal fees | #147 |
| tissue factor pathway | #147 |
| acute medical illness | #148 |
| rebuttal | #148 |
| antithrombotic drugs | #148 |
| 10 years patients | #148 |
| intention treat | #148 |
| 2076 | #148 |
| embolism diagnosis | #148 |
| partial thromboplastin | #148 |
| long‐acting | #148 |
| procoagulant | #149 |
| relevant publications | #149 |
| 0·45 | #149 |
| diagnostic score | #149 |
| vte hospitalization | #149 |
| risk subgroups | #149 |
| thrombocyte | #149 |
| individual patient data | #149 |
| dimer level | #150 |
| humans injections | #151 |
| enoxaparin unfractionated heparin | #151 |
| additional imaging | #151 |
| coagulation dic | #151 |
| longterm treatment | #152 |
| patients primary outcome | #152 |
| bleeding patients | #152 |
| continuous venovenous | #152 |
| patient eligibility | #152 |
| point systems | #153 |
| extracorporeal circuit | #153 |
| thrombosis prevention | #153 |
| cardiopulmonary bypass surgery | #153 |
| hypercoagulable state | #153 |
| bleeding scores | #154 |
| angioplasty patients | #154 |
| direct thrombin | #154 |
| dimer levels | #154 |
| thrombosis factor | #154 |
| active cancer | #154 |
| activity mortality | #154 |
| tomography patients | #155 |
| curve sensitivity | #155 |
| warfarin apixaban | #155 |
| drug factor | #155 |
| fiia | #155 |
| states venous | #155 |
| thromboembolic event | #155 |
| daily oral | #156 |
| patients gastrointestinal | #156 |
| fvl | #156 |
| vte treatment | #156 |
| 09 | #156 |
| recurrent symptoms | #156 |
| stockings | #156 |
| coagulant activity | #156 |
| enoxaparin dose | #156 |
| cross‐sectional survey | #157 |
| increased thrombin | #157 |
| hemodynamically | #157 |
| prophylaxis patients | #157 |
| 2126 | #158 |
| months chemotherapy | #158 |
| 97 | #158 |
| duration anticoagulation | #158 |
| dfl | #158 |
| underlying malignancy | #158 |
| increased risk thrombosis | #159 |
| adjusted relative risk | #159 |
| plasma dimer | #160 |
| thrombotic disorders | #160 |
| guidelines prevention | #160 |
| schering | #160 |
| children fh | #160 |
| 120 minutes | #160 |
| 145 patients | #160 |
| antithrombotic efficacy | #160 |
| pvo | #161 |
| prophylactics | #161 |
| antagonists patients | #161 |
| patients imaging | #162 |
| incidence vte | #162 |
| women time | #162 |
| 2206 | #162 |
| lysine analogues | #162 |
| strain gauge | #163 |
| 198 patients | #163 |
| imaging test | #163 |
| increased plasma levels | #163 |
| coagulation blood | #163 |
| lmwh therapy | #163 |
| rates vte | #163 |
| venous thrombus | #163 |
| factors bleeding | #163 |
| 028 | #164 |
| justified | #164 |
| age comorbidity | #164 |
| inborn humans | #164 |
| observer variability | #164 |
| subhazard | #165 |
| patients enoxaparin | #165 |
| relatives patients | #165 |
| mutation factor | #165 |
| pravastatin therapy | #166 |
| microvascular thrombosis | #166 |
| strategies patients | #166 |
| stockings compression | #166 |
| phlebography | #166 |
| viii factor | #166 |
| management venous thromboembolism | #166 |
| thrombin venous | #167 |
| recurrent thrombosis | #167 |
| 3658 | #167 |
| ankle brachial abi | #167 |
| syndrome pts | #168 |
| cstatistics | #168 |
| warfarin | #168 |
| treatment 3 months | #168 |
| current clinical practice | #168 |
| cvcs | #168 |
| double heterozygosity | #168 |
| recurrent acute | #168 |
| patients infections | #169 |
| fold increased | #169 |
| risk profile | #169 |
| postthrombotic syndrome pts | #169 |
| 3 12 | #169 |
| preexistent | #169 |
| therapeutic range | #169 |
| interobserver agreement | #170 |
| thrombosis cancer | #170 |
| postoperative blood loss | #170 |
| cart patients | #170 |
| heavy menstrual bleeding | #170 |
| 57 years | #171 |
| aged algorithms | #171 |
| adamts‐13 | #171 |
| recombinant factor | #171 |
| venous thrombotic events | #171 |
| pulmonology | #172 |
| risk factors patients | #172 |
| patients blood transfusion | #172 |
| vaginal bleeding | #172 |
| antifibrinolytic | #172 |
| clinical trials patients | #172 |
| lmw heparin | #172 |
| pulmonary | #173 |
| inr | #173 |
| bleeds | #173 |
| hospitalized medical patients | #173 |
| patients initial | #174 |
| arterial occlusions | #174 |
| laboratory monitoring | #174 |
| clinically bleeding | #174 |
| bleeding tendency | #174 |
| vte common | #175 |
| data control | #175 |
| reocclusion | #175 |
| arterial venous | #175 |
| fragment 1 | #175 |
| mitsubishi | #177 |
| prothrombin | #177 |
| picotamide | #177 |
| intention analysis | #178 |
| 122 | #178 |
| short‐ | #178 |
| aspirin ticlopidine | #178 |
| hyperthyroidism hypothyroidism | #178 |
| noninferior | #179 |
| concomitance | #179 |
| baseline day | #179 |
| vte event | #179 |
| oral female humans | #179 |
| thromboplastin time | #180 |
| referral bias | #180 |
| additional risk factors | #180 |
| patients deficiency | #180 |
| ventilation perfusion | #180 |
| isth | #180 |
| aged partial | #181 |
| acute episode | #182 |
| testing patients | #182 |
| antithrombin | #182 |
| painkillers | #182 |
| patients major | #183 |
| biological variation | #183 |
| 2–4 | #183 |
| hyperhomocysteinemic | #183 |
| risk bleeding | #184 |
| incidental | #184 |
| prognosis pulmonary | #184 |
| n110 | #184 |
| subsequent diagnosis | #184 |
| thromboinflammation | #184 |
| antithrombin iii atiii | #184 |
| 4150 | #184 |
| pregnancy vte | #184 |
| coagulation factors | #184 |
| treat analysis | #184 |
| deficient patients | #185 |
| vte age | #185 |
| anticoagulated | #186 |
| patients thromboprophylaxis | #186 |
| symptomatic | #186 |
| live birth rate | #186 |
| patients intensive units | #186 |
| brain natriuretic | #186 |
| studies heparin | #186 |
| hemostatic effects | #186 |
| antifibrinolytic agents | #187 |
| patients haemophilia | #187 |
| risk composite | #187 |
| cutoff level | #187 |
| safety apixaban | #187 |
| absolute rate | #188 |
| 926 | #188 |
| ratio inr | #188 |
| prevalence cancer | #188 |
| doacs vkas | #188 |
| spontaneous rupture | #188 |
| humans international | #188 |
| willebrand factor antigen | #189 |
| viia female | #189 |
| 64slice | #189 |
| blood loss patients | #189 |
| heparin administration | #189 |
| clinical validity | #189 |
| fibrinolysis | #189 |
| riete | #189 |
| patients netherlands | #189 |
| ccus | #190 |
| ischemic event | #190 |
| thrombosis patients | #190 |
| current views | #190 |
| anticoagulant drugs | #190 |
| venous outflow | #191 |
| acute thrombosis | #191 |
| 07 | #191 |
| gogh | #191 |
| score patients | #191 |
| attending physicians | #191 |
| 058 | #192 |
| stroke systemic | #192 |
| 1495 | #192 |
| endothelial cell activation | #193 |
| coagulation assays | #193 |
| blood coagulation | #194 |
| 070 | #194 |
| prothrombin activation | #194 |
| heparin patients | #194 |
| anticoagulation | #194 |
| recurrent ischemic events | #195 |
| risk major | #195 |
| antixa levels | #195 |
| 65 months | #195 |
| antagonist treatment | #195 |
| target range | #195 |
| complications cardiovascular | #196 |
| coagulation status | #196 |
| abnormal test | #196 |
| 29 95 | #196 |
| sew2871 | #198 |
| difference treatment | #198 |
| treatment groups patients | #198 |
| vii rfviia | #198 |
| ate | #198 |
| vwf adamts13 | #198 |
| coagulation monitoring | #199 |
| patient diagnosis | #199 |
| cachectin | #199 |
| patients 12 months | #200 |
| obese controls | #200 |
| screening patients | #200 |
| incidence cardiovascular events | #200 |
| validation sets | #201 |
| patients abnormal | #201 |
| thrombin factor | #201 |
| thromboembolic disease | #201 |
| vte incidence | #201 |
| peritoneovenous | #202 |
| arterial thrombosis | #202 |
| johnson | #202 |
| 17 95 | #202 |
| heparin dose | #203 |
| invitees | #203 |
| symptomatic pad | #203 |
| induced activation | #203 |
| worldwide survey | #203 |
| levonorgestrel | #204 |
| antithrombotic agents | #204 |
| period time | #205 |
| low incidence | #205 |
| extended thromboprophylaxis | #205 |
| stroke systemic embolism | #205 |
| thrombophilia risk | #205 |
| 0 95 | #205 |
| fgt | #206 |
| data synthesis | #206 |
| patients anticoagulant therapy | #206 |
| venous ultrasonography | #206 |
| varese | #206 |
| methods consecutive | #207 |
| desogestrel | #207 |
| 06 | #207 |
| platelet activation patients | #207 |
| imt patients | #207 |
| fviii | #207 |
| systematic review studies | #207 |
| algorithms anticoagulants | #207 |
| objectively | #207 |
| death female humans | #207 |
| cardiologist | #207 |
| bleeding compared | #208 |
| patients hypothyroidism | #208 |
| thrombocythaemia | #208 |
| free protein | #209 |
| deficiency risk | #209 |
| women frequency | #210 |
| tgt | #210 |
| antixa activity | #210 |
| hirudins | #210 |
| systemic embolism patients | #211 |
| toxaemia | #211 |
| ioxaglate | #211 |
| stocking | #211 |
| anticoagulation management | #212 |
| atrial fibrillation study | #212 |
| plasminogen activator activity | #213 |
| heparitin sulfate | #213 |
| topic practice | #214 |
| correct interpretation | #214 |
| dabigatran dose | #214 |
| current developments | #215 |
| factors vte | #215 |
| thrombin inhibition | #215 |
| studies rivaroxaban | #215 |
| standard duration | #215 |
| betatg | #216 |
| deamino | #216 |
| community hospital | #216 |
| duplex venous | #216 |
| warfarin stroke | #216 |
| diagnostic algorithm | #217 |
| studies difference | #217 |
| mildest | #217 |
| obviates | #217 |
| undergoing total | #217 |
| npv 100 | #218 |
| conclusive evidence | #218 |
| cstatistic | #218 |
| plasminogen activator inhibitor | #218 |
| g20210a | #218 |
| cancer | #219 |
| patients cart | #219 |
| deamino arginine | #219 |
| 077 95 | #219 |
| hip replacement surgery | #220 |
| vii factor | #220 |
| techniques female | #220 |
| viii female | #220 |
| data extraction | #220 |
| preventive measures | #221 |
| heparin humans | #221 |
| postoperative vte | #221 |
| healthy human subjects | #221 |
| hmvec | #221 |
| vte events | #222 |
| apc resistance | #222 |
| proximally | #222 |
| engl | #223 |
| substantial proportion | #223 |
| pulmonologists | #223 |
| 1 january | #223 |
| 1541 | #223 |
| thromboendarterectomy | #224 |
| protein pathway | #224 |
| topic factor | #224 |
| subsequent cancer | #224 |
| neoplasms prospective | #225 |
| balloon coronary anticoagulants | #225 |
| kruskalwallis | #225 |
| thrombosis warfarin | #225 |
| org | #225 |
| 0·67 | #226 |
| vascular events patients | #226 |
| 16 95 | #226 |
| extremity amputation | #226 |
| inr monitoring | #226 |
| haemostasis | #227 |
| 35 ± | #227 |
| acute medical | #227 |
| tests diagnosis | #227 |
| ipe | #228 |
| mild hyperhomocysteinemia | #228 |
| dalteparin | #229 |
| cgp | #229 |
| scant | #229 |
| residual thrombus | #229 |
| 037 | #230 |
| advocated | #230 |
| severe preeclampsia | #231 |
| patients discontinuation | #231 |
| ft4 | #231 |
| habitual abortion | #231 |
| 6 studies | #231 |
| equinox | #231 |
| thiazoles | #231 |
| urosepsis | #231 |
| major orthopaedic surgery | #231 |
| resource utilisation | #231 |
| patients warfarin | #232 |
| aspirin dipyridamole | #232 |
| anticoagulant effects | #233 |
| dimer | #233 |
| cancer prevalence | #233 |
| surgical embolectomy | #233 |
| humans netherlands | #233 |
| recurrence risk factors | #233 |
| endogenous thrombin potential | #233 |
| effective alternative | #234 |
| prothrombotic state | #235 |
| doac | #235 |
| graduated compression | #235 |
| humans meta | #236 |
| venous thromboembolic events | #236 |
| brain natriuretic peptide | #236 |
| myocardial infarction 95 | #237 |
| oral anticoagulants | #237 |
| treatment continuation | #237 |
| 6500 | #238 |
| predictive tests | #238 |
| 009 | #238 |
| patients vkas | #238 |
| factor tnf | #239 |
| anticoagulants aspirin | #239 |
| factor viii fviii | #239 |
| crossover study | #239 |
| rational approach | #239 |
| arterial venous thrombosis | #240 |
| patients initial treatment | #240 |
| 045 | #241 |
| hip knee arthroplasty | #241 |
| aspirin heparin | #241 |
| time therapeutic range | #242 |
| bleeding incidence | #242 |
| prothrombin fragment | #243 |
| pivotal trials | #243 |
| patients intermittent claudication | #243 |
| iohexol | #244 |
| vte risk factors | #245 |
| n89 | #245 |
| casecontrol | #246 |
| vte cases | #246 |
| children neonates | #246 |
| thrombogenesis | #246 |
| 23 95 | #247 |
| antithrombotic | #247 |
| lipoproteina levels | #247 |
| warfarin aged | #247 |
| treatment compared | #248 |
| committees | #248 |
| patients solid tumours | #248 |
| coronary anticoagulants | #248 |
| anti activity | #248 |
| diagnostic models | #249 |
| bleeding rates | #249 |
| score risk | #249 |
| multiple comorbidities | #249 |
| ischemic strokes | #250 |
| protein risk | #250 |
| fv leiden | #250 |
| ioxaglic | #250 |
| 8595 | #251 |
| finalized | #251 |
| patients contraindications | #251 |
| microthrombosis | #251 |
| vkas doacs | #252 |
| somit | #252 |
| simplification | #252 |
| thrombin thrombosis | #253 |
| incidence | #253 |
| agents anticoagulants | #254 |
| treatment duration | #254 |
| palga | #255 |
| fibrinolytic activity | #255 |
| medea | #256 |
| activation humans | #256 |
| haul | #256 |
| bleeding risk | #257 |
| activity assay | #257 |
| clinical utility | #257 |
| continuous intravenous | #257 |
| cost‐effectiveness | #257 |
| q24h | #257 |
| fibrin degradation | #258 |
| ctpa | #258 |
| patient subgroups | #258 |
| 30 50 | #259 |
| unpublished data | #259 |
| dvt risk | #260 |
| sspe | #260 |
| noncarriers | #261 |
| thrombus size | #261 |
| toxicosis | #261 |
| heparin dosing | #261 |
| patients hospitalization | #262 |
| optimal duration | #263 |
| risk pulmonary | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| einstein | #267 |
| pbac | #267 |
| statins risk | #268 |
| endotoxaemia | #268 |
| malignancy patients | #269 |
| randomised cross | #269 |
| relation time | #269 |
| versus aspirin | #269 |
| propeptide | #269 |
| lysis time | #269 |
| discontinuing | #270 |
| protein patients | #270 |
| single test | #270 |
| exclusion | #270 |
| protein apc | #271 |
| platelet serotonin | #271 |
| hormonal replacement therapy | #271 |
| orthopaedic patients | #271 |
| thrombosis inflammation | #271 |
| 3·0 | #271 |
| clopidogrel ticlopidine | #272 |
| vte recurrence | #272 |
| bleeding patient | #272 |
| patients combination | #272 |
| groups levels | #272 |
| efficacy analysis | #273 |
| ankle brachial | #273 |
| months 12 | #274 |
| cleavage sites | #274 |
| prevalence pad | #274 |
| risk levels | #274 |
| parenteral nutrition patients | #275 |
| performance score | #275 |
| international normalized | #275 |
| fourth quartile | #276 |
| antithrombotic agent | #276 |
| smoking hypertension | #277 |
| time aptt | #277 |
| dose reduction | #278 |
| imaging sensitivity | #278 |
| normalized ratio | #278 |
| blood test | #279 |
| rco | #279 |
| aptt | #279 |
| intracranial hemorrhage patients | #280 |
| hospitalized medical | #280 |
| propositi | #280 |
| partial thromboplastin time | #280 |
| obviate | #280 |
| exclusion criteria | #280 |
| patients presence | #281 |
| diagnostic test | #282 |
| thromboplastin | #282 |
| thyroid diseases | #283 |
| neutrophil degranulation | #283 |
| presentation patients | #283 |
| diagnostic sensitivity | #283 |
| puerperal | #283 |
| outpatient treatment | #284 |
| test characteristics | #284 |
| noninferiority margin | #284 |
| favor | #284 |
| departments | #284 |
| animals anticoagulants | #284 |
| major orthopaedic | #285 |
| patients apixaban | #286 |
| 2630 | #286 |
| plasma bnp | #286 |
| gentamicin treatment | #286 |
| disseminated intravascular | #287 |
| clinically | #287 |
| patients pancreatic cancer | #287 |
| levels measured | #287 |
| subdistribution | #287 |
| oral combined | #288 |
| md patients | #288 |
| 227 | #288 |
| premature atherosclerosis | #288 |
| cvt patients | #289 |
| clot lysis | #289 |
| vte women | #289 |
| substantiation | #289 |
| vte rates | #289 |
| n59 | #290 |
| thrombin time | #290 |
| 0·50 | #290 |
| 016 | #291 |
| oral contraceptives | #291 |
| current clinical | #291 |
| extracted data | #291 |
| carriers mutation | #291 |
| activator inhibitor | #292 |
| willebrand disease vwd | #292 |
| 2 studies | #292 |
| 1603 | #292 |
| pentasaccharide | #293 |
| patients dabigatran | #293 |
| 1000 personyears | #293 |
| plasmin activity | #293 |
| adverse outcome patients | #293 |
| cardiac troponin ctnt | #294 |
| tissuetype plasminogen activator | #294 |
| lower extremities | #294 |
| patients rivaroxaban | #294 |
| 1025 | #295 |
| extremity dvt | #295 |
| scenario analysis | #295 |
| classified | #296 |
| coagulation factor viii | #296 |
| peripheral vascular | #296 |
| observer agreement | #297 |
| routine monitoring | #297 |
| recurrent miscarriage | #298 |
| episode patients | #298 |
| specificity npv | #298 |
| thrombocytes | #298 |
| patients inr | #299 |
| inferiority | #300 |
| 041 | #301 |
| heparitin | #301 |
| subclinical thyroid dysfunction | #302 |
| 155 patients | #302 |
| toxemia | #302 |
| thromboglobulin | #302 |
| aged neoplasms | #302 |
| 1214 | #304 |
| absolute difference | #304 |
| rivaroxaban dabigatran | #305 |
| medline embase | #306 |
| prophylactic administration | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| vte pregnancy | #310 |
| thrombotic | #310 |
| surgery day | #310 |
| hematologic pregnancy | #310 |
| patients 100 | #311 |
| clinical presentation | #311 |
| 105 patients | #311 |
| antithrombins blood | #311 |
| percentage points | #311 |
| leg male | #312 |
| 598 | #312 |
| obesity risk factor | #313 |
| hereditary thrombophilia | #313 |
| negative reactions | #313 |
| vte 95 | #313 |
| diagnosis | #314 |
| funding | #315 |
| puerperium | #315 |
| postpartum haemorrhage | #315 |
| cardiologists | #315 |
| heparin aspirin | #315 |
| apixaban versus | #316 |
| therapeutic dose | #316 |
| patients followup | #317 |
| adjudicators | #317 |
| deciding | #318 |
| 0·92 | #318 |
| failure rates | #319 |
| decision model | #319 |
| safety outcomes | #319 |
| bnp levels | #320 |
| 1731 | #320 |
| patients pregnancy | #320 |
| influenza infections | #320 |
| catheter thrombosis | #320 |
| combined administration | #320 |
| ventricular dysfunction patients | #321 |
| patients noacs | #322 |
| intermediate phenotype | #322 |
| additional data | #322 |
| difference risk | #322 |
| inrs | #324 |
| glaxosmithkline | #324 |
| peripheral arterial | #324 |
| convincing evidence | #325 |
| mortality odds ratio | #325 |
| mechanical heart valves | #326 |
| blood coagulation factor | #326 |
| pulmonary embolus | #326 |
| 122 patients | #326 |
| clinical | #327 |
| surgery trauma | #327 |
| association vte | #329 |
| thrombotic event | #331 |
| pregnancy outcome women | #331 |
| incidence bleeding | #331 |
| vitamin administration | #331 |
| new oral | #332 |
| embase databases | #333 |
| analysis trials | #333 |
| n69 | #333 |
| 95 percent | #333 |
| complicate | #334 |
| incidences | #334 |
| 95 confidence limits | #334 |
| minor effects | #334 |
| patients healthy volunteers | #335 |
| fibrillation benzimidazoles | #335 |
| rationale design | #335 |
| central venous catheter | #336 |
| pulmonary perfusion | #336 |
| septicaemia | #336 |
| total hip replacement | #337 |
| recurrent | #337 |
| plethysmographic | #337 |
| 2 points | #337 |
| 035 | #337 |
| 065 | #337 |
| fatal bleeding | #338 |
| coagulation abnormalities | #338 |
| outpatient management | #338 |
| aged netherlands | #338 |
| noacs warfarin | #339 |
| prospective clinical study | #339 |
| placebo trials | #339 |
| 024 | #340 |
| antithrombotic effects | #340 |
| patients 12 | #340 |
| activatable | #341 |
| 217 | #341 |
| coagulation markers | #341 |
| noac patients | #342 |
| knee arthroscopy | #342 |
| patients covid19 infection | #344 |
| pretest | #344 |
| vte prevention | #345 |
| rfviia | #345 |
| antithrombotic strategies | #345 |
| splanchnic vein thrombosis | #345 |
| diagnosis vte | #346 |
| embolisms | #346 |
| patients thrombosis | #347 |
| activated protein resistance | #347 |
| 073 | #347 |
| cochrane central | #348 |
| 044 | #348 |
| chads2 | #349 |
| 2575 | #349 |
| bsf | #349 |
| tafia | #350 |
| trousseau | #350 |
| randomized studies | #350 |
| brain predictive | #350 |
| versus warfarin | #351 |
| 013 | #351 |
| factor viii | #351 |
| factor activation | #352 |
| dermatan sulphate | #352 |
| anticoagulants noacs | #352 |
| selection bias | #352 |
| vein | #353 |
| 1590 | #353 |
| oral anticoagulant therapy | #353 |
| relative efficacy | #353 |
| 5075 | #353 |
| international normalized ratio | #354 |
| aged pulmonary | #354 |
| patients gp | #355 |
| studies diagnostic accuracy | #355 |
| protein deficiency | #356 |
| post hoc | #357 |
| tests prospective studies | #357 |
| intestinal microbiome | #357 |
| categorised | #357 |
| 127 patients | #358 |
| pilots | #360 |
| sucra | #360 |
| intermittent claudication | #361 |
| consensus agreement | #362 |
| treatment risk | #362 |
| anticoagulation patients | #364 |
| conventional therapy | #365 |
| humans risk | #365 |
| bleeding rate | #366 |
| topic female | #366 |
| prediction models | #367 |
| time recurrence | #368 |
| patients 3 | #368 |
| infrainguinal | #368 |
| thrombin inhibitor | #369 |
| 6week | #370 |
| patients acl reconstruction | #370 |
| influenza infection | #370 |
| endotoxin infusion | #371 |
| venous stasis | #371 |
| 055 | #372 |
| 803 | #372 |
| patients svt | #373 |
| recombinant activated | #373 |
| clinical suspicion | #373 |
| knee surgery | #373 |
| aprotinin blood | #373 |
| patients scores | #374 |
| human cytomegalovirus infection | #374 |
| helical computed tomography | #374 |
| hmb | #375 |
| subcutaneous | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| stroke venous | #380 |
| contraceptives oral | #380 |
| ethinyloestradiol | #381 |
| tafi | #381 |
| antitnf | #382 |
| prefilter | #383 |
| standardized questionnaire | #384 |
| 0·8 | #384 |
| reassessed | #384 |
| thromboembolic complications | #384 |
| multivariate regression analysis | #384 |
| alpha2m | #385 |
| systemic activation | #385 |
| surrogate outcome | #386 |
| conference proceedings | #386 |
| bleeding events | #386 |
| cumulative incidences | #387 |
| antithrombins | #387 |
| sensitivity npv | #387 |
| major orthopedic | #388 |
| delegates | #388 |
| 880 | #389 |
| referred | #389 |
| safety rivaroxaban | #389 |
| systemic embolism | #389 |
| vitt | #390 |
| tinzaparin | #390 |
| apixaban warfarin | #390 |
| drug prescription | #391 |
| comparison patients | #391 |
| increased bleeding | #391 |
| biosis | #391 |
| postop | #391 |
| abi | #391 |
| time presentation | #392 |
| patients chest | #392 |
| topic female humans | #392 |
| factors thrombosis | #393 |
| kappa values | #393 |
| pulmonary emboli | #394 |
| injections intravenous | #394 |
| background patients | #394 |
| clinical score | #394 |
| 007 | #395 |
| popliteal | #396 |
| 95 12 | #396 |
| bleeding event | #396 |
| factors factor | #397 |
| 665 | #397 |
| hirudins humans | #397 |
| replacement surgery | #397 |
| embolic events | #397 |
| risk score patients | #399 |
| heparin induced | #400 |
| risk factors asthma | #400 |
| patients risk | #400 |
| echography | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| dabigatran | #403 |
| increased risk vte | #403 |
| controversy | #403 |
| massive pulmonary embolism | #405 |
| 2215 | #406 |
| thrombolytic agents | #406 |
| treatment patient | #406 |
| 075 | #406 |
| oral anticoagulant | #408 |
| factor levels | #408 |
| biologic effects | #410 |
| fviii levels | #411 |
| safety combination | #411 |
| noacs patients | #411 |
| patients assigned | #411 |
| major risk factor | #412 |
| transfusion patients | #412 |
| 20 microg | #412 |
| coagulation patients | #414 |
| maastricht | #414 |
| euthyroidism | #414 |
| aged odds | #415 |
| hypocortisolism | #415 |
| xii | #415 |
| pai1 levels | #416 |
| deserve | #416 |
| intravascular coagulation | #416 |
| dose heparin | #416 |
| data risk | #417 |
| comparable | #417 |
| 95 10 | #417 |
| 95 | #418 |
| carotid femoral | #418 |
| pretest probability | #418 |
| risk factors thrombosis | #419 |
| dermatan | #419 |
| 269 | #419 |
| ototoxicity | #420 |
| xia | #420 |
| fibrillation risk | #421 |
| 2850 | #422 |
| tests radiography | #422 |
| fibrillation clinical | #422 |
| 1989 | #422 |
| fibrinolysin | #423 |
| subanalysis | #424 |
| fviia | #424 |
| prevalence patients | #425 |
| adjunct | #426 |
| randomised double | #426 |
| fii | #426 |
| cancer cohort | #426 |
| consecutive | #427 |
| activated factor | #427 |
| plg | #428 |
| excessive bleeding | #428 |
| conferences | #428 |
| daily practice | #428 |
| undergoing elective | #429 |
| prolactin levels | #429 |
| patients testing | #429 |
| idiopathic myelofibrosis | #429 |
| daily clinical practice | #429 |
| 1904 | #430 |
| rule | #431 |
| heparinoids | #431 |
| bleeding complications | #431 |
| 04 | #432 |
| incidence length | #433 |
| outpatients | #433 |
| patients systematic review | #434 |
| ncb | #434 |
| firstdegree relatives patients | #436 |
| blood cultures | #436 |
| bolus injection | #437 |
| 059 | #437 |
| prostatic cancer | #439 |
| composite point | #439 |
| dose adjustment | #439 |
| women compared | #439 |
| proven | #439 |
| concomitant medications | #441 |
| highrisk populations | #441 |
| rate vte | #442 |
| 074 | #442 |
| –control study | #444 |
| standard therapies | #444 |
| prespecified | #445 |
| febrile patients | #446 |
| patients atrial fibrillation | #446 |
| female fibrinolytic | #447 |
| hellp | #449 |
| 58 | #449 |
| patients parenteral nutrition | #449 |
| utrecht | #449 |
| 3 12 months | #450 |
| prevalence distribution | #450 |
| category | #451 |
| stigmatisation | #451 |
| pipecolic | #452 |
| thrombin generation | #453 |
| noninvasive tests | #453 |
| fatal disease | #453 |
| aspirin risk | #453 |
| portal blood | #454 |
| 30 40 | #454 |
| placebo day | #454 |
| factor xii | #454 |
| 12week | #455 |
| 026 | #455 |
| microthrombi | #455 |
| fviii vwf | #456 |
| dichotomized | #456 |
| squibb | #457 |
| onwards | #457 |
| dicumarol | #457 |
| anti levels | #458 |
| hazard ratio 95 | #458 |
| iii complexes | #458 |
| svt | #460 |
| recommend | #460 |
| plasma lipoprotein | #460 |
| gastrointestinal cancer | #461 |
| factor fxa | #461 |
| hip arthroplasty replacement | #462 |
| expert consensus document | #462 |
| curve biomarkers | #462 |
| haemolysis | #463 |
| guidelines patients | #463 |
| gp iib | #464 |
| patients values | #464 |
| studies ultrasonography | #464 |
| month follow | #465 |
| cancerassociated thrombosis | #466 |
| diabetes stroke | #466 |
| accuracy detection | #467 |
| thrombin formation | #467 |
| intimamedia thickness | #468 |
| patients nsaids | #468 |
| prophylaxis | #468 |
| eligible studies | #469 |
| bmi≥30 | #469 |
| teaching hospitals | #469 |
| inr patients | #470 |
| 077 | #470 |
| test probability | #470 |
| hemihepatectomy | #470 |
| roc analysis | #470 |
| placebo recipients | #471 |
| hypercoagulability | #472 |
| case control study | #472 |
| prophylactic anticoagulation | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| intermittent pneumatic | #475 |
| 15 95 | #475 |
| endotoxemia | #475 |
| heterozygote humans | #475 |
| patients heparin | #475 |
| plethysmograph | #475 |
| atria | #477 |
| haemophiliacs | #479 |
| 08 | #479 |
| patients score | #479 |
| versus standard | #480 |
| thrombosis cvt | #481 |
| acutely | #481 |
| hit patients | #481 |
| postoperative blood | #482 |
| transportability | #482 |
| advisory | #482 |
| 1162 | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| patients hematologic malignancies | #485 |
| diagnostic efficacy | #485 |
| awaited | #486 |
| secondary prophylaxis | #487 |
| composite scores | #487 |
| silent | #488 |
| travel | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| treatment period | #493 |
| new therapy | #493 |
| p00007 | #493 |
| pan troglodytes | #493 |
| residual risk | #493 |
| hemophilic | #493 |
| vcf | #494 |
| activated protein | #495 |
| heterozygote | #496 |
| favour | #496 |
| replacement hip arthroplasty | #496 |
| dose oral | #496 |
| topic risk factors | #497 |
| 271 | #497 |
| willebrand disease | #498 |
| risk factors stroke | #498 |
| discriminative ability | #498 |
| blockages | #498 |
| hip knee | #501 |
| nri | #502 |
| ptp | #502 |
| ft4 tsh | #503 |
| subcategories | #503 |
| deficiencies | #503 |
| rapid decrease | #504 |
| nondiagnostic | #505 |
| complications pulmonary | #505 |
| 1107 | #505 |
| patients referred | #505 |
| 310 | #506 |
| net clinical | #506 |
| oftentimes | #507 |
| nonionic | #507 |
| day surgery | #507 |
| inhibitors rivaroxaban | #508 |
| contraceptives | #509 |
| 13 95 | #509 |
| aminocaproates | #509 |
| coagulation tests | #509 |
| guidelines diagnosis | #509 |
| degradation products | #510 |
| new oral anticoagulants | #510 |
| angiography patients | #510 |
| thrombosis animals | #510 |
| viii fviii | #511 |
| epiphenomenon | #512 |
| 019 | #512 |
| serial | #513 |
| 056 | #514 |
| highintensity | #514 |
| interim analysis | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| thrombophilia thrombosis | #518 |
| protein antithrombin | #518 |
| bleeding outcomes | #518 |
| thrombotic diseases | #518 |
| sensitivity diagnosis | #518 |
| groups treatment | #519 |
| treatment cancer patients | #519 |
| study sensitivity | #520 |
| 1599 | #521 |
| duration intensity | #521 |
| 8090 | #521 |
| warfarin therapy | #524 |
| general practitioner | #525 |
| fixed doses | #525 |
| 062 | #527 |
| cancer age | #528 |
| cindices | #528 |
| 051 | #529 |
| convincing | #529 |
| 378 | #529 |
| 923 | #529 |
| fatal | #530 |
| health female | #530 |
| thrombosis hemostasis | #531 |
| betaalanine | #531 |
| medically patients | #531 |
| humans postoperative | #531 |
| intensive units icu | #532 |
| 068 | #532 |
| ≥50 years | #532 |
| thrombosis risk | #532 |
| factor thrombin | #534 |
| therapy cancer | #534 |
| 730 | #536 |
| factor pathway | #537 |
| humans neoplasms | #538 |
| 449 | #538 |
| patients idiopathic | #538 |
| concise | #539 |
| ddavp | #539 |
| comprehensive search | #539 |
| cbo | #539 |
| clinical review | #540 |
| diagnosis acute | #540 |
| diagnostic accuracy studies | #540 |
| 234 | #543 |
| vascular obstruction | #543 |
| patients eligible | #543 |
| thrombotic risk | #543 |
| bleeding episodes | #543 |
| conventional treatment | #543 |
| pad abi | #544 |
| jak2 mutation | #544 |
| coagulative | #544 |
| 00 | #544 |
| prospective cohort study | #545 |
| perc | #545 |
| hellp syndrome | #545 |
| v617f | #545 |
| screening strategies | #546 |
| association statin | #546 |
| bureau | #547 |
| prothrombin complex | #547 |
| primary | #548 |
| adequate | #549 |
| 95 difference | #549 |
| overt | #549 |
| reviewers | #550 |
| 1103 | #550 |
| percent patients | #550 |
| cancer type | #550 |
| platelet inhibitors | #550 |
| conduction anesthesia | #550 |
| day patients | #552 |
| amsterdam | #552 |
| studies sensitivity | #552 |
| 500 patients | #552 |
| careful | #552 |
| management bleeding | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| factor vii | #558 |
| 66 patients | #558 |
| vivo treatment | #558 |
| orthopedic surgery | #559 |
| bleeding time | #559 |
| limulus | #561 |
| patients transfusion | #563 |
| female humans tests | #563 |
| board directors | #563 |
| risk development | #563 |
| anamnesis | #564 |
| hip replacement | #564 |
| appears | #564 |
| increasing risk | #565 |
| hyperfibrinolysis | #565 |
| solid tumours | #566 |
| cardiac troponins | #566 |
| withholding | #566 |
| roc curves | #568 |
| n46 | #568 |
| patients 2 years | #568 |
| levothyroxine | #571 |
| alpha1antitrypsin | #571 |
| aggravation | #572 |
| ctnt | #573 |
| cutoff point | #574 |
| revascularization procedures | #574 |
| menstrual bleeding | #574 |
| subcutaneously | #575 |
| women proportion | #575 |
| major bleedings | #575 |
| progression cancer | #577 |
| patients vka | #578 |
| endothelial barrier | #578 |
| thiophenes | #579 |
| endotoxin | #579 |
| pharma | #579 |
| diagnostic tools | #580 |
| notice | #580 |
| 99 | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| unselected patients | #584 |
| dummy | #584 |
| 094 | #585 |
| coagulation disorders | #585 |
| chondroitin sulfates | #586 |
| major orthopedic surgery | #588 |
| feasibility safety | #588 |
| helminth proteins | #589 |
| healthy human | #590 |
| thrombophilias | #590 |
| malignancy | #590 |
| reversal agents | #590 |
| beta alanine | #590 |
| doppler ultrasound | #592 |
| conventional management | #592 |
| massive pulmonary | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| severe bleeding | #597 |
| major hemorrhage | #597 |
| replacement knee | #597 |
| patency rates | #597 |
| ldf | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| tests sensitivity | #600 |
| loss surgical | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| events occurred | #604 |
| comorbid conditions | #604 |
| clinical characteristics patients | #604 |
| diagnostic studies | #606 |
| patients antibodies | #607 |
| initial increase | #607 |
| activated coagulation | #607 |
| 0·3 | #607 |
| treatment acute | #608 |
| tissue factor | #609 |
| pfizer | #609 |
| arbitrage | #609 |
| 100 years | #610 |
| benefit risk | #610 |
| airline | #610 |
| patients death | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| patients bariatric surgery | #615 |
| reluctant | #615 |
| leg | #615 |
| complications risk | #616 |
| arterial disease | #617 |
| treatment rivaroxaban | #617 |
| occurred | #618 |
| 467 | #618 |
| stroke atrial fibrillation | #618 |
| fh patients | #620 |
| compared placebo | #620 |
| patients elevated | #621 |
| advisory committees | #621 |
| 1002 | #622 |
| thyrotoxic | #623 |
| sgs | #623 |
| thrombocytopenia hit | #623 |
| peptide bnp | #625 |
| cochrane central register | #625 |
| topic practice guidelines | #626 |
| stopped | #626 |
| stroke warfarin | #627 |
| warfarin risk | #628 |
| 66 | #628 |
| 5000 | #628 |
| women risk factors | #628 |
| physical training | #629 |
| referral patients | #629 |
| human subjects | #629 |
| diagnostic algorithms | #629 |
| absolute | #630 |
| sanofi | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| uneventful | #635 |
| outweigh | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 95 allcause mortality | #640 |
| 14 95 | #640 |
| proceedings | #641 |
| study quality | #641 |
| predictive performance | #642 |
| 3050 | #642 |
| neutrophilia | #643 |
| threatening bleeding | #643 |
| association mortality | #647 |
| primary outcome measure | #647 |
| statin treatment | #648 |
| studies efficacy | #648 |
| necessitating | #648 |
| thrombolysis patients | #651 |
| fixed | #651 |
| 036 | #651 |
| organisations | #652 |
| troglodytes | #652 |
| fxa | #653 |
| hemorrhagic stroke | #653 |
| 127 | #655 |
| patients review | #657 |
| 69 | #659 |
| bleeding death | #659 |
| coronary stent implantation | #659 |
| haematoma | #660 |
| physical examination | #661 |
| coagulation proteins | #661 |
| tertiles | #661 |
| clinical presentations | #662 |
| haemophilia | #662 |
| 95 studies | #663 |
| 1028 | #663 |
| long term treatment | #664 |
| provoked | #664 |
| sepsis shock | #665 |
| deep | #666 |
| phase iii studies | #666 |
| presence patients | #667 |
| onethird | #667 |
| patients completed | #667 |
| guideline adherence | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| patients cteph | #673 |
| elevated plasma | #673 |
| hospitalization hf | #674 |
| managing | #674 |
| il6 levels | #675 |
| inhibitor 1 | #675 |
| clotting factors | #675 |
| highincome countries | #676 |
| prothrombotic | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| medicine humans | #681 |
| pulmonary endarterectomy | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| ambulatory patients | #692 |
| patients bleeding | #692 |
| myocardial infarctions | #693 |
| graduated | #693 |
| activator pa | #693 |
| composite outcome | #694 |
| intracranial bleeding | #694 |
| administer | #694 |
| precise mechanisms | #694 |
| 1718 | #695 |
| combined oral contraceptives | #696 |
| stroke prevention patients | #696 |
| moyamoya | #696 |
| participant data | #698 |
| ratio male | #698 |
| difference 95 | #698 |
| compression devices | #700 |
| episode | #700 |
| prothrombin gene | #702 |
| therapeutic management | #702 |
| diagnostic errors | #702 |
| veins venous | #703 |
| patients confirmed | #703 |
| surgery risk | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| directors | #709 |
| clinical expression | #709 |
| starters | #711 |
| gastrointestinal bleeding | #712 |
| gynaecology | #712 |
| medical patients | #712 |
| 048 | #712 |
| radionuclide imaging | #713 |
| 1098 | #714 |
| neurosurgical patients | #714 |
| rate death | #714 |
| intravenous bolus | #715 |
| menstrual period | #716 |
| rivaroxaban stroke | #716 |
| cancer groups | #717 |
| adequately | #717 |
| 10 30 | #718 |
| solid cancer | #718 |
| falsely | #718 |
| reagent kits | #719 |
| plasminogen | #719 |
| pulmonary medicine | #720 |
| clinical judgment | #721 |
| accp | #721 |
| pyrazoles pyridines | #721 |
| nordisk | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| abnormal | #726 |
| follow period | #726 |
| gentamicins | #727 |
| 59 patients | #727 |
| orthopaedic surgery | #728 |
| diagnostic therapeutic | #728 |
| diagnostic tests | #730 |
| leeches | #732 |
| gentamicin | #732 |
| oral contraception | #733 |
| tumor necrosis factor | #733 |
| relative risk 95 | #734 |
| patients levels | #735 |
| hull | #735 |
| disease pad | #735 |
| clinical prediction rule | #736 |
| tests retrospective studies | #736 |
| atrial fibrillation risk | #736 |
| 6 12 | #739 |
| post hoc analysis | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| 040 | #742 |
| unclear | #742 |
| early pregnancy loss | #742 |
| topic predictive | #743 |
| illness time factors | #744 |
| betathromboglobulin | #744 |
| molecular weight | #744 |
| 285 | #746 |
| antithrombin activity | #746 |
| patients 50 years | #746 |
| etp | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| fibrin formation | #754 |
| advisable | #754 |
| primary patients | #755 |
| pneumatic compression | #756 |
| 95 combination | #756 |
| answer | #756 |
| hf risk | #756 |
| 95 risk factors | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| loe | #759 |
| 85 | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| 435 | #763 |
| proportion women | #763 |
| start treatment | #764 |
| cprs | #764 |
| hip surgery | #765 |
| 689 | #767 |
| aspirin clopidogrel | #767 |
| risk pregnancy | #767 |
| 732 | #768 |
| method drug | #769 |
| groups patients | #770 |
| 566 | #770 |
| relevant | #770 |
| graft patency | #772 |
| baseline values | #772 |
| patients criteria | #773 |
| subcutaneous injections | #774 |
| bmi patients | #774 |
| 1·5 | #776 |
| 992 | #777 |
| dose warfarin | #778 |
| patients 65 years | #778 |
| study groups | #778 |
| dose intravenous | #778 |
| miscarriage | #779 |
| patients hyperthyroidism | #780 |
| thromboembolism prophylaxis | #780 |
| 066 | #780 |
| plasmin generation | #780 |
| age ≥ | #782 |
| onefifth | #785 |
| factor ixa | #785 |
| abnormalities patients | #786 |
| 100 personyears | #787 |
| polypharmacy | #787 |
| topic disease models | #787 |
| general practitioners | #787 |
| cteph | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| recombinant tissue | #793 |
| mechanical heart | #793 |
| inactivators | #795 |
| 047 | #795 |
| risk factors risk | #795 |
| patency | #796 |
| patient years | #796 |
| studies prevalence | #797 |
| eligible | #797 |
| netherlands | #797 |
| femoropopliteal | #798 |
| lupus anticoagulant | #798 |
| estrogen therapy | #799 |
| patients lower | #799 |
| theme | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| randomized patients | #804 |
| subclinical | #804 |
| anticoagulant agents | #805 |
| microvesicles | #805 |
| fibrillation blood | #806 |
| adverse outcomes patients | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| hypertension cteph | #809 |
| efficacy patients | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| flights | #816 |
| factor vwf | #816 |
| 0·4 | #818 |
| vehicle control | #820 |
| health predictive | #820 |
| irrespective | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| reduction mortality | #823 |
| prevention patients | #823 |
| coc | #824 |
| single administration | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| cardioembolic stroke | #828 |
| gp | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| myers | #833 |
| antithrombotic treatment | #833 |
| 93 | #833 |
| abortion habitual | #835 |
| plough | #836 |
| oral adult | #836 |
| noac | #837 |
| versus placebo | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| antithrombotic therapy | #846 |
| 49 | #846 |
| 072 | #847 |
| multidetector row | #847 |
| advise | #848 |
| recurrence risk | #849 |
| caesarean | #850 |
| patients diagnosis | #850 |
| area roc curve | #852 |
| reference method | #853 |
| 30 patients | #853 |
| pre‐eclampsia | #853 |
| advanced prostate | #854 |
| fibrin | #855 |
| clopidogrel aspirin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| pyridones | #870 |
| 6 month | #870 |
| individual participant | #872 |
| longterm clinical outcomes | #872 |
| favoring | #873 |
| tasman | #873 |
| thromboembolic pulmonary | #874 |
| imaging reproducibility | #874 |
| targeted inhibition | #874 |
| titles | #875 |
| plasminogen activation | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| risk thromboembolic | #878 |
| dabigatran rivaroxaban | #878 |
| 57 | #879 |
| anticoagulants atrial | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| domiciliary | #894 |
| male mexico | #894 |
| 084 | #894 |
| loading dose | #896 |
| p011 | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| 064 | #908 |
| factor activity | #908 |
| subcutaneous administration | #909 |
| documented | #911 |
| patients clinical trials | #911 |
| haemostatic | #912 |
| initially | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| haemodialysis patients | #916 |
| combined approach | #916 |
| 317 | #917 |
| thromboembolic events | #918 |
| 022 | #918 |
| chronic thromboembolic | #919 |
| antagonist oral | #920 |
| standard patients | #920 |
| randomeffects model | #920 |
| ultrasound examination | #921 |
| optimal dose | #921 |
| loss patients | #921 |
| practise | #923 |
| estimate male | #923 |
| multifactorial disease | #925 |
| study medication | #925 |
| total hip | #926 |
| 902 | #928 |
| safer | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| treatment placebo | #934 |
| wording | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| 60 patients | #938 |
| subgroup patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| women preeclampsia | #944 |
| echocardiographically | #944 |
| stroke atrial | #944 |
| emboli | #945 |
| predictive values | #946 |
| ssc | #946 |
| anticoagulation treatment | #947 |
| diagnostic | #948 |
| extensive disease | #948 |
| knee replacement | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| dic | #956 |
| cancer humans | #956 |
| network metaanalysis | #956 |
| registro | #956 |
| reassuring | #957 |
| venous insufficiency | #957 |
| day1 | #958 |
| efficacy | #958 |
| retropubic | #961 |
| combined oral | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| inhibitor1 | #966 |
| reference lists | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| prevalence characteristics | #973 |
| risk allcause mortality | #973 |
| hoc | #973 |
| antiplatelet | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| female fibrinogen | #976 |
| vascular humans | #976 |
| fvii | #978 |
| false negative | #979 |
| 071 | #980 |
| 50 100 | #980 |
| onset aged aged | #980 |
| early gestation | #984 |
| 426 | #986 |
| prophylactic treatment | #987 |
| randomised trials | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| rises | #991 |
| missed | #991 |
| academic medical center | #992 |
| seminar | #992 |
| normal lung | #993 |
| counteracted | #993 |
| treatment bleeding | #994 |
| aged | #999 |
| 226 | #999 |
| lower extremity | #1000 |
| thromboembolic risk | #1000 |
| justification | #1000 |
| tissue type | #1001 |
| rivaroxaban apixaban | #1002 |
| parenteral administration | #1002 |
| eclamptic | #1003 |
| extended | #1005 |
| interleukin 6 | #1005 |
| hyperprolactinaemia | #1005 |
| pyridines | #1006 |
| easier | #1007 |
| orthosis | #1007 |
| 50 patients | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| ticlopidine | #1018 |
| pounds | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| cha2ds2 vasc | #1023 |
| years risk | #1023 |
| international prospective | #1024 |
| humans randomized | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| decision analysis | #1030 |
| firstdegree relatives | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| relatives | #1033 |
| cardiovascular event | #1033 |
| risk hemorrhage | #1033 |
| 052 | #1035 |
| male netherlands | #1037 |
| graft occlusion | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| vwf levels | #1047 |
| patients severe asthma | #1047 |
| examiner | #1050 |
| patients massive | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| 221 | #1054 |
| mean±sd | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| birth rate | #1060 |
| 179 | #1060 |
| coagulant | #1060 |
| 610 | #1061 |
| pad | #1061 |
| primary data | #1062 |
| published literature | #1062 |
| false | #1064 |
| prekallikrein | #1065 |
| 150 | #1065 |
| 101 | #1066 |
| 00008 | #1066 |
| live birth | #1066 |
| lysosphingolipid | #1067 |
| cut | #1067 |
| pmol | #1068 |
| register controlled | #1070 |
| 95 increased risk | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| thorax | #1074 |
| laboratory diagnosis | #1074 |
| systematic search | #1078 |
| advocate | #1080 |
| 063 | #1080 |
| drawbacks | #1082 |
| f1 | #1087 |
| longterm therapy | #1087 |
| bandages | #1089 |
| stopping | #1095 |
| clarifications | #1095 |
| mandated | #1096 |
| diagnostic utility | #1096 |
| idarucizumab | #1096 |
| 083 | #1099 |
| 1223 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| fourfold | #1105 |
| blueprint | #1105 |
| peptide brain | #1107 |
| clinical protocols | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| haemodialysis | #1116 |
| bypass grafts | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| probands | #1123 |
| resistance factor | #1123 |
| new developments | #1124 |
| advised | #1125 |
| 445 | #1126 |
| new perspectives | #1126 |
| cip | #1127 |
| heparininduced thrombocytopenia | #1127 |
| patients pad | #1128 |
| discretion | #1132 |
| judged | #1132 |
| statistic | #1133 |
| ≤10 | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| 635 | #1141 |
| superior efficacy | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| roc curve | #1150 |
| refusal | #1150 |
| medline | #1151 |
| medical records | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| anticoagulation therapy | #1156 |
| patients influenza | #1156 |
| blood loss | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| published guidelines | #1163 |
| bristol | #1163 |
| viii | #1164 |
| safety concerns | #1164 |
| stable angina | #1164 |
| hyperhomocysteinemia | #1164 |
| intermittent | #1164 |
| thromboembolism risk | #1165 |
| age 65 years | #1165 |
| angiogram | #1167 |
| crossover design | #1172 |
| atherosclerotic disease | #1172 |
| perioperative bleeding | #1172 |
| glucocorticoid treatment | #1172 |
| occlusive diseases | #1173 |
| practice guideline | #1173 |
| macroglobulin | #1176 |
| 5 years patients | #1176 |
| findings patients | #1178 |
| analysis studies | #1178 |
| 79 | #1179 |
| concealed | #1181 |
| conceive | #1181 |
| patients obesity | #1182 |
| unaware | #1182 |
| hospitalized patients | #1182 |
| combined therapy | #1186 |
| conclusive | #1186 |
| degree relatives | #1189 |
| occult | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| mandate | #1199 |
| cardiotonic agents | #1199 |
| international society | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| quantitative trait locus | #1204 |
| 015 | #1204 |
| categorized | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| pph | #1214 |
| multicenter randomized | #1214 |
| 103 | #1218 |
| warranted | #1221 |
| scores patients | #1221 |
| patient treatment | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| peak levels | #1224 |
| 64 patients | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| blind | #1227 |
| sixfold | #1227 |
| consensus guidelines | #1228 |
| metabolic syndrome patients | #1228 |
| peptide hydrolases | #1229 |
| trial background | #1229 |
| radionuclide | #1229 |
| 65 patients | #1230 |
| rules | #1232 |
| doubles | #1232 |
| aspirin | #1234 |
| postoperative hemorrhage | #1238 |
| milliliter | #1238 |
| coronary angiography patients | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| matter lesions | #1252 |
| subgroups | #1252 |
| ml1 | #1252 |
| artery pulmonary | #1254 |
| extensive | #1257 |
| search strategy | #1257 |
| oral vitamin | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| entity | #1266 |
| visiting | #1266 |
| troponins | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| intensive patients | #1274 |
| equally | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| routine screening | #1281 |
| statin users | #1281 |
| 75 years | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| perfusion defects | #1295 |
| janssen | #1295 |
| scan | #1295 |
| predictive | #1297 |
| hemofiltration | #1297 |
| insufficiently | #1298 |
| low prevalence | #1299 |
| cardiovascular complications | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| 61 | #1303 |
| pf4 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| cyproterone | #1312 |
| apoa | #1312 |
| 1st | #1312 |
| risk difference | #1312 |
| adamts13 activity | #1313 |
| 0·7 | #1314 |
| current strategies | #1314 |
| tests severity | #1314 |
| atrial fibrillation | #1316 |
| claudication | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| lipoproteina | #1325 |
| glycoprotein gpiib | #1325 |
| patients coronavirus disease | #1326 |
| antibodies monoclonal antibodies | #1329 |
| vascular diseases | #1329 |
| beneficial | #1329 |
| plasminogen activators | #1330 |
| thyroid disorders | #1330 |
| low moderate | #1330 |
| 77 | #1331 |
| 6 months patients | #1331 |
| coagulation cascade | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| 91 | #1342 |
| likelihood ratio | #1342 |
| venous catheters | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| antitrypsin | #1347 |
| surgical trauma | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| 15 patients | #1359 |
| allcause mortality 95 | #1359 |
| experimental model | #1359 |
| limb salvage | #1363 |
| vwf | #1363 |
| arsenal | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| dl1 | #1385 |
| noninferiority | #1385 |
| 224 | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| patients control subjects | #1400 |
| record linkage | #1400 |
| equipoise | #1402 |
| antisense oligonucleotide | #1402 |
| 82 | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| 1886 | #1405 |
| patients advanced cancer | #1405 |
| obese patients | #1406 |
| pregnancy loss | #1406 |
| categories | #1408 |
| 515 | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| thrombotic complications | #1419 |
| 3 6 | #1419 |
| 7 weeks | #1419 |
| 6 weeks | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| university hospitals | #1422 |
| followup data | #1422 |
| ≥55 | #1424 |
| 061 | #1424 |
| daily | #1424 |
| eightfold | #1425 |
| 080 | #1427 |
| randomised controlled trials | #1427 |
| rgs | #1430 |
| casecontrol study | #1430 |
| outcome pregnancy | #1438 |
| imaging radiopharmaceuticals | #1439 |
| 096 | #1439 |
| 78 | #1443 |
| principal | #1443 |
| 1123 | #1445 |
| outcome studies | #1446 |
| drug levels | #1446 |
| weight bmi | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| confusion | #1454 |
| population patients | #1454 |
| platelet factor | #1455 |
| aged blood | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| funded | #1466 |
| actual | #1466 |
| avoided | #1468 |
| 0·9 | #1468 |
| heart failure hf | #1469 |
| 26 patients | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| 1215 | #1473 |
| prevalences | #1473 |
| centrally | #1474 |
| systemic infection | #1477 |
| probability | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| cushing syndrome | #1485 |
| analysis randomized | #1485 |
| methodologic | #1486 |
| phase iii trials | #1486 |
| general practice | #1491 |
| procoagulant activity | #1495 |
| patients control | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| growing body | #1514 |
| adverse outcome | #1514 |
| proximal | #1516 |
| ganz | #1520 |
| pregnancy postpartum | #1520 |
| patients 10 | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| contraindicated | #1527 |
| thrombotic events | #1527 |
| score | #1529 |
| time study | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| live births | #1552 |
| patients severe sepsis | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| pfa | #1564 |
| enfermedad | #1564 |
| iii topic | #1565 |
| treatment prevention | #1566 |
| topic | #1566 |
| hyperlipoproteinemia type | #1568 |
| 95ci | #1568 |
| cushings syndrome | #1568 |
| deficient | #1568 |
| aged biomarkers | #1571 |
| 36 | #1575 |
| plasminogen activator | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| thyroid dysfunction | #1586 |
| study entry | #1586 |
| activation markers | #1586 |
| cocs | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| total mortality | #1594 |
| 1·1 | #1594 |
| translates | #1597 |
| placebo | #1598 |
| noncancer | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| 162 | #1613 |
| general surgery | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| tests reproducibility | #1616 |
| prospective cohort studies | #1616 |
| factors tomography | #1616 |
| postpartum period | #1616 |
| positive effects | #1616 |
| perinatal outcome | #1618 |
| 155 | #1618 |
| cvd patients | #1619 |
| imaging tomography | #1619 |
| female hemostasis | #1619 |
| proportion | #1620 |
| uncertain | #1621 |
| 12month followup | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| pa patients | #1632 |
| incidentally | #1632 |
| venous disease | #1632 |
| clinical patients | #1633 |
| fresh frozen plasma | #1633 |
| study outcomes | #1639 |
| double | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| stroke prevention | #1644 |
| ctni | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| dorsiflexion | #1651 |
| 997 | #1651 |
| 35 years | #1652 |
| ≤4 | #1652 |
| thrombin activity | #1653 |
| studies data | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| disease adult | #1670 |
| homocysteine levels | #1670 |
| thrombi | #1674 |
| inpatient treatment | #1676 |
| daily dosing | #1676 |
| plasma level | #1677 |
| deficiency | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| unreliable | #1686 |
| steroidal anti | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| yielded | #1712 |
| 033 | #1712 |
| hemorheology | #1715 |
| intravenous | #1715 |
| bronchospasm | #1720 |
| hematologic malignancies | #1720 |
| female femoral | #1721 |
| mb | #1721 |
| diagnostic evaluation | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| conference | #1726 |
| 107 | #1726 |
| derived microparticles | #1729 |
| 021 | #1730 |
| volunteer | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| clinical scores | #1735 |
| east asian | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| table | #1745 |
| patients ventricular | #1745 |
| 691 | #1745 |
| profession | #1746 |
| risk cardiovascular events | #1747 |
| hyperinsulinaemia | #1747 |
| apc | #1749 |
| turp | #1749 |
| homozygosity | #1750 |
| pselectin | #1750 |
| replacement | #1750 |
| 128 | #1752 |
| intracranial hemorrhages | #1753 |
| 133 | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| assessor | #1760 |
| audiometry | #1760 |
| treatment recommendations | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| human insulin | #1764 |
| fx | #1764 |
| duplicate | #1769 |
| arteriosclerosis | #1770 |
| initial management | #1770 |
| hemorrhage | #1770 |
| 2 6 | #1774 |
| allcause death | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| selfmanagement | #1790 |
| clinical consequences | #1790 |
| reid | #1793 |
| microparticle | #1793 |
| cardiac troponin | #1794 |
| vascular surgical | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| aggregation inhibitors | #1802 |
| 020 | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| 95 specificity | #1812 |
| slc6a4 | #1812 |
| tumor necrosis | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| conjoint | #1819 |
| economic evaluation | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| screening middle | #1825 |
| preference | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| definite | #1837 |
| compressibility | #1837 |
| cushing | #1838 |
| kaplanmeier estimate | #1838 |
| severe sepsis | #1839 |
| 1 week | #1842 |
| central venous | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| explanations | #1852 |
| hydroxyethyl starch | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| diagnostic techniques | #1892 |
| thromboses | #1892 |
| shrs | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 5 10 | #1897 |
| 067 | #1897 |
| contraindications | #1900 |
| diagnostic testing | #1901 |
| tnf | #1901 |
| extremity | #1901 |
| clt | #1905 |
| plaster | #1906 |
| hazard ratio | #1906 |
| induced thrombocytopenia | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| referral | #1910 |
| efficacy treatment | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 793 | #1920 |
| 13 patients | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| stroke 95 | #1923 |
| 868 | #1923 |
| biotin | #1924 |
| 55 years | #1924 |
| venous pressure | #1926 |
| trials patients | #1926 |
| intracranial hemorrhage | #1927 |
| μg | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| glucocorticoid | #1934 |
| nonfatal | #1934 |
| 3months | #1935 |
| relative risks | #1935 |
| acute | #1936 |
| 17 | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| femoral vein | #1950 |
| safety effectiveness | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| observer | #1962 |
| investigators | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| 48 hours | #1973 |
| surgical blood | #1973 |
| fibrin clot | #1973 |
| potent inhibitor | #1976 |
| renewed | #1976 |
| topic clinical trials | #1978 |
| 771 | #1981 |
| specificity ultrasonography | #1981 |
| hyperaldosteronism | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| 1·0 | #1986 |
| treatment cancer | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| 018 | #1992 |
| prospero | #1992 |
| drug drug therapy | #1994 |
| cmax | #1994 |
| computerized | #1995 |
| cvt | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| autopsy | #2000 |
| transient increase | #2000 |
| clinical severity | #2000 |
| 3 months patients | #2000 |
| 53 | #2003 |
| pneumonia patients | #2006 |
| 7 patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| angina unstable | #2017 |
| mongrel | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| 097 | #2033 |
| patients lung | #2033 |
| pertechnetate | #2036 |
| costs cost | #2041 |
| medical record | #2041 |
| undergoing major | #2042 |
| abstracts | #2042 |
| questioned | #2043 |
| thrice | #2045 |
| prediction rule | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| superior vena cava | #2051 |
| quartiles | #2051 |
| inadequately | #2052 |
| pregnancy trimester | #2053 |
| 277 | #2053 |
| controversial | #2055 |
| stent implantation | #2056 |
| adherence guidelines | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| requested | #2063 |
| varies | #2063 |
| clinical indications | #2064 |
| biological neoplasms | #2064 |
| hemostatics | #2070 |
| national institute | #2074 |
| mcnemar | #2074 |
| 188 | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| media thickness | #2087 |
| bypasses | #2087 |
| 03 | #2089 |
| versions | #2091 |
| 114 | #2092 |
| square distribution | #2092 |
| tissue plasminogen | #2093 |
| preformed | #2099 |
| reference range | #2099 |
| 038 | #2100 |
| lifetime risk | #2101 |
| desmopressin | #2101 |
| 59 | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| 1966 | #2109 |
| 031 | #2109 |
| substantial | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| independently | #2118 |
| unnecessary | #2118 |
| exists | #2119 |
| initial | #2119 |
| development validation | #2120 |
| coronary stent | #2122 |
| clinicaltrialsgov | #2122 |
| 11 | #2122 |
| original | #2125 |
| acl reconstruction | #2125 |
| topic surveys | #2127 |
| patients cardiovascular disease | #2127 |
| chose | #2129 |
| controlled | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| protamines | #2134 |
| congress | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| live | #2145 |
| clot | #2145 |
| bodyweight | #2146 |
| professionals | #2146 |
| pancreatic cancer patients | #2157 |
| oestrogens | #2160 |
| committee | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| 674 | #2183 |
| advanced cancer | #2183 |
| 2 × | #2185 |
| fifty | #2185 |
| giant cell arteritis | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| increased patients | #2205 |
| pravastatin | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| diagnosis differential | #2212 |
| neutrophil elastase | #2212 |
| doubled | #2213 |
| 364 | #2219 |
| pao2 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| 94 | #2225 |
| differential female | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| clots | #2257 |
| hivinfected patients | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| hyperthyroidism | #2265 |
| stroke aged | #2265 |
| 12 | #2266 |
| metaanalysis | #2267 |
| 6 months | #2267 |
| patients developed | #2273 |
| reverses | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| setting | #2284 |
| based case | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| metaanalysis studies | #2314 |
| tests | #2314 |
| nephelometry | #2316 |
| initial therapy | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| method female | #2324 |
| humans myocardial | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| inhibitor | #2344 |
| lacked | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| 099 | #2375 |
| risk bias | #2375 |
| patients active | #2376 |
| predictable | #2377 |
| hemostasis | #2377 |
| enrolling | #2379 |
| acute coronary syndromes | #2379 |
| 187 | #2381 |
| dosing regimen | #2382 |
| anticardiolipin | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| patients liver cirrhosis | #2401 |
| 757 | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| postinjection | #2413 |
| periodicals | #2413 |
| protein | #2413 |
| risk estimates | #2414 |
| sphingosine1 | #2415 |
| 22 | #2415 |
| internal medicine | #2424 |
| study drug | #2424 |
| 32 | #2425 |
| guidelines | #2426 |
| sensitivity 100 | #2426 |
| 0048 | #2430 |
| coagulants | #2430 |
| legs | #2430 |
| 002 | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| ptca | #2434 |
| prolonging | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| turbidimetry | #2448 |
| 719 | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| prognostic patients | #2464 |
| watchful | #2464 |
| potential benefits | #2466 |
| nephrotoxic | #2468 |
| therapy acute | #2468 |
| comprised | #2469 |
| 477 | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| current review | #2476 |
| cancer population | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| pathway inhibitor | #2485 |
| 648 | #2485 |
| treatment efficacy | #2489 |
| 1015 | #2490 |
| 829 | #2490 |
| chest | #2493 |
| duration | #2493 |
| 25 | #2495 |
| illness tomography | #2503 |
| 616 | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| 479 | #2516 |
| drug female humans | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| neutrophil extracellular traps | #2521 |
| 463 | #2521 |
| accurate diagnosis | #2523 |
| 152 | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 0046 | #2537 |
| 874 | #2537 |
| 164 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| hydroxyethyl | #2560 |
| haematology | #2560 |
| hours | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| kits | #2574 |
| humans logistic | #2574 |
| 73 | #2574 |
| pill | #2575 |
| prevalence | #2575 |
| patients total | #2577 |
| translate | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| 591 | #2585 |
| efficacious | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| burden disease | #2605 |
| manifest | #2605 |
| metaregression | #2606 |
| parenteral | #2606 |
| patients 2 | #2608 |
| fatal outcome | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| cost analysis | #2620 |
| aviation | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| coincided | #2635 |
| trials rcts | #2635 |
| chondroitin | #2635 |
| 10 day | #2637 |
| attractive | #2641 |
| 345 | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| benzimidazoles | #2662 |
| c677 | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| 516 | #2683 |
| outcome ultrasonography | #2683 |
| initial dose | #2685 |
| iii | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| 594 | #2691 |
| aso | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| management strategies | #2732 |
| dose low | #2732 |
| cart | #2736 |
| 595 | #2737 |
| 427 | #2739 |
| classifications | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| predetermined | #2746 |
| 848 | #2746 |
| patients asthma | #2747 |
| baseline characteristics | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| 143 | #2768 |
| management acute | #2768 |
| confounded | #2769 |
| expert consensus | #2772 |
| alpha animals | #2772 |
| antithyroid | #2772 |
| active control | #2775 |
| inpatient | #2776 |
| thrombomodulin | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| consecutive series | #2802 |
| 402 | #2802 |
| cirrhosis patients | #2805 |
| reaching | #2805 |
| international | #2809 |
| standardized | #2811 |
| secondary | #2811 |
| embolic | #2812 |
| follow studies | #2813 |
| 406 | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| bid | #2826 |
| antiplatelet drugs | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| recurrence rate | #2835 |
| contacting | #2835 |
| ketoprostaglandin | #2836 |
| helminth | #2836 |
| kruskal | #2839 |
| crossover | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| doppler ultrasonography | #2852 |
| iii trials | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| new treatment | #2857 |
| post discharge | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| excessive | #2880 |
| trimester pregnancy | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| systematic review metaanalysis | #2897 |
| 21 | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| slight | #2903 |
| severe asthma | #2903 |
| feasible | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| leading death | #2917 |
| lowrisk patients | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| 993 | #2928 |
| proportions | #2928 |
| clear | #2932 |
| risk stratification patients | #2934 |
| 2400 | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 270 | #2960 |
| 010 | #2960 |
| 20 | #2961 |
| exercise therapy | #2962 |
| followup | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| lecture | #2984 |
| declare | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| point | #2991 |
| pneumatic | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| factors surveys | #3015 |
| antigen levels | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| early recognition | #3025 |
| nested case | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 50 years | #3040 |
| 419 | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| nomogram | #3063 |
| 80 | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| subsequently | #3076 |
| 2 4 | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| angioplasty | #3088 |
| chronic renal failure | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| trimester | #3110 |
| benchmark | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| oac | #3122 |
| wallis | #3122 |
| lifelong | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 136 | #3134 |
| 12 months | #3134 |
| meta‐analysis | #3137 |
| levels risk | #3142 |
| 082 | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| idiopathic | #3153 |
| 507 | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| pregnancy women | #3194 |
| diethylstilbestrol | #3194 |
| pacientes | #3197 |
| plasmin | #3198 |
| 945 | #3198 |
| therapy risk | #3199 |
| tenth | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| suggested | #3219 |
| cancer types | #3219 |
| 153 | #3223 |
| intravenous infusion | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| meetings | #3241 |
| recombinant | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| 198 | #3251 |
| bivalirudin | #3251 |
| hypothyroid | #3253 |
| 29 | #3253 |
| scoring | #3255 |
| judgement | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| coumarin | #3289 |
| tumor markers | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| 465 | #3330 |
| reduces | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| inpatients | #3344 |
| cerebrovascular disease | #3344 |
| evaluating | #3349 |
| 362 | #3349 |
| spontaneous abortion | #3354 |
| diagnosing | #3354 |
| 273 | #3355 |
| common complication | #3356 |
| diagnosis cancer | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| 301 | #3379 |
| humans lower | #3379 |
| concluded | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| function patients | #3389 |
| calf | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| acute treatment | #3403 |
| 553 | #3403 |
| tunica | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| randomisation | #3419 |
| preventive | #3419 |
| hypothesised | #3420 |
| study risk | #3420 |
| surgical patients | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| prevalence incidence | #3452 |
| 168 | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| differ | #3470 |
| 34 | #3470 |
| intensive chemotherapy | #3471 |
| patients receive | #3472 |
| pregnancy complications | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| antiphospholipid | #3485 |
| cancer metastasis | #3485 |
| increased morbidity | #3486 |
| asymptomatic | #3487 |
| lower leg | #3487 |
| paradox | #3490 |
| personyears | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| inhibitors | #3506 |
| treat | #3506 |
| hemorrhagic complications | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| discusses | #3522 |
| confirmed | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| lupus | #3533 |
| human cytomegalovirus | #3533 |
| areas covered | #3537 |
| societies | #3541 |
| guidance | #3541 |
| 113 | #3544 |
| current practice | #3551 |
| gastro | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| necessity | #3596 |
| prognosis prospective | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| platelet function | #3619 |
| treated | #3619 |
| interval | #3622 |
| platelet activation | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| q3 | #3629 |
| kappa | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| undergo | #3642 |
| homozygote | #3642 |
| bypass surgery | #3642 |
| externally | #3645 |
| p006 | #3645 |
| occlusions | #3646 |
| 1960 | #3649 |
| 30 | #3649 |
| interindividual variability | #3651 |
| fibrillation | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| optimal management | #3671 |
| outcome administration | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| drug monitoring | #3721 |
| diagnostic process | #3721 |
| pharmacodynamics | #3725 |
| inhibitors humans | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| effective | #3739 |
| humans intracranial | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| randomised | #3754 |
| deterioration | #3754 |
| objectives | #3759 |
| 8 patients | #3762 |
| subgroup analyses | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| computed ultrasonography | #3774 |
| clinicians patients | #3774 |
| inherited | #3775 |
| 517 | #3778 |
| interpretable | #3778 |
| 483 | #3782 |
| total knee arthroplasty | #3789 |
| aminoglycosides | #3789 |
| thyroid hormones | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| compelling | #3804 |
| vessel wall | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| 330 | #3815 |
| patients lung cancer | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| irs | #3856 |
| meeting | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| review data | #3860 |
| acquired resistance | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| optimisation | #3884 |
| cancer survival | #3884 |
| record | #3885 |
| sensitivity | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| 351 | #3890 |
| 184 | #3890 |
| difference | #3890 |
| 10000 | #3902 |
| methylamines | #3903 |
| halflives | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| specificity tomography | #3915 |
| angiography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| case fatality | #3946 |
| 405 | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| p004 | #3961 |
| dichotomy | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| risk cancer | #3970 |
| uncontrolled | #3970 |
| austrian | #3971 |
| behalf | #3971 |
| cardiovascular events | #3972 |
| data studies | #3975 |
| 2nd | #3975 |
| quality assurance | #3980 |
| 986 | #3982 |
| pregnancy | #3982 |
| continuous infusion | #3983 |
| flying | #3986 |
| unstable | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| introduction | #4045 |
| 296 | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| bariatric | #4077 |
| pcc | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| oligosaccharides | #4089 |
| natriuretic peptide | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| cutoff | #4099 |
| indications | #4099 |
| activation | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| 008 | #4137 |
| withdrawn | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| 2030 | #4171 |
| patients prostate cancer | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 485 | #4212 |
| 411 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 289 | #4226 |
| 121 | #4226 |
| trough | #4229 |
| crosssectional analysis | #4230 |
| p0005 | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| patients mortality | #4242 |
| cox regression | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 455 | #4340 |
| 102 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| managed | #4350 |
| potential risk factors | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| rapid | #4383 |
| minutes | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| slice | #4394 |
| concurrently | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| 71 | #4407 |
| negative | #4407 |
| bowel diseases | #4407 |
| general | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| lacking | #4417 |
| splanchnic | #4417 |
| immunoassays | #4419 |
| dose aspirin | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| 192 | #4459 |
| vascular surgery | #4459 |
| proband | #4461 |
| cytomegalovirus infection | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| cd18 | #4486 |
| clinical manifestations | #4486 |
| pancreatic cancer | #4487 |
| inadequate | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| comprises | #4503 |
| activation platelet | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| cerebrovascular disorders | #4571 |
| calculating | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| preserves | #4594 |
| attenuating | #4594 |
| eventually | #4595 |
| gradual | #4595 |
| 204 | #4596 |
| simplified | #4596 |
| 4000 | #4601 |
| 4 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| acetylsalicylic acid | #4613 |
| vii | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| hospital costs | #4640 |
| risks benefits | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| 003 | #4658 |
| habitual | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| myelofibrosis | #4670 |
| 171 | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| day | #4680 |
| fh | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| unchanged | #4698 |
| ranging | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| chronic renal | #4775 |
| baseline patients | #4775 |
| acute coronary | #4784 |
| 44 | #4785 |
| scheduled | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| acl | #4861 |
| definition | #4861 |
| efficiency | #4869 |
| gpiib | #4870 |
| nonvalvular atrial fibrillation | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| total | #4891 |
| antiplatelet therapy | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| preparations | #4906 |
| tests prognosis | #4906 |
| served | #4910 |
| fmd | #4913 |
| chlamydophila | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| dose | #4976 |
| manufacturers | #4976 |
| albeit | #4982 |
| orthopedics | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| references | #5006 |
| 389 | #5006 |
| epoprostenol | #5009 |
| reminder | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| 156 | #5040 |
| screening test | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| evaluable | #5089 |
| regarded | #5089 |
| hip fractures | #5090 |
| relation | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| vivo studies | #5124 |
| bay | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| ischaemic stroke | #5130 |
| 0018 | #5130 |
| female | #5131 |
| 131 | #5131 |
| transfused | #5134 |
| balancing | #5136 |
| contrast media | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| shortly | #5157 |
| disagreement | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| 11 patients | #5170 |
| predispose | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| emergencies | #5233 |
| articles | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| 365 | #5289 |
| pooling | #5289 |
| aware | #5300 |
| thrombus | #5301 |
| 36 patients | #5301 |
| urokinase | #5302 |
| atherogenesis | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| acute ischemic stroke | #5341 |
| reagent | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| male | #5363 |
| schedule drug | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| 247 | #5490 |
| occurrences | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| patient risk | #5497 |
| 260 | #5497 |
| continuing | #5499 |
| discomfort | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| limitation | #5539 |
| erythema | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| receptor1 | #5563 |
| established | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| 46 | #5573 |
| reduce risk | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| equivalent | #5598 |
| circulating levels | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| reclassification | #5644 |
| 80 years | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| milder | #5771 |
| semiquantitative | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| mpo | #5804 |
| incidence rates | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| 1000 | #5819 |
| aircraft | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| true | #5852 |
| atrial | #5852 |
| 088 | #5854 |
| attending | #5856 |
| women pregnancy | #5857 |
| 290 | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| occurrence | #5894 |
| reliable | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| 22 patients | #5928 |
| aged platelet | #5928 |
| graded | #5934 |
| premenopause | #5938 |
| revision | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| 43 | #5962 |
| rcts | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| type iii | #6101 |
| topics | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| ffa | #6160 |
| generation | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| terminated | #6228 |
| mortality morbidity | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| colleagues | #6273 |
| practitioners | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 135 | #6340 |
| 63 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| roche | #6405 |
| factor gene | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| accuracy | #6501 |
| peripheral artery disease | #6501 |
| cancer cell | #6502 |
| incidence risk | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| washout | #6524 |
| 318 | #6524 |
| triiodothyronine | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| increased incidence | #6532 |
| cochrane | #6532 |
| highrisk patients | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| exogenous | #6538 |
| bowel | #6538 |
| aspirin patients | #6540 |
| thirteen | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| pancreatic neoplasms | #6641 |
| genetic testing | #6641 |
| individual | #6650 |
| complications | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| recognised | #6729 |
| hazard ratios | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| body temperature | #6766 |
| 385 | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| defined | #6780 |
| 2 groups | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| reached | #6803 |
| premedication | #6803 |
| plasma proteins | #6807 |
| response relationship | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| adverse event | #6912 |
| disturbances | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| 246 | #6976 |
| intensity | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| 222 | #6995 |
| shock septic | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| computed | #7104 |
| betacoronavirus covid19 | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| 5year | #7204 |
| withdrawal | #7204 |
| cardiovascular disease cvd | #7210 |
| acting | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| treatment children | #7250 |
| vldl | #7250 |
| hematocrit | #7255 |
| 199 | #7257 |
| retrospective cohort study | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| modest | #7290 |
| sensitivity analysis | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| pectoris | #7338 |
| ischemic stroke | #7338 |
| 1c | #7352 |
| interleukin6 | #7352 |
| myocardial infarction | #7356 |
| standardised | #7356 |
| p0001 | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| angina | #7522 |
| urgently | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| cinahl | #7578 |
| comorbid | #7578 |
| 191 | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| 29 patients | #7647 |
| epidemiological studies | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| medical conditions | #7705 |
| 18 | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| 110 | #7802 |
| manufacturer | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| 31 patients | #7828 |
| label | #7828 |
| hormone replacement | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| tramadol | #7878 |
| academic | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| highrisk | #7939 |
| urogenital | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| 600 | #8051 |
| medical | #8051 |
| preventable | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| patients heart | #8120 |
| training | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| investigational | #8141 |
| imaging studies | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| parenteral nutrition | #8204 |
| confidence | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| impairment | #8228 |
| renal function | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lowest | #8250 |
| lists | #8250 |
| version | #8260 |
| 125i | #8264 |
| activated | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| postulated | #8338 |
| endothelium vascular | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| absence presence | #8382 |
| 2 years | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| 28 patients | #8415 |
| occur | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| procedures operative | #8463 |
| transient ischemic | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| evaluate | #8501 |
| covariate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| adolescent | #8582 |
| 146 | #8582 |
| row | #8590 |
| thirty | #8596 |
| carotid arteries | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| 15 years | #8624 |
| fish oil | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| hold | #8723 |
| 1 2 | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| practical | #8756 |
| cardiovascular | #8756 |
| endovascular | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| convenient | #8837 |
| hydroxymethylglutaryl | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| planned | #8914 |
| micrograms | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| signs symptoms | #8945 |
| proportional hazards | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| patients placebo | #9002 |
| options | #9002 |
| comprise | #9005 |
| chemoprevention | #9005 |
| societies medical | #9007 |
| clinical events | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| diagnose | #9080 |
| mps | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| time points | #9147 |
| valve prosthesis | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| dyspnea | #9230 |
| pci | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| illness surveys | #9264 |
| hazards | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| positive | #9286 |
| rabbit | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| p0004 | #9355 |
| patients negative | #9355 |
| preceded | #9376 |
| loss | #9378 |
| 014 | #9380 |
| higher incidence | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| kidney failure | #9638 |
| primary point | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| precise | #9817 |
| easily | #9817 |
| nmol | #9828 |
| coa reductase | #9828 |
| classification | #9836 |
| craniotomy | #9839 |
| 212 | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| heterozygotes | #9871 |
| nonhuman primates | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| degradation | #9941 |
| 2003 | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| casecontrol studies | #9997 |
| pancreatic | #9997 |
| 12 hours | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| obstacles | #10045 |
| protective | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| investigations | #10199 |
| cell activation | #10199 |
| cardiovascular risk factors | #10209 |
| clinical data | #10213 |
| medical therapy | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| blood transfusion | #10293 |
| hospitalization | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| 032 | #10336 |
| dilution | #10336 |
| worldwide | #10337 |
| 667 | #10337 |
| greatly | #10352 |
| aorta | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| p0003 | #10408 |
| outcome measures | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| circulation | #10432 |
| reductase inhibitors | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| priority | #10461 |
| patients age | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| activity levels | #10489 |
| increased prevalence | #10489 |
| 1991 | #10491 |
| style | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| patients moderate | #10570 |
| ray | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| antisense | #10583 |
| recurrences | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| microvascular | #10605 |
| 159 | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| held | #10674 |
| concerned | #10674 |
| pulmonary vascular | #10690 |
| discriminate | #10697 |
| term | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| diagnoses | #10903 |
| airways | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| neutropenia | #11057 |
| ischemic | #11057 |
| ethical | #11062 |
| summarizes | #11062 |
| attained | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| location | #11108 |
| inability | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| humans kidney | #11281 |
| cerebrovascular | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| occlusion | #11533 |
| placebo treatment | #11533 |
| multicenter study | #11542 |
| outflow | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| baseline | #11624 |
| younger patients | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| thirds | #12057 |
| dietary intake | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| lung | #12208 |
| causality | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| switzerland | #12409 |
| inflammatory response | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| requires | #12540 |
| guide | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| prostatic | #12708 |
| 45 | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| oral administration | #13041 |
| instance | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| cancer risk | #13107 |
| escalation | #13107 |
| vomiting | #13112 |
| physical | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| pulmonary hypertension | #13563 |
| accurate | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| competence | #13708 |
| vascular | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| pelvic | #13773 |
| explanation | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| risk death | #14033 |
| members | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| situations | #14084 |
| focus | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| 6 patients | #14391 |
| min1 | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| renal insufficiency | #14637 |
| statistics | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| validity | #14787 |
| independent predictor | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| copd | #15201 |
| decrease | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| disorders | #15278 |
| drug | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| randomised controlled trial | #15474 |
| women age | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| effectively | #15813 |
| examination | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| severely | #15997 |
| discuss | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| prevented | #16513 |
| develop | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| cooperative | #17262 |
| lung neoplasms | #17262 |
| estimated | #17274 |
| largest | #17288 |
| acute phase | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| ventricular function | #18296 |
| metastases | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| 2002 | #20050 |
| gestational | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| persistent | #20562 |
| elisa | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| operative | #21137 |
| attenuated | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| 139 | #21894 |
| majority | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| adverse | #23767 |
| naive | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| commonly | #27411 |
| mass bmi | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
Open the FULL List in Excel | |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| Known for Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines |
KOL-Index: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| Known for Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| Known for Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range |
KOL-Index: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| Known for Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized |
KOL-Index: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| Known for Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors |
KOL-Index: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| Known for Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| Known for Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score |
KOL-Index: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| Known for Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio |
KOL-Index: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| Known for Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome |
KOL-Index: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| Known for Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months |
KOL-Index: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| Known for Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients |
KOL-Index: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| Known for Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| Known for Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections |
KOL-Index: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| Known for Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval |
Key People For Pulmonary Embolism
Top KOLs in the world
Select a search phrase pulmonary embolism , pulmonary embolism patients , pulmonary embolism 95 , pulmonary embolism diagnosis , pulmonary embolism treatment
Harry Roger Büller:Expert Impact
Concepts for whichHarry Roger Büllerhas direct influence:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:KOL impact
Concepts related to the work of other authors for whichfor which Harry Roger Büller has influence:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |